Stabilisation of biological samples

ABSTRACT

The present invention provides methods and composition suitable for stabilizing cell-containing samples such as blood samples. The stabilizers used are primary or secondary carboxylic acid amides.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of U.S.application Ser. No. 14/777,902 filed Sep. 17, 2015, now pending, whichis a U.S. national phase application of PCT/EP2014/000725 filed Mar. 18,2014, which claims priority to U.S. Provisional Application No.61/803,107 filed Mar. 18, 2013, EP Application No. 13160896.0 filed Mar.25, 2013 and EP Application No. 13180130.0 filed Aug. 12, 2013. U.S.application Ser. No. 14/777,902 is herein incorporated by reference inits entity.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided intext format in lieu of a paper copy, and is hereby incorporated byreference into the specification. The name of the text file containingthe Sequence Listing is 770025.471C1_SEQUENCE_LISTING.txt. The text fileis 25,845 bytes, was created on May 19, 2022, and is being submittedelectronically via EFS-Web.

The work leading to this invention has received funding from theEuropean Community's Seventh Framework Programme (FP7/2007-2013) undergrant agreement n° 222916.

FIELD OF THE INVENTION

The technology disclosed herein inter alia relates to methods andcompositions suitable for stabilizing a cell-containing sample, inparticular a blood sample, and to methods for isolating nucleic acidsfrom respectively stabilized biological samples.

BACKGROUND OF THE INVENTION

Nucleic acids are important biomarkers in the diagnostic field. E.g.profiles of transcripts of the genome (in particular mRNA and miRNA) arewidely used as biomarkers in molecular in vitro diagnostics and provideinside into normal biological and pathological processes with the hopeof predicting disease outcome and indicating individualised courses oftherapy. Therefore, profiling of nucleic acids, in particular RNA, isimportant in disease diagnosis, prognosis and in clinical trials forbiomarker discovery. The ability to obtain quantitative information fromthe transcriptional profile is a powerful tool to explore basic biology,diagnose disease, facilitate drug development, tailor therapeutics tospecific pathologies and genetic profiles and also to generate databasesrelevant to biological or therapeutic processes and pathways.Significant improvements of downstream assays and data analyses(analytical process) have been made during the last years. However, itwas found that the preanalytical steps, such as sample handling andsample stabilisation, in particular for new biomolecular targets, have asevere impact on the expression profile and may compromise thesubsequent analysis (see for example Hartel et al, 2001, Pahl and Brune,2002). Without precaution in the stabilisation of the sample to beanalysed, the sample will undergo changes during transport and storagethat may severely alter the expression profile of the targeted molecules(see for example Rainen et al, 2002; Baechler et al, 2004). Thus, geneexpression, in particular blood cell gene expression is sensitive to exvivo handling of the sample. If the expression profile is altered due tothe handling of the sample, the subsequent analysis does not reflect theoriginal situation of the sample and hence of the patient but rathermeasure an artificial profile generated during sample handling,transport and storage. Therefore, optimized stabilisation processes areneeded which stabilise the expression profile thereby allowing thereliable analysis. In particular, there is a need to stabilize bloodsamples in order to allow the analysis of blood cell gene expressionprofiles.

Stabilisation of samples such as in particular blood samples for alonger period was formally performed with the addition of organicsolvents such as phenol and/or chloroform or by direct freezing inliquid nitrogen or using dry ice. These methods are not at allpracticable techniques for hospitals, doctor surgeries or diagnosticroutine laboratories. To overcome these problems, PreAnalytiX developedthe first research product for the collection of human blood with anevacuated blood collection tube that contains reagents for an immediatestabilisation of the RNA gene expression profile at the point of samplecollection (PAXgene Blood RNA Tubes). The respective stabilisationcomposition allows the transport and storage at room temperature withoutthe risk of changes in the RNA profile by gene induction and transcriptdegradation (see for example U.S. Pat. Nos. 6,617,170, 7,270,953,Kruhoffer et al, 2007). Other stabilisation agents that achieve animmediate lysis of the sample, here blood, are sold by ABI/LifeTechnologies under the name Tempus Blood RNA tube product. Anotherproduct is the Biomatrica Vacuette RNAgard Blood Tube. Also with thistube lysis occurs immediately during collection and RNases areinactivated shown by intact RNA over time of blood incubation. Thedisadvantage of the respective methods is that the stabilisation resultsin the complete lysis of the cells. The destruction of the cells resultsin that intracellular nucleic acids become mixed with extracellularnucleic acids which prevents the separate analysis of these two nucleicacid populations. Furthermore, not only the quality and quantity of theisolated nucleic acids respectively their expression profile is ofanalytical interest, but also the presence, absence or number ofspecific cells contained in the sample such as for example a bloodsample. The destruction of the cells is a great disadvantage because anycell sorting or cell enrichment respectively cell analysis becomesimpossible.

Therefore, very often specific stabilisation reagents, respectivelyblood collection tubes are provided that are specifically intended forthe stabilisation of cells. The respective products allow to investigatethe cellular content of the sample after storage, for example to detectthe presence of tumor cells for example by fluorescence activated cellsorting (FACS) analysis or changes of the ratio of different white bloodcells to each other by flow cytometry (FC) or FACS analysis. E.g. manyworkflows use standard EDTA blood collection tubes for flow cytometry orFACS analysis, although blood cells show minor lysis over time ofstorage. A further product from Streck Inc. is a direct-draw vacuumblood collection tube for the preservation of whole blood samples forimmunophenotyping by flow cytometry. It preserves white blood cellantigens allowing subsets of leucocytes to be distinguished by flowcytometry analysis. The technology to maintain the integrity of thewhite blood cell cluster of differentiation (CD) markers is e.g. coveredby U.S. Pat. Nos. 5,460,797 and 5,459,073.

However, using different stabilisation reagents and accordinglystabilisation tubes for collecting the sample for nucleic acid analysisand cell analysis is tedious. There is a need to reduce the number ofdifferent sample collection tubes, for example blood collection tubes,per draw at the patients' site that are dedicated to differentdownstream assays (e.g. detection of cells and analysis of RNA).Therefore, sample collection and stabilisation systems are needed, whichpreserve the cell's morphology while at the same time stabilising thenucleic acids.

To address the need of simultaneous cell stabilisation and nucleic acidstabilisation, stabilisation systems were developed that are based onthe use of formaldehyde releasers. Respective stabilisation agents arecommercially available from Streck Inc. under the name of cell-free RNABCT (blood collection tube). The 10 ml blood collection tube is intendedfor the preservation and stabilisation of cell-free RNA in plasma for upto 3 days at room temperature. The preservative stabilizes cell-free RNAin plasma and prevents the release of non-target background RNA fromblood cells during sample processing and storage. US 2011/0111410describes the use of formaldehyde releasing components to achieve celland RNA stabilisation in the same blood sample. Therefore, this documentdescribes a technique wherein the stabilisation agent stabilises theblood cells in the drawn blood thereby preventing contamination ofcellular RNA with cell-free RNA or globin RNA, inhibits the RNAsynthesis for at least 2 hours and cellular RNA that is within the bloodcells is preserved to keep the protein expression pattern of the bloodcells substantially unchanged to the time of the blood draw. The whiteblood cells can be isolated from the respectively stabilised sample andcellular RNA is than extracted from the white blood cells. However,nucleic acid isolation from respectively stabilised samples is verydifficult, because the used formaldehyde releaser interferes with thesubsequent nucleic acid isolation process. Therefore, the nucleic acidyield and/or purity is severely reduced compared to the isolation ofnucleic acids that were stabilised using stabilization methods thatspecifically aim at the stabilization and isolation of nucleic acidssuch as RNA (for example the PAXgene Blood RNA Tubes).

Furthermore, methods are known in the prior art for stabilizingcell-containing samples, such as blood or tissue samples, whichstabilize the cells, the transcriptome, genome and proteome. Such amethod is e.g. disclosed in WO 2008/145710. Said method is based on theuse of specific stabilizing compounds. In contrast to stabilizationmethods that involve a formaldehyde releaser, the isolation of nucleicacids is not impaired by the stabilization agents.

A further nucleic acid species present in cell-containing biologicalsamples that are of clinical interest are extracellular nucleic acids.Extracellular nucleic acids have been identified in blood, plasma, serumand other body fluids. Extracellular nucleic acids that are found inrespective samples are to a certain extent degradation resistant due tothe fact that they are protected from nucleases (e.g. because they aresecreted in form of a proteolipid complex, are associated with proteinsor are contained in vesicles). The presence of elevated levels ofextracellular nucleic acids such as DNA and/or RNA in many medicalconditions, malignancies, and infectious processes is of interest interalia for screening, diagnosis, prognosis, surveillance for diseaseprogression, for identifying potential therapeutic targets, and formonitoring treatment response. Additionally, elevated fetal DNA/RNA inmaternal blood is being used to determine e.g. gender identity, assesschromosomal abnormalities, and monitor pregnancy-associatedcomplications. Thus, extracellular nucleic acids are in particularuseful in non-invasive diagnosis and prognosis and can be used e.g. asdiagnostic markers in many fields of application, such as non-invasiveprenatal genetic testing, oncology, transplantation medicine or manyother diseases and, hence, are of diagnostic relevance (e.g. fetal- ortumor-derived nucleic acids). However, extracellular nucleic acids arealso found in healthy human beings. Common applications and analysismethods of extracellular nucleic acids are e.g. described inWO97/035589, WO97/34015, Swarup et al, FEBS Letters 581 (2007) 795-799,Fleischhacker Ann. N.Y. Acad. Sci. 1075: 40-49 (2006), Fleischhacker andSchmidt, Biochmica et Biophysica Acta 1775 (2007) 191-232, Hromadnikovaet al (2006) DNA and Cell biology, Volume 25, Number 11 pp 635-640; Fanet al (2010) Clinical Chemistry 56:8.

Traditionally, the first step of isolating extracellular nucleic acidsfrom a cell-containing biological sample such as blood is to obtain anessentially cell-free fraction of said sample, e.g. either serum orplasma in the case of blood. The extracellular nucleic acids are thenisolated from said cell-free fraction, commonly plasma when processing ablood sample. However, obtaining an essentially cell-free fraction of asample can be problematic and the separation is frequently a tedious andtime consuming multi-step process as it is important to use carefullycontrolled conditions to prevent cell breakage during centrifugationwhich could contaminate the extracellular nucleic acids with cellularnucleic acids released during breakage. Furthermore, it is oftendifficult to remove all cells. Thus, many processed samples that areoften and commonly classified as “cell-free” such as plasma or serum infact still contain residual amounts of cells that were not removedduring the separation process. Another important consideration is thatcellular nucleic acid are released from the cells contained in thesample due to cell breakage during ex vivo incubation, typically withina relatively short period of time from a blood draw event. Once celllysis begins, the lysed cells release additional nucleic acids whichbecome mixed with the extracellular nucleic acids and it becomesincreasingly difficult to recover the extracellular nucleic acids fortesting. These problems are discussed in the prior art (see e.g. Chiu etal (2001), Clinical Chemistry 47:9 1607-1613; Fan et al (2010) andUS2010/0184069). Further, the amount and recoverability of availableextracellular nucleic acids can decrease substantially over time due todegradation.

Methods are known in the prior art that specifically aim at stabilizingcirculating nucleic acids contained in whole blood. One method employsthe use of formaldehyde to stabilize the cell membranes, therebyreducing the cell lysis and furthermore, formaldehyde inhibitsnucleases. Respective methods are e.g. described in U.S. Pat. Nos.7,332,277 and 7,442,506. However, the use of formaldehyde orformaldehyde-releasing substances has drawbacks, as they may compromisethe efficacy of extracellular nucleic acid isolation by induction ofcrosslinks between nucleic acid molecules or between proteins andnucleic acids. Alternative methods to stabilize blood samples aredescribed e.g. in US 2010/0184069 and US 2010/0209930. This demonstratesthe great need for providing means to stabilise cell-containingbiological samples, to allow the efficient recovery of e.g.extracellular nucleic acids contained in such samples.

There is still a continuous need to develop sample processing techniqueswhich result in a stabilisation of the gene expression profile and theextracellular nucleic acid population comprised in a cell-containingbiological sample, such as a whole blood sample, thereby making thehandling, respectively processing of such stabilized samples easier.

It is the object of the present invention to overcome at least one ofthe drawbacks of the prior art sample stabilization methods. Inparticular, it is an object to provide a method that is capable ofstabilising a cell-containing sample, in particular a whole bloodsample. In particular, it is an object to provide a sample stabilizationmethod, which allows stabilizing nucleic acids contained in thecell-containing sample. Furthermore, it is an object to provide a samplestabilization method, which is not based on cell lysis and stabilizesthe extracellular nucleic acid population contained in thecell-containing sample as well as the gene expression profile ofcontained cells.

SUMMARY OF THE INVENTION

The present invention is based on the finding that primary and secondarycarboxylic acid amides are surprisingly effective in stabilizingcell-containing biological samples, in particular whole blood samples orsamples derived from whole blood such as e.g. blood plasma. It was foundthat these additives are highly efficient in stabilizing theextracellular nucleic acid population and in particular are capable toavoid or at least significantly reduce contaminations with genomic DNA,in particular fragmented genomic DNA. Furthermore, it was found thatthese additives also capable of stabilizing gene expression profiles ofcontained cells, thereby allowing the reliable profiling of geneexpression. In contrast to prior art methods, the stabilization effectis not based on cell lysis. Therefore, the stabilization technologiesdescribed herein also allow the separate analysis of the extracellularand intracellular nucleic acid population if desired. Furthermore, thestabilization described herein allows to analyze cells contained in thestabilized sample, e.g. the cell morphology and/or cell surfacecharacteristics.

According to a first aspect of the present invention, a method forstabilizing a cell-containing sample is provided, comprising contactingthe sample with at least one carboxylic acid amide, wherein thecarboxylic acid amide is selected from primary carboxylic acid amidesand secondary carboxylic acid amides. Preferably, the resultingcomposition comprising the cell-containing biological sample and the atleast one carboxylic acid amide comprises the carboxylic acid amide in aconcentration of at least 0.25%.

Primary and secondary carboxylic acid amides such as formamide,butanamide, N-methylformamide and N-methylacetamide are very effectivestabilizing agents for cell-containing samples, in particular bloodsamples. It was found that adding a respective compound has anadvantageous stabilizing effect on the extracellular nucleic acidpopulation. As is shown by the examples, these compounds are suitablefor stabilizing an extracellular nucleic acid population comprised in acell-containing sample. Furthermore, as is shown by the examples, thesecompounds are suitable for stabilizing and thus preserving the genetranscription profile of contained cells. As is shown by the examples,after stabilization, changes in the gene expression profile are reducedor even prevented during the stabilization period. Thus, the geneexpression profile is basically “freezed” upon stabilization with aprimary or secondary carboxylic acid amide and thus is preserved at thestate of sample collection, respectively sample stabilization.Preferably, the cell-containing sample is selected from whole blood,plasma or serum. Furthermore, the cell stabilizing properties achievedallow analysing and also separating specific cells contained in thestabilized sample such as e.g. blood cells or circulating tumor cellscontained in a blood sample.

In order to enhance the stabilization effect, it is also an object ofthe present invention to provide combinations of stabilizing agents e.g.in order to stabilize the extracellular nucleic acid populationcomprised in a cell-containing sample and/or the gene transcriptionprofile of contained cells. A respective combination may comprise atleast one primary or secondary carboxylic acid amide and additionally atleast one tertiary amide and/or at least one apoptosis inhibitor.Surprisingly, it was found that an apoptosis inhibitor such as inparticular a caspase inhibitor reduces contaminations of theextracellular nucleic acid population with intracellular nucleic acids,in particular fragmented genomic DNA, that originate from cellscontained in the sample, e.g. from damaged or dying cells. Thus, thestabilization combination which includes an apoptosis inhibitor is veryeffective in substantially preserving the extracellular nucleic acidpopulation contained in the sample in the state it had shown at the timethe biological sample was obtained, respectively collected. A respectivecombination may also comprise additional additives that enhance thestabilizing effect such as e.g. chelating agents. In case the sample isblood or a sample derived from blood, usually an anticoagulant is alsoadded. Chelating agents such as e.g. EDTA are suitable for this purpose.Respective stabilizing combinations can be advantageously used in themethod for stabilizing a cell-containing sample according to the firstaspect.

According to a second aspect, a method for isolating nucleic acids froma biological sample is provided, wherein said method comprises the stepsof:

-   -   a) stabilizing a cell-containing sample according to the method        defined in the first aspect of the present invention;    -   b) isolating nucleic acids from the stabilized sample.

Stabilization in step a) is achieved according to the first aspectaccording to the present invention as described above. As discussedabove, the stabilization according to the present invention inter aliahas the effect that the extracellular nucleic acid population containedin the sample is substantially preserved in the state it had shown atthe time the biological sample was obtained, respectively collected.Therefore, extracellular nucleic acids obtained from a respectivelystabilized sample comprise less contaminations with intracellularnucleic acids, in particular fragmented genomic DNA, that results e.g.from decaying cells comprised in the sample compared to extracellularnucleic acids that are obtained from an unstabilized sample. Thesubstantial preservation of the extracellular nucleic acid population isan important advantage because this stabilization/preservation enhancesthe accuracy of any subsequent tests. It allows for standardizing theisolation and subsequent analysis of the extracellular nucleic acidpopulation, thereby making diagnostic or prognostic applications thatare based on the extracellular nucleic acid fraction more reliable andmore independent from the used storage/handling conditions. Inparticular, the teachings of the present invention have the advantagethat the ratio of certain extracellular nucleic acid molecules can bekept substantially constant compared to the ratio at the time the samplewas collected. The stabilization achieves that intracellular nucleicacids are substantially kept within the cells and that extracellularnucleic acids are substantially stabilized. Furthermore, thestabilization methods described herein are also suitable for stabilizingintracellular nucleic acids. After sample stabilization, intracellularRNA is protected from degradation and furthermore, changes in the genetranscription profile of contained cells are inhibited. Thus, thestabilization described herein in particular reduces in vitrodegradation and minimizes gene induction. Therefore, intracellularnucleic acids isolated from respectively stabilized samples are wellsuitable e.g. for gene expression profiling and other analytical methodsthat require an accurate representation of in vivo transcript levels inthe stabilized sample. Furthermore, advantageously, the stabilizationmethod described herein allows if desired to isolate stabilizedextracellular nucleic acids separately from stabilized intracellularnucleic acids from the same stabilized sample.

According to a third aspect, a composition suitable for stabilizing acell-containing biological sample is provided, comprising:

-   -   a) at least one carboxylic acid amide in a concentration of at        least 1%, wherein the carboxylic acid amide is selected from        primary carboxylic acid amides and secondary carboxylic acid        amides; and    -   b) at least one anticoagulant.

A respective stabilizing composition is particularly effective instabilizing a cell-containing biological sample, in particular wholeblood, plasma and/or serum by stabilizing the extracellular nucleic acidpopulation comprised in said sample. Furthermore, a respectivestabilizing composition is effective in stabilizing the genetranscription profile of contained cells. Furthermore, cells andimportant cell characteristics such as e.g. the cell morphology and/orcell surface characteristics of contained cells can be preserved as isshown by the examples. A respective stabilizing composition allows thestorage and/or handling, e.g. shipping, of the sample, e.g. whole blood,at room temperature for at least two, or preferably at least three dayswithout substantially compromising the quality of the sample,respectively the extracellular nucleic acid population containedtherein. Thus, when using the stabilization composition according to thepresent invention, the time between sample collection, e.g. bloodcollection, and nucleic acid extraction can vary without substantialeffect on the extracellular nucleic acid population contained in thesample or the gene expression profile of contained cells. This is animportant advantage as it reduces the variability in the extracellularnucleic acid population and the intracellular nucleic acid population,in particular transcript levels, attributable to different handlingprocedures. According to one embodiment, the composition additionallycomprises at least one apoptosis inhibitor, preferably a caspaseinhibitor.

According to a fourth aspect, a container for collecting acell-containing biological sample, preferably a blood sample, isprovided which comprises

-   -   a) at least one carboxylic acid amide, preferably in a        concentration of at least 1%, wherein the carboxylic acid amide        is selected from primary carboxylic acid amides and secondary        carboxylic acid amides; and    -   b) at least one anticoagulant.

The container for collecting a cell-containing biological sample,preferably a blood sample, may comprise a composition according to thethird aspect of the present invention. Providing a respective container,e.g. a sample collection tube comprising the stabilizing composition hasthe advantage that the sample is immediately stabilized as soon as thesample is collected in the respective container. Furthermore, arespective sample collection container, in particular a blood collectiontube, is capable of stabilising blood cells and their gene transcriptionprofile and is capable of stabilizing extracellular nucleic acids andoptionally, viruses respectively viral nucleic acids contained in ablood sample or a sample derived from blood. Thereby, a further problemwas overcome.

According to a fifth aspect, a method is provided comprising the step ofcollecting, preferably withdrawing, a biological sample, preferablyblood, from a patient directly into a chamber of a container accordingto the fourth aspect of the present invention.

According to a sixth aspect, a method of producing a compositionaccording to the third aspect of the present invention is provided,wherein the components of the composition are mixed, preferably aremixed in a solution. The term “solution” as used herein in particularrefers to a liquid composition, preferably an aqueous composition. Itmay be a homogenous mixture of only one phase but it is also within thescope of the present invention that a solution comprises solidcomponents such as e.g. precipitates.

Other objects, features, advantages and aspects of the presentapplication will become apparent to those skilled in the art from thefollowing description and appended claims. It should be understood,however, that the following description, appended claims, and specificexamples, while indicating preferred embodiments of the application, aregiven by way of illustration only.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1 to 4: Relative transcript levels of FOS, IL1B, IL8 and TP53(from FIGS. 1 to 4) from samples of example 1. Transcripts were analysedusing real time monoplex RT-PCR assays. Transcript levels given as cyclethresholds (CT) of individual samples are shown as white bars, means asblack solid bars with standard deviations and control samples of anadditional donor of a different experiment serving as positive controlof gene expression changes and RT-PCR within each PCR run (platecontrol) as shaded bars.

FIG. 5: Microscopic evaluation of H&E stained blood slides from aliquotsof peripheral blood samples of one donor of example 1.

FIG. 6: Flow cytometry (FC) analysis of peripheral blood samples of onedonor of example 1. Blood was directly drawn into BD EDTA tubes andPreAnalytiX PAXgene Blood RNA Tubes (PAXgene). Replicate EDTA bloodsamples were kept untreated ([+] control [EDTA], [−] control [EDTA+a.dest]) or were treated with final concentration of 5% v/v formamide and0.5×MOPS buffer (pH5.5) as described in example 1. Immediately aftercollection and treatment of samples, blood aliquots were analysedwithout incubation (0 h samples), while remaining samples were incubatedat RT for one and three days (24 h and 72 h samples) prior to FCanalysis. Shown per picture are the size (x-axis=forward scatter) andgranularity (y-axis=sideward scatter) of 10,000 events per samplealiquot tested that contain signals of cells, cell debris and particles.The different populations of white blood cells that are distinguishablefrom each other in FC analysis (L, M, NG) and the cell-free fraction (D)are indicated by circles for the (+) control (EDTA) sample. They are asfollows:

D=Debris, subcellular components, fragments of cells

L=Lymphocytes

M=Monocytes

NG=Neutrophilic granulocytes

(+) control (EDTA): Untreated EDTA blood sample serving as a positivecontrol of cell stabilisation.

(−) control (EDTA+a. dest): Untreated EDTA blood sample that wascompletely lysed by addition of deionized water serving as a negativecontrol of cell stabilisation.

(−) control (PAXgene): PAXgene blood sample that contains completelylysed cells as all cells get directly lysed during blood collection intothe tube as soon as blood gets into contact with the RNA stabilisationadditive in the tube. This sample served as an additional negativecontrol of cell stabilisation.

Calibration control: CALIBRITE Beads (BD) of known fluorescence anddiameter serving to calibrate the BD FACSCalibur™ instrument.

Test solution 5% v/v Formamide: EDTA blood samples containing 5% v/vformamide and 0.5×MOPS buffer (pH5.5).

FIGS. 7 to 10: Relative transcript levels of FOS, IL1B, IL8 and TP53(from FIGS. 7 to 10) in blood samples collected from eight donors intoEDTA tubes and PAXgene Blood RNA Tubes. EDTA blood samples were keptuntreated or mixed with final concentration of 8% w/v acetamideimmediately after blood collection. RNA isolation was performed fromblood samples without and from replicate tubes after incubation for oneday at RT. Transcripts were analysed using real time monoplex RT-PCRassays. Transcript levels given as cycle thresholds (CT) of individualsamples are shown as white bars, means as black solid bars with standarddeviations and control samples of an additional donor of a differentexperiment serving as positive control of gene expression changes andsuccessful RT-PCR within each PCR run (plate control) as shaded bars.

FIGS. 11 to 14: Relative transcript levels of FOS, IL1B, IL8 and TP53(from FIGS. 11 to 14) in blood samples collected from three donors intoEDTA tubes and PAXgene Blood RNA Tubes. EDTA blood samples were keptuntreated or mixed with final concentration of 2% w/v N-methylacetamide(final concentration in the stabilized blood composition) immediatelyafter blood collection. RNA isolation was performed from blood sampleswithout and from replicate tubes after incubation for one and three daysat RT. Transcripts were analysed using real time monoplex RT-PCR assays.Transcript levels given as cycle thresholds (CT) of individual samplesare shown as white bars, means as black solid bars with standarddeviations and control samples of an additional donor of a differentexperiment serving as positive control of gene expression changes andsuccessful RT-PCR within each PCR run (plate control) as shaded bars.

FIGS. 15 to 21: Stabilization of the extracellular nucleic acidpopulation using formamide in different concentrations either alone orin combination with a caspase inhibitor.

FIGS. 22 to 23: Stabilization of the extracellular nucleic acidpopulation using acetamide in different concentrations in combinationwith a caspase inhibitor.

FIG. 24: Stabilization of the extracellular nucleic acid populationusing propanamide in different concentrations in combination with acaspase inhibitor.

FIGS. 25 to 29: Stabilization of the extracellular nucleic acidpopulation using butanamide in different concentrations either alone orin combination with a caspase inhibitor.

FIG. 30: Stabilization of the extracellular nucleic acid populationusing N-methylformamide in different concentrations in combination witha caspase inhibitor.

FIG. 31: Stabilization of the extracellular nucleic acid populationusing N-methylacetamide in different concentrations in combination witha caspase inhibitor.

DETAILED DESCRIPTION OF THIS INVENTION

The present invention is directed to methods, compositions and devicesand thus to technologies suitable for stabilizing the extracellularnucleic acid population comprised in a cell-containing biological sampleand/or for stabilizing the gene transcription profile and thus thetranscriptome of contained cells. The stabilization technologiesdisclosed herein e.g. reduce the risk that the extracellular nucleicacid population is contaminated with intracellular nucleic acids, inparticular fragmented genomic DNA, which derives from, e.g. is released,from damaged and/or dying cells contained in the sample. Furthermore,the stabilizing technologies disclosed herein substantially preserve thegene transcription profile of contained cells, thereby allowing thereliable analysis of gene expression profiles. Furthermore, thestabilization described herein prevents contaminations of extracellularnucleic acids with intracellular nucleic acids and vice versa whichallows a separate analysis of the extracellular nucleic acid populationand the intracellular nucleic acids from the same stabilizedcell-containing sample if desired. Therefore, the present inventionachieves the stabilization of the sample and hence the stabilization ofthe extracellular nucleic acid population and/or the intracellularnucleic acid population without the lysis of the contained cells.Rather, cells contained in the sample are stabilized therebysubstantially preventing or reducing the release of intracellularnucleic acids. Furthermore, as is shown by the examples, the genetranscription profile of contained cells is substantially preserved, byinhibiting changes and thus alterations in the transcript levels.Furthermore, cells can be recovered from the stabilized samples and aresuitable for different analyses. E.g. the cell morphology and/or thecell surface characteristics of contained can be analsed if desired.Furthermore, the stabilized sample can be analyzed for the presence orabsence of specific cells such as e.g. tumor cells, e.g. circulatingtumor cells present in whole blood samples.

The remarkable stabilization of nucleic acids that is achieved with themethods and compositions of the present invention allows the storageand/or handling of the stabilized sample for a prolonged period of timeat room temperature without jeopardizing the quality of the sample,respectively the extracellular nucleic acids contained therein. As thecomposition of the extracellular nucleic acid population and theintracellular transcriptome is stabilized and thus substantiallypreserved at the time the sample is obtained by using the teachings ofthe present invention, the time between sample collection and nucleicacid extraction can vary without significant effect on the compositionof the extracellular nucleic acids population. This allows thestandardization of e.g. diagnostic or prognostic extracellular nucleicacid analysis because variations in the handling/storage of the sampleshave less influence on the quality, respectively the composition of theextracellular nucleic acid population, thereby providing an importantadvantage over prior art methods. Hence, the samples, respectively theextracellular nucleic acids obtained from respectively stabilizedsamples become more comparable. Furthermore, the achieved stabilizationof the gene transcription profile of contained cells allows a reliablegene expression analysis even after prolonged storage of the stabilizedsamples. Furthermore, advantageously, the teachings of the presentinvention obviate the necessity to directly separate cells contained inthe sample from the cell-free portion of the sample in order to avoid,respectively reduce contaminations of the extracellular nucleic acidswith intracellular nucleic acids, in particular fragmented genomic DNA,that is otherwise released from decaying cells. This advantageconsiderably simplifies the handling of the samples, in particular thehandling of whole blood samples. E.g. whole blood samples obtained in aclinic and stabilized according to the teachings of the presentinvention can be shipped at room temperature and the plasma containingthe extracellular nucleic acids can be conveniently separated from thecontained cells in the receiving clinical lab. However, the teachings ofthe invention are also advantageous when processing cell-depletedbiological samples, or samples commonly referred to as “cell-free” suchas e.g. blood plasma or serum. Respective cell-depleted or “cell-free”biological samples may still (also depending on the used separationprocess) comprise residual cells, in particular white blood cells whichcomprise genomic DNA, which accordingly, pose a risk that theextracellular nucleic acid population becomes increasingly contaminatedwith intracellular nucleic acids, in particular fragmented genomic DNA,if the (potentially) remaining cells are damaged or die during theshipping of storing process. This risk is considerably reduced whenusing the stabilization method taught by the present invention. Becausethe technology of the present invention allows to efficiently preservethe extracellular nucleic acid population of the sample and the geneexpression profile of contained cells at the time the sample iscollected and contacted with the stabilizing agents, said samples can beproperly worked up in the receiving facilities in order to isolate theextracellular nucleic acids from said samples while substantiallyavoiding respectively reducing contaminations of the extracellularnucleic population with intracellular nucleic acids. Intracellularnucleic acids can be isolated from the stabilized cells and can be usede.g. for gene expression profiling. The facilities receiving the samplessuch as e.g. laboratories usually also have the necessary equipment suchas e.g. high speed centrifuges (or other means, see also below) toefficiently remove cells comprised in the samples, including residualcells that might be present in cell-depleted samples such as e.g. inblood plasma. Such equipment is often not present in the facilitieswhere the sample is obtained. Thus, the present invention has manyadvantages when stabilizing biological samples which comprise a largeamount of cells such as e.g. whole blood samples, but also has importantadvantages when stabilizing biological samples which comprise only asmall amount of cells or which may only be suspected of containing cellssuch as e.g. plasma, serum, urine, saliva, synovial fluids, amnioticfluid, lachrymal fluid, ichors, lymphatic fluid, liquor, cerebrospinalfluid and the like.

Method for Stabilizing a Cell-Containing Sample

According to a first aspect, a method for stabilizing a cell-containingsample, preferably a blood sample, is provided, by contacting the samplewith at least one carboxylic acid amide, wherein the carboxylic acidamide is selected from primary carboxylic acid amides and secondarycarboxylic acid amides. Preferably, the resulting composition comprisingthe cell-containing biological sample and the at least one carboxylicacid amide comprises the carboxylic acid amide in a concentration of atleast 0.25%.

As is shown by the provided examples such compounds are inter aliaeffective in achieving a remarkable stabilizing effect on thecell-containing sample e.g. in substantially preserving the compositionof the extracellular nucleic acid population in the stabilized sample.Thereby, the risk is reduced that the extracellular nucleic acidpopulation is contaminated with intracellular nucleic acids, inparticular fragmented genomic DNA originating from contained cells, e.g.from damaged or dying cells and/or the degradation of nucleic acidspresent in the sample is reduced, respectively inhibited. This has theeffect that the composition of the extracellular nucleic acid populationcomprised in said sample is substantially preserved, respectivelystabilized. Also a mixture of one or more of primary and/or secondarycarboxylic acid amides can be used for stabilization. Furthermore,nucleic acids can be efficiently isolated from respectively stabilizedsamples using standard nucleic acid isolation methods because thecarboxylic acid amides used herein for stabilization do not havecross-linking properties. This is an important advantage as it e.g.simplifies the further processing of the stabilized samples and alsoincreases the chance that e.g. rare target nucleic acids comprised inthe extracellular nucleic acid population can be subsequently detected.

According to one embodiment, the carboxylic acid amide which is selectedfrom primary carboxylic acid amides and secondary carboxylic acid amideshas the formula 1

wherein R1 is a hydrogen residue or an alkyl residue, wherein R2 isselected from a hydrogen residue and a hydrocarbon residue with a lengthof the carbon chain of 1-20 atoms arranged in a linear or branchedmanner, wherein R3 is a hydrogen residue, and wherein R4 is oxygen.Suitable and preferred examples of R1, R2 and R3 are also describedbelow.

In one embodiment, R1 is a C1-C5 alkyl residue, preferably a C1-C4 alkylresidue or a 01-C3 alkyl residue, more preferred a C1-C2 alkyl residue.In another embodiment, R1 is a hydrogen residue. The chain length n ofR1 preferably has the value 1, 2, 3, 4 or 5. Particularly preferred is achain length of 1 or 2 for R1. In particularly preferred embodiments, R1is selected from the group consisting of a hydrogen residue, a methylresidue, an ethyl residue and a propyl residue.

R2 and R3 of the compound according to formula 1 are identical ordifferent and are selected from a hydrogen residue and a hydrocarbonresidue. According to one embodiment, the compound according to formula1 is a primary amide and R2 and R3 are both hydrogen residues. Accordingto another embodiment, the compound according to formula 1 is asecondary amide and R2 is a hydrocarbon residue and R3 is a hydrogenresidue. According to another embodiment described below, the compoundaccording to formula 1 is a tertiary amide and R2 and R3 are identicalor different hydrocarbon residues (see below). The hydrocarbon residuesR2 and/or R3 can be selected independently of one another from the groupcomprising of alkyl, including short chain alkyl and long-chain alkyl,alkenyl, alkoxy, long-chain alkoxy, cycloalkyl, aryl, haloalkyl,alkylsilyl, alkylsilyloxy, alkylene, alkenediyl, arylene, carboxylatesand carbonyl. General groups, for instance alkyl, alkoxy, aryl etc. areclaimed and described in the description and the claims. Preferably, thefollowing groups are used within the generally described groups withinthe scope of the present invention:

-   (1) alkyl: preferably short chain alkyls, in particular linear and    branched C1-C5 alkyls or long-chain alkyls: linear and branched    C5-C20 alkyls;-   (2) alkenyl: preferably C2-C₆ alkenyl;-   (3) cycloalkyl: preferably C3-C8 cycloalkyl;-   (4) alkoxy: preferably C1-C6 alkoxy;-   (5) long-chain alkoxy: preferably linear and branched C5-C20 alkoxy;-   (6) alkylenes: preferably a divalent linear or branched aliphatic,    cycloaliphatic or aromatic hydrocarbon residue with 2 to 18 carbon    atoms optionally containing heteroatoms, e.g. selected from the    group comprising: methylene; 1,1-ethylene; 1,1-propylidene;    1,2-propylene; 1,3-propylene; 2,2-propylidene; butan-2-01-1,4-diyl;    propan-2-01-1,3-diyl; 1,4-butylene; 1,4-pentylene; 1,6-hexylene;    1,7-heptylene; 1,8-octylene; 1,9-nonylene; 1,10-decylene;    1,11-undecylene; 1,12-docedylene; cyclohexane-1,1-diyl;    cyclohexane-1,2-diyl; cyclohexane-1,3-diyl; cyclohexane-1,4-diyl;    cyclopentane-1,1-diyl; cyclopentane-1,2-diyl; and    cyclopentane-1,3-diyl;-   (7) alkenediyl: preferably selected from the group comprising:    1,2-propenediyl; 1,2-butenediyl; 2,3-butenediyl; 1,2-pentenediyl;    2,3-pentenediyl; 1,2-hexenediyl; 2,3-hexenediyl; and 3,4-hexenediyl;-   (8) alkynediyl: is equal to —C═C—;-   (9) aryl: preferably selected from aromatics with a molecular weight    below 300 Da;-   (10)arylenes: preferably selected from the group comprising:    1,2-phenylene; 1,3-phenylene; 1,4-phenylene; 1,2-naphtthalenylene;    1,3-naphtthalenylene; 1,4-naphtthalenylene; 2,3-naphtthalenylene;    1-hydroxy-2,3-phenylene; 1-hydroxy-2,4-phenylene;    1-hydroxy-2,5-phenylene; 1-hydroxy-2,6-phenylene;-   (11) carboxylate: preferably the group —C(O)OR, where R is selected    from: hydrogen; C1-C6 alkyl; phenyl; C1-C6 alkyl-C6H5; Li; Na; K;    Cs; Mg; Ca;-   (12) carbonyl: preferably the group —C(O)R, where R is selected    from: hydrogen; C1-C6 alkyl; phenyl; C1-C6 alkyl-C6H5 and amine    (resulting in an amide) selected from the group: —NR′2, where each    R′ is selected independently from: hydrogen; C1-C6 alkyl; C1-C6    alkyl-C6H5 and phenyl, where, if both Rs represent C1-C6 alkyl they    can form an NC3 to NC5 heterocyclic ring with alkyl substituents of    the ring forming the other alkyl chain;-   (13) alkylsilyl: preferably the group —SiR1R2R3, where R1, R2 and R3    are selected independently of one another from: hydrogen; alkyl;    long-chain alkyl; phenyl; cycloalkyl; haloalkyl; alkoxy; long-chain    alkoxy;-   (14) alkylsilyloxy: preferably the group —O—SiR1R2R3, where R1, R2    and R3 are selected independently of one another from: hydrogen;    alkyl; long-chain alkyl; phenyl; cycloalkyl; haloalkyl; alkoxy;    long-chain alkoxy.

In certain embodiments, R1, R2 and/or R3 are a hydrogen residue or anunsubstituted, saturated, linear or branched hydrocarbon residue.

The chain length n of R2 and/or R3 can in particular have the values 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20.Preferably R2 and R3 have a length of the carbon chain of 1-10. In thiscase the chain length n can in particular have the values 1, 2, 3, 4, 5,6, 7, 8, 9, and 10. Preferably, R2 and R3 have a length of the carbonchain of 1-5 and in this case the chain length can in particular havethe values 1, 2, 3, 4 and 5. Particularly preferred is a chain length of1 or 2 for R2 and R3. Preferably, R2 and R3 are both alkyl residues inthe tertiary amides described below, preferably C1-C5 alkyl residues. Inparticularly preferred embodiments, R2 and/or R3 are selected from thegroup consisting of a hydrogen residue and an alkyl residue, preferablya methyl residue.

R4 preferably is oxygen.

In preferred embodiments, the carboxylic acid amide according to theinvention which is selected from primary carboxylic acid amides andsecondary carboxylic acid amides is a compound according to formula 1,wherein R3 is a hydrogen residue and wherein R4 is an oxygen residue.Preferably, R2 is selected from the group consisting of a hydrogenresidue and a C1-C5 alkyl residue, preferably a methyl residue.Furthermore, R1 preferably is selected from the group consisting of ahydrogen residue, a methyl residue, an ethyl residue and a propylresidue. Preferably, the primary carboxylic acid amide is selected fromthe group consisting of formamide, acetamide, propanamide andbutanamide. Preferably, the carboxylic acid amide is selected frombutanamide and formamide. More preferred, it is butanamide, inparticular for stabilizing the extracellular nucleic acid population. Asis shown by the examples, butanamide is a particularly effectivestabilizer and furthermore, non-toxic according to GHS classification.According to one embodiment, the primary carboxylic acid amide is notpropanamide.

According to one embodiment, the cell-containing biological sample iscontacted with at least one secondary carboxylic acid amide which isselected from the group consisting of N-alkylformamide, N-alkylacetamideand N-alkylpropanamide, and preferably is selected fromN-methylformamide, N-methylacetamide and N-methylpropanamide. As isshown in the examples, these compounds are all effective stabilizingagents.

The mixture that is obtained when contacting the cell-containingbiological sample with the at least one primary or secondary carboxylicacid amide or a mixture of respective compounds (and optionally furtheradditives such as preferably a caspase inhibitor) may comprise saidcompound (or mixture of such compounds) in a concentration of at least0.1%, at least 0.25%, at least 0.5%, at least 0.75%, at least 1%, atleast 1.25%, at least 1.5% or at least 2%. Suitable concentration rangesinclude but are not limited to 0.1% to 30%, 0.25% to 20%, 0.5% to 15%,0.7% to 10%, 0.8% to 7.5%, 0.9% to 6% and 1% to 5%. Concentrations orconcentration ranges indicated in percentage values as used herein arein particular given as percentage weight per volume (w/v) for solidcompounds, substances or compositions in a liquid composition, and aspercentage volume per volume (v/v) for liquid compounds, substances orcompositions in a liquid composition. As can be seen from the examples,the primary and secondary carboxylic acid amides are effectivestabilizers over a broad concentration range. Suitable concentrationsfor different compounds and/or for different sample types can also bedetermined by the skilled person using routine experiments, e.g. bytesting different concentrations in the test assays described in theexamples.

According to one embodiment, butanamide is used as carboxylic acid amideand the mixture that is obtained after contacting the cell-containingbiological sample with butanamide and optionally further additives maycomprise butanamide in a concentration of at least 0.1% (w/v), at least0.2% (w/v), at least 0.3% (w/v), at least 0.4% (w/v), at least 0.5%(w/v), at least 0.6% (w/v), at least 0.75% (w/v), at least 1% (w/v), atleast 1.25% (w/v), at least 1.5% (w/v), at least 1.75% (w/v), at least1.85% (w/v), at least 2% (w/v), at least 2.1% (w/v), at least 2.2%(w/v), at least 2.3% (w/v), at least 2.4% (w/v), at least 2.5% (w/v), atleast 2.6% (w/v), at least 2.7% (w/v), at least 2.8% (w/v), at least2.9% (w/v) or at least 3% (w/v). Butanamide is used in a concentration,wherein it exerts a stabilizing effect on the cell-containing biologicalsample, in particular the extracellular nucleic acid population that iscontained in the cell-free portion of the cell-containing sample. As isshown by the examples, butanamide is effective in variousconcentrations. Suitable concentrations of butanamide for differentsample types can also be determined by the skilled person using routineexperiments, e.g. by testing different concentrations of butanamide inthe test assays described in the examples. As is shown by the examples,the suitable concentration range for butanamide also depends on whetherone or more additional stabilizers are used in combination withbutanamide. E.g. lower concentrations of butanamide can be used if oneor more additional stabilizing additives as described herein, preferablyat least one caspase inhibitor and/or a tertiary amide according toformula 1 (see below), are used in combination with butanamide forstabilizing a cell-containing biological sample such as e.g. blood.Suitable concentration ranges for butanamide when mixed with thecell-containing biological sample and optionally further additives,include but are not limited to 0.1% (w/v) up to 15%, 0.25% (w/v) to 13%(w/v), 0.4% (w/v) to 12% (w/v), 0.5% (w/v) to 10% (w/v), 0.75% (w/v) to8% (w/v), 1% (w/v) to 7.5% (w/v), 1.25% (w/v) to 7% (w/v), 1.5% (w/v) to6.5% (w/v), 1.75% (w/v) to 6% (w/v), 1.8% (w/v) to 5.5% (w/v), 1.9%(w/v) to 5.25% (w/v), 2% (w/v) to 5% (w/v), 2.1% (w/v) to 4.75% (w/v),2.2% (w/v) to 4.5% (w/v), 2.3% (w/v) to 4.25% (w/v), 2.4% (w/v) to 4%(w/v), 2.5% (w/v) to 3.75% (w/v) or 2.5% (w/v) to 3.5% (w/v). Accordingto one embodiment, said mixture that is obtained after contacting thecell-containing biological sample with butanamide and optionally furtheradditives, comprises butanamide in a concentration that lies in therange of 0.5% (w/v) to 3.5% (w/v), preferably 0.75% (w/v) to 3.25% or0.9% (w/v) to 3% (w/v). Such concentrations are particularly suitablefor stabilizing blood samples. As is shown by the examples, usingbutanamide in a concentration that lies in these ranges provides anexcellent stabilizing effect on blood samples and furthermore, preventsthe hemolysis of the red blood cells contained in the blood sample. Alower butanamide concentration of 2% (w/v) is particularly effectivewhen additionally using a further stabilizing agent such as preferably acaspase inhibitor and/or a tertiary amide according to formula 1. As isshown by the examples, using a combination of these stabilizing agentsis particularly advantageous for stabilizing blood samples.

According to one embodiment, formamide is used as carboxylic acid amide.Formamide is particularly effective in stabilizing the transcriptome aswell as the extracellular nucleic acid population. The mixture that isobtained after contacting the cell-containing biological sample withformamide and optionally further additives may comprise formamide in aconcentration of at least 0.1% (v/v), at least 0.25% (v/v), at least0.5% (v/v), at least 0.75% (v/v), at least 1% (v/v), at least 1.25%(v/v), at least 1.5% (v/v) or at least 2% (v/v). Formamide is used in aconcentration, wherein it exerts a stabilizing effect on thecell-containing biological sample, in particular the extracellularnucleic acid population that is contained in the cell-free portion ofthe cell-containing sample and/or the transcriptome. As is shown by theexamples, formamide is effective in various concentrations. Suitableconcentrations of formamide for different sample types can also bedetermined by the skilled person using routine experiments, e.g. bytesting different concentrations of formamide in the test assaysdescribed in the examples. As is shown by the examples, the suitableconcentration range for formamide also depends on whether one or moreadditional stabilizers are used in combination with formamide. E.g.lower concentrations of formamide can be used if one or more additionalstabilizing additives as described herein, preferably at least onecaspase inhibitor, are used in combination with formamide forstabilizing a cell-containing biological sample such as e.g. blood.Suitable concentration ranges for formamide when mixed with thecell-containing biological sample and optionally further additives,include but are not limited to 0.25% (v/v) to 20% (v/v), 0.5% (v/v) to15% (v/v), 0.7% (v/v) to 10% (v/v), 0.8% (v/v) to 7.5% (v/v), 0.9% (v/v)to 6% (v/v) and 1% (v/v) to 5% (v/v). According to one embodiment, saidmixture that is obtained after contacting the cell-containing biologicalsample with formamide and optionally further additives, comprisesformamide in a concentration that lies in the range of 0.5% (v/v) to 15%(w/v), preferably 0.7% (v/v) to 10% (v/v). Such concentrations areparticularly suitable for stabilizing blood samples. As is shown by theexamples, using formamide in a concentration that lies in these rangesprovides an excellent stabilizing effect on blood samples. Forstabilizing the transcriptome, the concentration of formamide in theresulting mixture with the cell-containing sample is preferably at least2% (v/v), preferably at least 3% (v/v). As is shown by the examples, aconcentration of approx. 5% (v/v) is particularly effective. Thus,preferably, the concentration lies in a range of 2% (v/v) to 7.5% (v/v)for this purpose.

The term “extracellular nucleic acids” or “extracellular nucleic acid”as used herein, in particular refers to nucleic acids that are notcontained in cells. Respective extracellular nucleic acids are alsooften referred to as cell-free nucleic acids. These terms are used assynonyms herein. Hence, extracellular nucleic acids usually are presentexterior of a cell or exterior of a plurality of cells within a sample.The term “extracellular nucleic acids” refers e.g. to extracellular RNAas well as to extracellular DNA. Examples of typical extracellularnucleic acids that are found in the cell-free fraction (respectivelyportion) of biological samples such as body fluids such as e.g. bloodplasma include but are not limited to mammalian extracellular nucleicacids such as e.g. extracellular tumor-associated or tumor-derived DNAand/or RNA, other extracellular disease-related DNA and/or RNA,epigenetically modified DNA, fetal DNA and/or RNA, small interfering RNAsuch as e.g. miRNA and siRNA, and non-mammalian extracellular nucleicacids such as e.g. viral nucleic acids, pathogen nucleic acids releasedinto the extracellular nucleic acid population e.g. from prokaryotes(e.g. bacteria), viruses, eukaryotic parasites or fungi. Theextracellular nucleic acid population usually comprises certain amountsof intracellular nucleic acids that were released from damaged or dyingcells. E.g. the extracellular nucleic acid population present in bloodusually comprises intracellular globin mRNA that was released fromdamaged or dying cells. This is a natural process that occurs in vivo.Such intracellular nucleic acid present in the extracellular nucleicacid population can even serve the purpose of a control in a subsequentnucleic acid detection method. The stabilization method described hereinin particular reduces the risk that the amount of intracellular nucleicacids, such as genomic DNA, that is comprised in the extracellularnucleic acid population is significantly increased after thecell-containing sample was collected due to the ex vivo handling of thesample. Thus, alterations of the extracellular nucleic acid populationbecause of the ex vivo handling are reduced and can even be prevented.According to one embodiment, the extracellular nucleic acid is obtainedfrom respectively is comprised in a body fluid as cell-containingbiological sample such as e.g. blood, plasma, serum, saliva, urine,liquor, cerebrospinal fluid, sputum, lachrymal fluid, sweat, amniotic orlymphatic fluid. Herein, we refer to extracellular nucleic acids thatare obtained from circulating body fluids as circulating extracellularor circulating cell-free nucleic acids. According to one embodiment, theterm extracellular nucleic acid in particular refers to mammalianextracellular nucleic acids. Examples include, but are not limited todisease-associated or disease-derived extracellular nucleic acids suchas tumor-associated or tumor-derived extracellular nucleic acids,extracellular nucleic acids released due to inflammations or injuries,in particular traumata, extracellular nucleic acids related to and/orreleased due to other diseases, or extracellular nucleic acids derivedfrom a foetus. The term “extracellular nucleic acids” or “extracellularnucleic acid” as described herein also refers to extracellular nucleicacids obtained from other samples, in particular biological samplesother than body fluids. Usually, more than one extracellular nucleicacid is comprised in a sample. Usually, a sample comprises more than onekind or type of extracellular nucleic acids. The term “extracellularnucleic acid population” as used herein in particular refers to thecollective of different extracellular nucleic acids that are comprisedin a cell-containing sample. A cell-containing sample usually comprisesa characteristic and thus unique extracellular nucleic acid population.Thus, the type, kind and/or the amount of one or more extracellularnucleic acids comprised in the extracellular nucleic acid population ofa specific sample are important sample characteristics. As discussedabove, it is therefore important to stabilize and thus to substantiallypreserve said extracellular nucleic acid population as its compositionand/or the amount of one or more extracellular nucleic acids comprisedin the extracellular nucleic acid population of a sample, can providevaluable information in the medical, prognostic or diagnostic field.Therefore, it is advantageous if the profile of the extracellularnucleic acid population is efficiently stabilized. The stabilizationtechnologies described herein reduce contaminations and hence a dilutionof the extracellular nucleic acid population by intracellular nucleicacids, in particular by genomic DNA, after sample collection andstabilization. Thus, a substantial preservation of the extracellularnucleic acid population is achieved. As is shown by the examples,changes in the extracellular nucleic acid population with respect to thequantity, the quality and/or the composition of the comprisedextracellular nucleic acids, in particular changes attributable to anincrease of released genomic DNA, are over the stabilization periodconsiderably reduced compared to an unstabilized sample or acorresponding sample that is e.g. stabilized by EDTA in case of a bloodsample or a sample derived from blood. According to one embodiment theincrease in genomic DNA from T₀ (stabilization point) to the end of thestabilization period (preferably 48 h, 72 h or 96 h after T₀) is reducedby at least 60%, at least 70%, at least 75%, at least 80%, at least 85%,at least 90% or at least 95% compared to an unstabilized sample or acorresponding sample that is e.g. stabilized by EDTA in case of a bloodsample (e.g. 1.5 mg EDTA/ml stabilized blood sample) or a sample derivedfrom blood.

Furthermore, as described above, the method of the invention is alsosuitable for stabilizing intracellular nucleic acids, in particularintracellular RNA. Contacting the cell-containing sample with primaryand/or secondary carboxylic acid amides as described herein results inthat gene transcript levels of contained cells are stabilized. Thus, thegeneration of new transcripts and the degradation of existingtranscripts in the stabilized sample are inhibited compared to anunstabilized sample, thereby substantially “freezing” the genetranscription profile of contained cells upon stabilization. Therefore,the stabilization is also suitable for stabilizing the transcriptome bymaintaining transcript levels at the state they had shown at samplecollection and stabilization. The term transcriptome in particularrefers to the set of all RNA molecules, including mRNA, rRNA, tRNA andother non-coding RNA such as miRNA, produced in one or a population ofcells. As is demonstrated by the examples, cell-containing biologicalsamples such as blood samples could be stabilized for at least threedays and even longer without substantial changes of transcript levels.The gene transcription profile is in particular stabilized by reducingRNA degradation and minimizing alterations of the gene expression suchas in particular gene induction or down-regulation. Without being boundin theory, it is believed that primary and/or secondary carboxylic acidamides used herein for stabilization inhibit cellular processes wherebythe new synthesis of transcripts as well as the degradation of existingtranscripts is inhibited. It is believed that they enter the cell andare thus cell-permeable to achieve these effects. Thus, after collectionand stabilization of the cell-containing sample, the in vivo geneexpression profile existing at collection, respectively stabilization ispreserved. Furthermore, the quality and integrity of the RNA ismaintained, thereby providing an accurate representation of the in vivotranscript levels at the time of sample collection, respectively samplestabilization, and allowing to obtain a true and accurate transcriptlevel. The preservation of the in vivo gene transcription profile uponstabilization allows performing e.g. gene expression profiling or otheranalytical methods that require an accurate representation of thetranscript levels using respectively stabilized samples. However, eventhough desired, it is often not necessary that all transcript levels arestabilized or are stabilized equally well. The stabilization and thusperformance characteristics for a specific or new target transcriptshould be validated as is also usual with the prior art technologieswhich stabilize gene transcription profiles. That stabilization of thegene transcription profile or of specific transcript levels was achievedcan be determined e.g. based on marker genes that are established foranalyzing the stabilization of the gene transcription profile. Accordingto one embodiment, the stabilization of the gene transcription profileor the transcript level of contained cells achieved by the methodresults in that one or more, preferably two or more marker genesselected from c-fos, IL-1beta, IL-8 and p53 is/are stabilized for atleast 48 h upon stabilization. These marker genes were identified asproviding very unstable transcripts during storage and thus are in theabsence of appropriate stabilization up- or downregulated after samplecollection. Therefore, the transcript levels of these genes are suitableas marker to analyse whether a stabilization of the gene transcriptionlevel was achieved. The stabilization effect can be analysed using thereal time RT-PCR assays described in the examples. According to oneembodiment, the transcript levels of one or more of these marker genesis not altered by more than 1.5 CT values, preferably not more than1.25CT values, more preferred not more than 1CT value between T₀(stabilization point) and the end of the stabilization period.Preferably, a respective stabilization effect is achieved for at least48 h, at least 72 h or at least 96 h. Preferably, respectivestabilization characteristics are achieved at least with the markergenes c-fos, IL8 and IL-1beta and preferably with all of theaforementioned marker genes. As is shown by the examples, variousprimary and/or secondary carboxylic acid amides, in particularformamide, achieve a respective stabilization performance.

Furthermore, as the method according to the present invention is notbased on cell lysis, cells can be separated from the stabilized sampleafter the stabilization period and cells isolated from the stabilizedsample are suitable for analysis. E.g. as described above, intracellularnucleic acids such as RNA can be isolated from the comprised cells andcan be analyzed. Furthermore, the preservation of cells in thestabilized samples opens the possibility to sort or capture cells andeven to enrich specific cells such as e.g. tumor cells that can then beanalyzed specifically. E.g. circulating tumor cells can be isolated andtheir gene expression profile can be analyzed. Furthermore, the cellmorphology and/or cell markers in particular cell surface markers can beanalyzed in order to characterize the obtained cells. Furthermore,intracellular nucleic acids can be isolated from said enriched specificcells. E.g. RNA can be isolated from said cells. The transcript levelstabilizing properties of the stabilizing method described hereinadvantageously allows using the isolated RNA for gene expressionprofiling and other important analyses. The stabilisation methoddescribed herein is thus advantageous for example in the moleculardiagnostic of cancer or other diseases, because it allows an enrichmentof cells prior to the extraction of the nucleic acids from the enrichedcells and thereby increases e.g. the chance to detect rare events ofcirculating tumor cells in the cell-containing samples, for example in ablood sample. This also increases the chance that a specific biomarker,in particular a rare biomarker, is identified in the sample.

According to one embodiment, the cell-containing sample is a bloodsample and wherein white blood cells are stabilized. This allowsseparating white blood cells from the stabilized sample. White bloodcells are stabilized, if at least one type of the contained blood cellsis stabilized during the stabilization period which preferably, is atleast 48 h. According to one embodiment, lymphocytes and/or monocytescontained in the blood sample are stabilized. The stabilizationdescribed herein does not induce or promote the lysis of nucleated cellscontained in the cell-containing sample. Thus, stabilization is notbased on cell lysis. Preferably, when the cell containing sample isblood and the nucleic acid of interest is extracellular nucleic acid, inparticular extracellular RNA, the stabilization used herein preventshemolysis. Most causes of in vitro hemolysis are related to specimencollection. However, in vitro hemolysis usually also occurs in a bloodsample during ex vivo storage if no proper stabilization method is used.Depending on the extracellular nucleic acid of interest, hemolysis canbe a considerable problem. If the extracellular nucleic acid of interestis DNA, hemolysis is less of a problem because red blood cells do notcontain a nucleus and consequently, do not contain genomic DNA.Therefore, no intracellular DNA is released from the red blood cellsduring hemolysis. When the extracellular nucleic acid of interest isDNA, in particular the lysis or decay of white blood cells is a problembecause in this case genomic DNA is released in addition tointracellular RNA. Therefore, when the extracellular nucleic acid ofinterest is extracellular DNA, in particular the lysis of white bloodcells must be prevented. White blood cells may differ among each otherin their stability characteristics. Thus, some types of white bloodcells are more stable than others. However, generally, white blood cellsare significantly more stable than red blood cells. Therefore, the lysisof red blood cells does not necessarily indicate that white blood cellswere lysed. The different susceptibility of white blood cells and redblood cells to lysis is also used in the art to e.g. specifically lysered blood cells, while preserving white cells in order to allow e. g.the collection of white blood cells. However, if the extracellularnucleic acid of interest is RNA, hemolysis and thus the lysis of redblood cells does constitute a problem. Mature red blood cells also donot contain RNA, however, their precursors (reticulocytes) do.Reticulocytes make up approximately 0.5% to 1% of the red blood cellsand contain large amounts of globin RNA. Therefore, in particular whenthe extracellular nucleic acid of interest is RNA, a lysis of red bloodcells and thus reticulocytes during storage should be prevented/reducedin order to reduce a dilution of the extracellular nucleic acidpopulation, in particular the extracellular RNA population, with globinmRNA. Furthermore, as described above, it is important to maintain thecomposition and thus profile of the extracellular nucleic acidpopulation what is achieved using stabilization methods described hereinas this is important for many diagnostic applications. Hemolysis can beefficiently prevented/reduced when using the stabilization methodaccording to the present invention. Thereby, the extracellular nucleicacid population is substantially preserved and furthermore, thestabilized blood sample, in particular the plasma or serum obtained fromthe stabilized blood sample, is due to the prevention of hemolysis andcell lysis in general also suitable for other standard laboratoryanalyses. Furthermore, prevention of lysis of white blood cells allowsto isolate and analyse the respective cells. In particular, it allowsisolating intracellular nucleic acids such as intracellular RNA fromwhite blood cells or other preserved cells contained in the stabilizedsample.

According to one embodiment, the morphology of cells is preserved duringthe stabilization period which preferably is at least 48 h. This allowsanalyzing and optionally characterizing contained cells based on theirmorphology. According to one embodiment, the morphology of nucleatedcells is preserved. According to one embodiment, the morphology oflymphocytes contained in a blood sample is preserved duringstabilization.

According to one embodiment, cell surface epitopes of cells arepreserved. According to one embodiment, cell surface proteins such as CDproteins are preserved. The preservation of cell surface epitopes andcell surface proteins is an advantage as it allows characterizing and/orisolating contained cells based on these cell surface characteristics.In particular, it allows the analysis of tumor markers present on thecell surface or the isolation of specific cells based on said markers.

According to one embodiment, the stabilization method comprisescontacting a blood sample with a primary and/or secondary carboxylicacid amide and an anticoagulant, wherein transcript levels in containedcells are stabilized. Furthermore, as is shown in the examples, theextracellular nucleic acid population is additionally stabilized. Thisis advantageous, as it allows to analyse the extracellular nucleic acidspopulation separately from the intracellular nucleic acid populationfrom the same stabilized sample. According to one embodiment, formamideis used for that purpose. According to one embodiment, butanamide isused for stabilizing the extracellular nucleic acid population.

According to one embodiment, a combination of stabilizing agents is usedwhich comprises using at least one primary and/or secondary carboxylicacid amide and an apoptosis inhibitor. Already the apoptosis inhibitoralone is effective in stabilizing a cell-containing sample and tosubstantially preserve the extracellular nucleic acid population fromchanges in its composition in particular arising from contaminationswith fragmented genomic DNA. Thus, the stabilization effect that isobtained when additionally using an apoptosis inhibitor is enhanced. Thesample can be contacted with the apoptosis inhibitor, e.g. by adding theapoptosis inhibitor to the sample, or vice versa. Preferably, astabilization composition comprising at least one primary and/orsecondary carboxylic acid amide and an apoptosis inhibitor is used, inparticular for stabilizing the extracellular nucleic acid population.The at least one apoptosis inhibitor present in the resulting mixturesupports the stabilization of cells contained in the sample and inhibitsthe degradation of nucleic acids comprised in the sample therebycontributing to substantially preserving the extracellular nucleic acidpopulation.

The term “apoptosis inhibitor” as used herein in particular refers to acompound whose presence in a cell-containing biological sample providesa reduction, prevention and/or inhibition of apoptotic processes in thecells and/or makes the cells more resistant to apoptotic stimuli.Apoptosis inhibitors include but are not limited to proteins, peptidesor protein- or peptide-like molecules, organic and inorganic molecules.Apoptosis inhibitors include compounds that act as metabolic inhibitors,inhibitors of nucleic acid degradation respectively nucleic acidpathways, enzyme inhibitors, in particular caspase inhibitors, calpaininhibitors and inhibitors of other enzymes involved in apoptoticprocesses. Respective apoptosis inhibitors are listed in Table 1.Preferably, the at least one apoptosis inhibitor that is used forstabilizing the cell-containing biological sample is selected from thegroup consisting of metabolic inhibitors, caspase inhibitors and calpaininhibitors. Suitable examples for each class are listed in Table 1 inthe respective category. Preferably, the apoptosis inhibitor iscell-permeable.

It is also within the scope of the present invention to use acombination of different apoptosis inhibitors, either from the same or adifferent class of apoptosis inhibitors, respectively to use acombination of different apoptosis inhibitors which inhibit apoptosiseither by the same or a different working mechanism.

In an advantageous embodiment, the apoptosis inhibitor is a caspaseinhibitor. Members of the caspase gene family play a significant role inapoptosis. The substrate preferences or specificities of individualcaspases have been exploited for the development of peptides thatsuccessfully compete caspase binding. It is possible to generatereversible or irreversible inhibitors of caspase activation by couplingcaspase-specific peptides to e.g. aldehyde, nitrile or ketone compounds.E.g. fluoromethyl ketone (FMK) derivatized peptides such as Z-VAD-FMKact as effective irreversible inhibitors with no added cytotoxiceffects. Inhibitors synthesized with a benzyloxycarbonyl group (BOC) atthe N-terminus and O-methyl side chains exhibit enhanced cellularpermeability. Further suitable caspase inhibitors are synthesized with aphenoxy group at the C-terminus. An example is Q-VD-OPh which is a cellpermeable, irreversible broad-spectrum caspase inhibitor that is evenmore effective in preventing apoptosis than the caspase inhibitorZ-VAD-FMK.

According to one embodiment, the caspase inhibitor used in addition tothe at least one primary and/or secondary carboxylic acid amide is apancaspase inhibitor and thus is a broad spectrum caspase inhibitor.According to one embodiment, the caspase inhibitor comprises a modifiedcaspase-specific peptide. Preferably, said caspase-specific peptide ismodified by an aldehyde, nitrile or ketone compound. According to apreferred embodiment, the caspase specific peptide is modifiedpreferably at the carboxyl terminus with an 0-Phenoxy or a fluoromethylketone (FMK) group. According to one embodiment, the caspase inhibitoris selected from the group consisting of Q-VD-OPh and Z-VAD(OMe)-FMK. Inone embodiment, Z-VAD(OMe)-FMK, a pancaspase inhibitor, is used, whichis a competitive irreversible peptide inhibitor and blocks caspase-1family and caspase-3 family enzymes. In a preferred embodiment,Q-VD-OPh, which is a broad spectrum inhibitor for caspases, is used.Q-VD-OPh is cell permeable and inhibits cell death by apoptosis.Q-VD-OPh is not toxic to cells even at extremely high concentrations andconsists of a carboxy terminal phenoxy group conjugated to the aminoacids valine and aspartate. It is equally effective in preventingapoptosis mediated by the three major apoptotic pathways, caspase-9 andcaspase-3, caspase-8 and caspase-10, and caspase-12 (Caserta et al,2003). Further caspase inhibitors are listed in Table 1. According toone embodiment, the caspase inhibitor that is used as apoptosisinhibitor for stabilizing the cell-containing sample is one which actsupon one or more caspases located downstream in the intracellular celldeath pathway of the cell, such as caspase-3. In one embodiment thecaspase inhibitor is an inhibitor for one or more caspases selected fromthe group consisting of caspase-3, caspase-8, caspase-9, caspase-10 andcaspase-12. It is also within the scope of the present invention to usea combination of caspase inhibitors.

When using a caspase inhibitor in addition to the at least one primaryand/or secondary carboxylic acid amide, the mixture that is obtainedafter contacting the biological sample with the at least one apoptosisinhibitor may comprise the apoptosis inhibitor (or combination ofapoptosis inhibitors) in a concentration selected from the group of atleast 0.01 μM, at least 0.05 μM, at least 0.1 μM, at least 0.5 μM, atleast 1 μM, at least 2.5 μM or at least 3.5 μM. Of course, also higherconcentrations can be used. Suitable concentration ranges for theapoptosis inhibitor(s) when mixed with the cell-containing biologicalsample, include but are not limited to 0.01 μM to 100 μM, 0.05 μM to 100μM, 0.1 μM to 50 μM, 0.5 μM to 50 μM, 1 μM to 40 μM, more preferably 1μM to 30 μM or 2.5 μM to 25 μM. The higher concentrations were found tobe more effective, however, good stabilizing results were also achievedat lower concentrations. Hence, an efficient stabilization is alsoachieved at lower concentrations e.g. in a range selected from 0.1 μM to10 μM, 0.5 μM to 7.5 μM or 1 μM to 5 μM, in particular if the apoptosisinhibitor is used in combination. The above mentioned concentrationsapply to the use of a single apoptosis inhibitor as well as to the useof a combination of caspase inhibitors. If a combination of caspaseinhibitors is used, the concentration of an individual apoptosisinhibitor that is used in said mixture of apoptosis inhibitors may alsolie below the above mentioned concentrations, if the overallconcentration of the combination of apoptosis inhibitors fulfils theabove mentioned features. Using a lower concentration that stillefficiently stabilizes the cells and/or reduce the degradation ofnucleic acids in present in the sample has the advantage that the costsfor stabilisation can be lowered. Lower concentrations can be usedbecause the apoptosis inhibitor is used in combination with one or morestabilizers as described herein. The aforementioned concentrations arein particular suitable when using a caspase inhibitor, in particular amodified caspase specific peptide such as Q-VD-OPh and/or Z-VAD(OMe)-FMKas apoptosis inhibitor. The above mentioned concentrations are e.g. verysuitable for stabilizing whole blood, in particular 10 ml blood.Suitable concentration ranges for other apoptosis inhibitors and/or forother cell-containing biological samples can be determined by theskilled person using routine experiments, e.g. by testing the apoptosisinhibitors, respectively the different concentrations in the test assaysdescribed in the examples.

According to one embodiment, the apoptosis inhibitor will, in aneffective amount, decrease or reduce apoptosis in a cell-containingbiological sample by at least 25 percent, at least 30 percent, at least40 percent, at least 50 percent, preferably, by at least 75 percent,more preferably, by at least 85 percent as compared to a control samplewhich does not contain a respective apoptosis inhibitor.

Thus, according to one embodiment, a combination of stabilizing agentsis used which comprises at least one apoptosis inhibitor and at leastone primary and/or secondary carboxylic acid amide, preferably selectedfrom formamide and butanamide. A respective combination may alsocomprise additional additives that enhance the stabilizing effect suchas e.g. anticoagulants and chelating agents. According to oneembodiment, the combination of stabilizing agents comprises a caspaseinhibitor and an anticoagulant, preferably a chelating agent such asEDTA. Respective combinations can be advantageously used in a methodsuitable for stabilizing an extracellular nucleic acid populationcomprised in a cell-containing sample according to the first aspect. Thestabilizing effect observed with combinations of stabilizing agents isstronger than the effect observed for any of the individual stabilizingagents when used alone and/or allows using lower concentrations, therebymaking combinatorial use of stabilizing agents an attractive option.Suitable and preferred embodiments of the apoptosis inhibitor and the atleast one primary and/or secondary carboxylic acid amide, as well assuitable and preferred concentrations of the respective agents suitablefor achieving an efficient stabilization of the sample are described indetail above.

As discussed in the background of the invention, extracellular nucleicacids are usually not present “naked” in the sample but are e.g.stabilized to a certain extent by being released protected in complexesor by being contained in vesicles and the like. This has the effect thatextracellular nucleic acids are already to a certain extent stabilizedby nature and thus, are usually not degraded rapidly by nucleases incell-containing samples such as whole blood, plasma or serum. Thus, whenintending to stabilize extracellular nucleic acids that are comprised ina biological sample, one of the primary problems is the dilution,respectively the contamination of the extracellular nucleic acidpopulation by intracellular nucleic acids, in particular fragmentedgenomic DNA, that originates from damaged or dying cells that arecontained in the sample. This also poses a problem when processingcell-depleted samples such as plasma or serum (which are sometimes alsodescribes as being “cell-free” even though they may comprise minoramounts of cells). The stabilization technology according to the presentinvention is of particular advantage in this respect because it not onlysubstantially preserves the extracellular nucleic acids present in thesample and e.g. inhibits degradation of the comprised extracellularnucleic acids (preferably at least by 60%, at least by 70%, at least by75%, at least by 80%, at least by 85%, at least by 90% or mostpreferably at least by 95% over the stabilization period compared to anunstabilized sample or an EDTA stabilized sample) but furthermore,efficiently reduces the release of genomic DNA from cells contained inthe sample and/or reduces the fragmentation of respective genomic DNA.According to one embodiment, using at least one primary and/or secondarycarboxylic acid amide and optionally an apoptosis inhibitor forstabilizing the cell-containing sample according to the teachings of thepresent invention has the effect that the increase of DNA that resultsfrom a release of DNA from cells contained in the sample is reducedcompared to a non-stabilized sample. According to one embodiment, saidrelease of genomic DNA is reduced by at least 3-fold, at least 4-fold,at least 5-fold, at least 6-fold, at least 7-fold, at least 10-fold, atleast 12-fold, at least 15-fold, at least 17-fold or at least 20-foldover the stabilization period compared to the non-stabilized sample or acorresponding sample that is stabilized with EDTA (in particular in caseof a blood sample or a sample derived from blood such as plasma orserum). According to one embodiment, said release of genomic DNA isreduced by at least 60%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90% or at least 95% over the stabilization periodcompared to the non-stabilized sample or a corresponding sample that isstabilized with EDTA (in particular in case of a blood sample or asample derived from blood such as plasma or serum). The release of DNAcan be determined e.g. by quantifying the ribosomal 18S DNA as isdescribed herein in the example section. Thus, the extracellular nucleicacid population contained in the sample is considerably stabilizedcompared to samples stabilized in standard EDTA tubes. Thus, accordingto one embodiment, the stabilization effect that is achieved thecompound according to formula 1 as taught by the present invention,which may be used in combination with an apoptosis inhibitor, results inthat the release of DNA from cells contained in the sample is at leastreduced to a maximum of 10-fold, preferably 7-fold, more preferably5-fold and most preferably is at least reduced to a maximum of 4-fold,as is e.g. determinable in the 18S DNA assay described in the examples.As is shown by the examples, an effective stabilization of theextracellular nucleic acid population is achievable for a period of atleast up to 6 days. During a shorter storage of the samples, e.g. up tothree days, the DNA release can be reduced at least to a maximum oftwo-fold as e.g. determinable in the 18S DNA assay described in theexamples. Thus, the DNA release can be reduced to 2fold or less up tothree days of storage when using the stabilizing methods according tothe present invention. This is a remarkable improvement in thestabilization of the extracellular nucleic acid population compared tothe prior art methods. This significantly enhances the accuracy of anysubsequent tests. In certain cases, for example if the sample materialhas to be transported for long distances or stored for longer periodse.g. at room temperature (as can be e.g. the case in certain countries),the process according to the invention makes it possible for the firsttime for these tests to be carried out after such a period of time.However, of course, the samples may also be further processed earlier,if desired. It is not necessary to make use of the full achievablestabilization period. The stabilization that is achieved with thepresent invention reduces variations in the extracellular nucleic acidpopulation that may result from a different handling/processing of thesamples (e.g. storage conditions and periods) after they were collected.This greatly improves the standardization of handling and molecularanalysis.

Further additives may be used in addition to the at least one primaryand/or secondary carboxylic acid amide in order to further stabilize thecell-containing sample. They may be used in addition to or asalternative to the apoptosis inhibitor. The selection of suitableadditives that may also contribute to the stabilization effect may alsodepend on the type of cell-containing sample to be stabilized. E.g. whenprocessing whole blood as cell-containing biological sample, it isadvantageous and also common to include an anticoagulant e.g. selectedfrom the group consisting of heparin, ethylenediamine tetraacetic acid,citrate, oxalate, and any combination thereof. In an advantageousembodiment, the anticoagulant is a chelating agent. A chelating agent isan organic compound that is capable of forming coordinate bonds withmetals through two or more atoms of the organic compound. Chelatingagents according to the present invention include, but are not limitedto diethylenetriaminepentaacetic acid (DTPA),ethylenedinitrilotetraacetic acid (EDTA), ethylene glycol tetraaceticacid (EGTA) and N,N-bis(carboxymethyl)glycine (NTA). According to apreferred embodiment, EDTA is used. As used herein, the term “EDTA”indicates inter alia the EDTA portion of an EDTA compound such as, forexample, K₂EDTA, K₃EDTA or Na₂EDTA. Using a chelating agent such as EDTAalso has the advantageous effect that nucleases such as DNases areinhibited, thereby e.g. preventing a degradation of extracellular DNA byDNases. Furthermore, it was found that EDTA used/added in higherconcentrations is capable of reducing the release of intracellularnucleic acids, in particular genomic DNA, from the cells therebysupporting the stabilizing effect that is achieved by the at least onecompound according to formula 1. However, EDTA alone is not capable ofefficiently inhibiting the fragmentation of e.g. genomic DNA that isreleased from the cells contained in the sample. Thus, EDTA does notachieve a sufficient stabilization effect. But used in combination withthe teachings of the present invention, in particular in combinationwith the apoptosis inhibitor, in particular the caspase inhibitor, itcan further improve the stabilization for the above discussed reasons.Furthermore, it also appears to increase the chemical stability of RNA.According to one embodiment, the concentration of the chelating agent,preferably EDTA, in the biological sample that is mixed with one or moreof the stabilizing compounds described above is in the range selectedfrom the group consisting of 0.05 mM to 100 mM, 0.05 mM to 50 mM, 0.1 mMto 30 mM, 1 mM to 20 mM and 2 mM to 15 mM after the contacting step.Respective concentrations are particularly effective when stabilisingblood, plasma and/or serum samples, in particular 10 ml blood samples.

Additional additives can also be used in order to further support thestabilization of the cell-containing sample, respectively support thepreservation of the extracellular nucleic acid population. Examples ofrespective additives include but are not limited to nuclease inhibitors,in particular RNase and DNase inhibiting compounds. Examples of RNaseinhibitors include but are not limited to anti-nuclease antibodies orribonucleoside-vanadyl-complexes. When choosing a respective furtheradditive, care should be taken not to compromise and/or counteract thestabilizing effect of the at least one primary and/or secondarycarboxylic acid amide used as stabilizing agent. Thus, no additivesshould be used in concentrations that result in or support the lysisand/or degradation of the cells contained in the biological sampleand/or which support the degradation of the nucleic acids contained inthe cell-free fraction of the biological sample. Thus, no chaotropicsalts should be used. Furthermore, also no additives should be used inconcentration which counteract and overrule the transcriptomestabilizing effect of the at least one primary and/or secondarycarboxylic acid amide that is used for stabilization.

According to one embodiment, the cell-containing sample is additionallycontacted with at least one tertiary amide which is a compound accordingto formula 1

wherein R1 is a hydrogen residue or an alkyl residue, wherein R2 and R3are identical or different hydrocarbon residues with a length of thecarbon chain of 1-20 atoms arranged in a linear or branched manner, andwherein R4 is an oxygen, sulphur or selenium residue, preferably R4 isoxygen.

R1 and R2 have the same meaning as R1 and R2 in the formula 1 describingthe primary and secondary carboxylic acid amides (see above).Furthermore, in the tertiary amides, R3 may have the same meaning andthus is a hydrocarbon residue with a length of the carbon chain of 1-20atoms arranged in a linear or branched manner. Suitable and preferredembodiments described for R2 also apply for R3 in the tertiary amides.

According to one embodiment, the tertiary amide according to formula 1is a carboxylic acid amide. According to one embodiment, the tertiaryamide according to formula 1 is a N,N-dialkylpropanamide, preferablyN,N-dimethylpropanamide. According to one embodiment, the tertiary amideaccording to formula 1 is selected from the group consisting ofN,N-dimethylformamide, N, N-dimethylacetamide, N, N-dimethylpropanamide,N, N-dimethylbutanamide.

According to one embodiment, after the cell-containing biological samplehas been contacted with at least one primary or secondary carboxylicacid amide and a tertiary amide according to formula 1 and optionallyfurther additives used for stabilization, the resulting mixturecomprises the tertiary amide according to formula 1

-   -   i) in a concentration of at least 0.1%, at least 0.25%, at least        0.5%, at least 0.75%, at least 1%, at least 1.25% or at least        1.5%; and/or    -   ii) in a concentration that lies in the range of 0.1% to 30%,        0.25% to 20%, 0.5% to 15%, 0.7% to 10%, 0.8% to 7.5%, 0.9% to 6%        or 1% to 5%.

According to one embodiment, the cell-containing biological sample to bestabilized is additionally contacted with at least one poly(oxyethylene)polymer as stabilizing agent. The term poly(oxyethylene) polymer inparticular refers to an an oligomer or polymer of ethylene oxide. Itcomprises at least two ethylene oxide units. Poly(oxyethylene) polymersare known in low and high molecular weights. According to oneembodiment, the molecular weight lies in a range of 200 to 20000 Da. Thepoly(oxyethylene) polymer may be linear or branched or may have othergeometries. A linear poly(oxyethylene) polymer is preferred. Thepoly(oxyethylene) polymer may be unsubstituted or substituted andpreferably is a polyethylene glycol. The polyethylene glycol preferablyis unbranched and may be unsubstituted or substituted. Known substitutedforms of polyethylene glycol include alkylpolyethylene glycols that aree.g. substituted at one or both ends with a C1-05 alkyl group.Preferably, unsubstituted polyethylene glycol of the formulaHO—(CH₂CH₂O)_(n)—H is used. All disclosures described in thisapplication for the poly(oxyethylene) polymer in general, specificallyapply and particularly refer to the preferred embodiment polyethyleneglycol even if not explicitly stated. The poly(oxyethylene) polymer canbe used in various molecular weights. Preferably, the term polyethyleneglycol refers to oligomers or polymers as is also evident from themolecular weights specified herein as suitable and preferred for thepoly(oxyethylene) polymer which specifically also apply to the preferredembodiment polyethylene glycol. The additional use of apoly(oxyethylene) polymer such as polyethylene glycol is advantageous asit was found that such polymers, in particular polyethylene glycol,stabilize cells and therefore can be used to support the stabilizationeffect on the cell-containing sample which preferably is a blood sample.

The stabilization methods as disclosed herein, provide a significantadvantage over state-of-the-art stabilization methods that are based onthe use of cross-linking reagents, such as formaldehyde, formaldehydereleasers and the like. Crosslinking reagents cause inter- orintra-molecular covalent bonds between nucleic acid molecules or betweennucleic acids and proteins. This cross-linking effect can hamper thesubsequent isolation of nucleic acids from such stabilized samples. As,for example, the concentration of circulating nucleic acids in a wholeblood sample is already relatively low, any measure which furtherreduces the yield of such nucleic acids should be avoided. This may beof particular importance when detecting and analyzing very rare nucleicacid molecules derived e.g. from malignant tumors or from a developingfetus in the first trimester of pregnancy. As is shown by the examples,the method of the invention does not require cross-linking agents forstabilization. Therefore, according to one embodiment, the stabilizationmethod according to the present invention does not involve the use of across-linking agent that induces protein-nucleic acid and/orprotein-protein crosslinks. In particular, the stabilization does notinvolve the use of formaldehyde, formaline, paraformaldehyde or aformaldehyde releaser. Furthermore, the stabilization method accordingto the invention does not involve the use of additives that result in alysis of nucleated cells.

In an advantageous embodiment of the present invention, thecell-containing biological sample, which preferably is a blood sample ora sample derived from blood such as plasma or serum, is contacted with:

-   a) at least one primary and/or secondary carboxylic acid amide,    preferably formamide or butanamide (preferred concentrations are    described above), and-   b) at least one caspase inhibitor, preferably with Q-VD-OPh,    preferably in a concentration range of 1 μM to 30 μM; and-   c) a further additive, preferably a chelating agent preferably in a    concentration range of 2 mM to 100 mM or 4 mM to 50 mM, preferably 4    mM to 20 mM, most preferably EDTA.

The components of the stabilizing composition can be comprised,respectively dissolved in a buffer, e.g. a biological buffer such asMOPS, TRIS, PBS and the like. Furthermore, they can be dissolved inwater or any other suitable solvent. According to one embodiment, thestabilizing composition comprises a solvent such as DMSO.

The at least one primary and/or secondary carboxylic acid amide as wellas the optionally present further additives can be e.g. present in adevice, preferably a container, for collecting the sample or can beadded to a respective collection device immediately prior to collectionof the biological sample; or can be added to the collection deviceimmediately after the sample was collected therein. Suitable andpreferred primary and secondary carboxylic acid amides were describedabove and it is referred to the above disclosure which also applieshere. According to one embodiment, formamide or butanamide is used forstabilization. It is also within the scope of the present invention toadd the stabilizing agent(s) and optionally, the further additive(s)separately to the cell containing biological sample. However, for theease of handling, it is preferred that the one or more stabilizingagents and optionally the further additives are provided in therespective collection device, e.g. in form of one composition. However,they may also be present as separate components or compositions in thecollection device. Furthermore, in an advantageous embodiment, the atleast one primary and/or secondary carboxylic acid amide and optionallythe further additive(s) are present in the collection device prior toadding the sample. This ensures that the cell-containing biologicalsample is immediately stabilized upon contact with the stabilizingagent(s). The stabilisation agent(s) are present in the container in anamount effective to provide the stabilisation of the amount of cellcontaining sample to be collected, respectively comprised in saidcontainer. As described, the sample can be mixed with the stabilizationagent(s) directly after and/or during collection of the sample therebyproviding a stabilized sample. According to one embodiment, thestabilization involves the use of at least one poly(oxyethylene)polymer, preferably polyethylene glycol in order to support thestabilization of the cells.

Preferably, the sample is mixed with the stabilization agent(s) directlyafter and/or during the collection of the sample. Therefore, preferably,the stabilization agent(s) and additives described above are provided inform of a stabilizing composition. Preferably, said stabilizingcomposition is provided in liquid form. It can be e.g. pre-filled in thesample collection device so that the sample is immediately stabilizedduring collection. According to one embodiment, the stabilizingcomposition is contacted with the cell-containing sample in a volumetricratio selected from 10:1 to 1:20, 5:1 to 1:15, 1:1 to 1:10 and 1:2 to1:5. It is a particular advantage of the teachings of the presentinvention that stabilization of a large sample volume can be achievedwith a small volume of the stabilizing composition. Therefore,preferably, the ratio of stabilizing composition to sample lies in arange from 1:2 to 1:7, more preferred 1:3 to 1:5.

The term “cell-containing sample” as used herein, in particular refersto a sample which comprises at least one cell. The cell-containingsample may comprise at least two, at least 10, at least 50, at least100, at least 250, at least 500, at least 1000, at least 1500, at least2000 or at least 5000 cells. Furthermore, also cell-containing samplescomprising considerably more cells are encompassed by said term and canbe stabilized with the teachings according to the present invention.However, the term “cell-containing sample” also refers to and thusencompasses cell-depleted samples, including cell-depleted samples thatare commonly referred to as “cell-free” such as e.g. blood plasma asrespective samples often include residual cells. At least, it can oftennot be fully excluded that even so-called “cell-free” samples such asblood plasma comprise residual amounts of cells which accordingly, posea risk that the extracellular nucleic acid population becomescontaminated with intracellular nucleic acids released from saidresidual cells. Therefore, respective cell-depleted and “cell-free”samples are according to one embodiment also encompassed by the term“cell-containing sample”. Thus, the “cell-containing sample” maycomprise large amounts of cells, as is the case e.g. with whole blood,but may also only comprise merely minor amounts of cells. Hence, theterm “cell containing sample” also encompasses samples that may only besuspected of or pose a risk of containing cells. As discussed above,also with respect to biological samples which only comprise minor,respectively residual amounts of cells such as e.g. blood plasma (bloodplasma contains—depending on the preparation method—usually smallresidual amounts of cells, even though it is commonly referred to asbeing cell-free), the method according to the present invention hasconsiderable advantages as these residual cells may also result in aundesired contamination of the comprised extracellular nucleic acids.Using the stabilizing technology of the present invention also ensuresthat respective samples which only comprise residual amounts of cells orare merely suspected of or pose a risk of residual amounts of cells, areefficiently stabilized as is also described in detail above. Accordingto one embodiment, the cellular portion makes up at least 1%, at least2%, at least 2.5%, at least 5%, preferably at least 10%, at least 15%,at least 20%, more preferably at least 25%, at least 30%, at least 35%or at least 40% of the cell-containing biological sample.Cell-containing samples wherein the cellular fraction makes up more than40% can also be stabilized using teachings described herein. Using thestabilizing method according to the present invention has the advantagethat irrespective of the composition of the sample and the number ofcells contained therein, the extracellular nucleic acid populationcontained therein is substantially preserved, respectively stabilized,thereby allowing for standardizing the subsequent isolation and/oranalysis of the contained extracellular nucleic acids.

According to one embodiment, the cell-containing biological sample isselected from the group consisting of whole blood, samples derived fromblood, plasma, serum, sputum, lachrymal fluid, lymphatic fluid, urine,sweat, liquor, cerebrospinal fluid, ascites, milk, stool, bronchiallavage, saliva, amniotic fluid, nasal secretions, vaginal secretions,semen/seminal fluid, wound secretions, and cell culture supernatants andsupernatants obtained from other swab samples. According to oneembodiment, the cell-containing biological sample is a body fluid, abody secretion or body excretion, preferably a body fluid, mostpreferably whole blood, plasma or serum. The cell-containing biologicalsample comprises extracellular nucleic acids. According to anotherembodiment, the cell-containing biological sample is a non-fluid samplederived from a human or animal, such as e.g. stool, tissue or a biopsysample. Other examples of cell-containing biological samples that can bestabilized with the method according to the present invention includebut are not limited to biological samples cell suspensions, cellcultures, supernatant of cell cultures and the like, which compriseextracellular nucleic acids.

As is described above and as is demonstrated by the examples, using themethods of the present invention allows for stabilizing thecell-containing sample without refrigeration or freezing for a prolongedperiod of time period. Thus, the samples can be kept at room temperatureor even at elevated temperatures e.g. up to 30° C. or up to 40° C.According to one embodiment, a stabilization effect is achieved for atleast two days, preferably at least three days; more preferred at leastone day to six days, most preferred for at least one day to at leastseven days at room temperature. As is shown in the examples, the samplesthat were stabilized according to the method of the present inventionwere not substantially compromised when stored for 3 days at roomtemperature. Even during longer storages for up to 6 or even 7 days atroom temperature the extracellular nucleic acid population wassubstantially more stabilized compared to non-stabilized samples or e.g.compared to samples that were stabilized using standard method such asan EDTA treatment. Even though the stabilization effect may decreaseover time, it is still sufficient to preserve the composition of theextracellular nucleic acid population to allow the analysis and/orfurther processing. Thus, samples that were stabilized according to themethods of the present invention were still suitable for isolating andoptionally analyzing the extracellular nucleic acids contained thereineven after longer storage at room temperature. Furthermore, thetranscriptome was efficiently stabilized. Thus, as the samples were notcompromised in particular when using the preferred combination ofstabilisation agents, even longer storage/shipping times areconceivable. However, usually, longer periods are not necessary, as theregular storage and e.g. shipping time to the laboratory, wherein thenucleic acid isolation and optionally analysis is performed, usuallydoes not exceed 6 or 7 days, but usually is even completed after two orthree days. As is shown in the examples, the stabilisation efficiency isparticularly good during this time period. However, the extraordinarylong stabilisation times and stabilisation efficiencies that areachievable with the method according to the present invention providesan important safety factor.

The methods and also the subsequently described compositions accordingto the present invention allow the stabilization also of large volumesof biological samples with small volumes of added substances because theadditives that are used according to the teachings of the presentinvention are highly active. This is an important advantage because thesize/volume of the sample poses considerable restrains on the subsequentisolation procedure in particular when intending to use automatedprocesses for isolating the extracellular nucleic acids contained in thesamples. Furthermore, one has to consider that extracellular nucleicacids are often only comprised in small amounts in the contained sample.Thus, processing larger volumes of a cell-containing sample such as e.g.a blood sample has the advantage that more circulating nucleic acids canbe isolated from the sample and thus are available for a subsequentanalysis.

The stabilization of the biological sample may either be followeddirectly by techniques for analysing nucleic acids, or the nucleic acidsmay be purified from the sample. Hence, the sample that was stabilizedaccording to the method of the present invention can be analysed in anucleic acid analytic and/or detection method and or may be furtherprocessed. E.g. extracellular nucleic acid can be isolated from thestabilized sample and can then be analysed in a nucleic acid analyticand/or detection method or may be further processed. Furthermore, cellscan be removed from the stabilized sample and analysed and/or nucleicacids can be isolated from the obtained cells. Details regarding thenucleic acid isolation and analysis are described below in conjunctionwith the second aspect of the present invention and it is referred tosaid disclosure. As described, one important advantage of thestabilizing method according to the invention lies in that thesubsequent isolation of nucleic acids is not hampered due to thestabilization as is, e.g., the case when using a cross-linking agentsuch as a formaldehyde releaser for stabilization. Furthermore, thecells can be analysed for their morphology or cell surfacecharacteristics. This allows e.g. to identify tumor cells. According toone embodiment, intracellular RNA is isolated from the cells containedin the stabilized sample and analysed. According to one embodiment, themethod comprises performing a qualitative or quantitative analysis ofone or more gene transcripts.

Method for Isolating Nucleic Acids

Furthermore, according to a second aspect, a method for isolatingnucleic acids from a biological sample is provided comprising the stepsof:

-   -   a) stabilizing a cell-containing sample according to the method        according to the first aspect;    -   b) isolating nucleic acids from the stabilized sample.

According to one embodiment, said method comprises

-   -   a) stabilizing a cell-containing sample according to the method        according to the first aspect;    -   b) isolating intracellular nucleic acids from the stabilized        sample.

According to one embodiment, said method is for isolating extracellularnucleic acids from a cell-containing biological sample, wherein saidmethod comprises the steps of:

-   -   a) stabilizing the extracellular nucleic acid population        comprised in a cell-containing sample according to the method        defined in the first aspect of the present invention;    -   b) isolating extracellular nucleic acids.

As discussed above, the stabilization according to the present inventionhas the effect that the extracellular nucleic acid population containedin the sample is substantially preserved in the state it had shown atthe time the biological sample was obtained, respectively drawn. Inparticular, the usually observed high increase in nucleic acids thatresults from intracellular nucleic acids, in particular genomic DNA,more specifically fragmented genomic DNA, released from damaged or dyingcells is efficiently reduced as is demonstrated in the examples.Therefore, the extracellular nucleic acids obtained from a respectivelystabilized sample comprise fewer contaminations with intracellularnucleic acids originating from degraded or dying cells comprised in thesample and in particular comprise less amounts of fragmented genomic DNAcompared to non-stabilized samples. Furthermore, the uniquestabilization step allows to increase the amount of recoverableextracellular nucleic acids. The stabilization method according to thepresent invention can be performed without the crosslinking of thesample. This is an important advantage over the use of cross-linkingagents such as formaldehyde or formaldehyde releasers, as these reagentsmight reduce the recoverable amount of extracellular nucleic acids dueto cross-linking. Thus, the method according to the present inventionimproves the diagnostic and prognostic capability of the extracellularnucleic acids. Furthermore, said stabilization allows the sample to bestored and/or handled, e.g. transported,—even at room temperature—for aprolonged period of time prior to separating the cells contained in thesample and/or prior to isolating the extracellular nucleic acidscomprised therein in step b). With respect to the details of thestabilization that is performed in step a), it is referred to the abovedisclosure which also applies here.

According to one embodiment, the cell-containing biological sample suchas e.g. a whole blood sample is stabilized in step a) as is described indetail above using at least one primary or secondary carboxylic acidamide, and optionally, further additives. Suitable and preferredembodiments were described above. Particularly preferred is theadditional use of a caspase inhibitor in combination with ananticoagulant, preferably a chelating agent as described above, forstabilizing whole blood samples.

If the sample comprises large amounts of cells as is e.g. the case withwhole blood, the cells are separated from the remaining sample in orderto obtain a cell-free, respectively cell-reduced or cell-depletedfraction of the sample which comprises the extracellular nucleic acids.Thus, according to one embodiment, cells are removed from thecell-containing sample between step a) and step b). This intermediatestep is only optional and e.g. may be obsolete if samples are processedwhich merely comprise minor amounts of residual cells such as e.g.plasma or serum and/or wherein the extracellular nucleic acid ofinterest is DNA. Due to the stabilization of the invention, the releaseof genomic DNA during the stabilization period from the contained cellsis reduced or even prevented and furthermore, in particular when using acaspase inhibitor in addition to butanamide, the fragmentation ofgenomic DNA is reduced. As described herein due to its considerablylarger size, unfragmented genomic DNA can be distinguished from thesmaller extracellular DNA. This allows to selectively isolateextracellular DNA even in the presence of unfragmented genomic DNA byusing a size selective isolation protocol. However, in order improve theresults, it is preferred that cells (or potentially remaining cells) areremoved from the stabilized sample prior to isolating the extracellularnucleic acids in step b) in order to reduce contaminations of theextracellular nucleic acid population with intracellular nucleic acidsthat would otherwise be released from the cells during nucleic acidisolation. To remove the contained cells is in particular advantageousif the extracellular nucleic acids of interest are RNA, because it canbe difficult to distinguish intracellular RNA from extracellular RNA andfurthermore, a dilution of the extracellular RNA can thereby beprevented. However, a cell removal step prior to step b) is generallyadvantageous and thus preferred, also if the extracellular nucleic acidof interest is DNA, because this allows to use standard nucleic acidisolation procedures in step b). Depending on the type ofcell-containing biological sample, cells, including residual cells, canbe separated and removed e.g. by centrifugation, preferably high speedcentrifugation, or by using means other than centrifugation, such ase.g. filtration, sedimentation or binding to surfaces e.g. on(optionally magnetic) particles if a centrifugation step is to beavoided. Respective cell separation methods are well-known in the priorart and thus, do not need to be described in detail. Respective cellremoval steps can also be easily included into an automated samplepreparation protocol. Respectively removed cells may also be processedfurther if desired. The cells can e.g. be stored, analysed and/orbiomolecules such as e.g. nucleic acids or proteins can be isolated fromthe removed cells. Furthermore, it was found that intracellular nucleicacids such as intracellular RNA can be stabilized using the methodsdescribed herein (see above). The additional stabilization of thetranscriptome is advantageous as it allows e.g. to analyse profiles oftranscripts in the isolated intracellular nucleic acids which can alsobe important biomarkers for in vitro diagnostics.

Furthermore, it is also within the scope of the present invention toinclude further intermediate steps to work up the sample.

Extracellular nucleic acids are then isolated in step b), e.g. from thecell-free, respectively cell-depleted fraction, e.g. from supernatants,plasma and/or serum. For isolating extracellular nucleic acids, anyknown nucleic acid isolation method can be used that is suitable forisolating nucleic acids from the respective sample, respectively thecell-depleted sample. Examples for respective purification methodsinclude but are not limited to extraction, solid-phase extraction,silica-based purification, magnetic particle-based purification,phenol-chloroform extraction, chromatography, anion-exchangechromatography (using anion-exchange surfaces), electrophoresis,filtration, precipitation, chromatin immunoprecipitation andcombinations thereof. It is also within the scope of the presentinvention to specifically isolate specific target extracellular nucleicacids, e.g. by using appropriate probes that enable a sequence specificbinding and are coupled to a solid support. Also any other nucleic acidisolating technique known by the skilled person can be used. Accordingto one embodiment, the nucleic acids are isolated using a chaotropicagent and/or alcohol. Preferably, the nucleic acids are isolated bybinding them to a solid phase, preferably a solid phase comprisingsilica or anion exchange functional groups. Suitable methods and kitsare also commercially available such as the QIAamp® Circulating NucleicAcid Kit (QIAGEN), the Chemagic Circulating NA Kit (Chemagen), theNucleoSpin Plasma XS Kit (Macherey-Nagel), the Plasma/Serum CirculatingDNA Purification Kit (Norgen Biotek), the Plasma/Serum Circulating RNAPurification Kit (Norgen Biotek), the High Pure Viral Nucleic Acid LargeVolume Kit (Roche) and other commercially available kits suitable forextracting and purifying circulating nucleic acids.

According to one embodiment, total nucleic acids comprised in the samplethat is obtained after step a) or optionally obtained after the cellshave been removed in the intermediate step are isolated, e.g. areisolated from the, or a cell-free, respectively cell-depleted fraction.E.g. total nucleic acids can be isolated from plasma or serum and theextracellular nucleic acids will be comprised as a portion in theseextracted nucleic acids. If the cells are efficiently removed, the totalnucleic acids isolated will predominantly comprise or even consist ofextracellular nucleic acids.

It is also within the scope of the present invention to isolate at leastpredominantly a specific target nucleic acid. A target nucleic acid canbe e.g. a certain type of extracellular nucleic acid, e.g. DNA or RNA,including mRNA, microRNA, other non-coding nucleic acids, epigeneticallymodified nucleic acids, and other nucleic acids. E.g. the targetextracellular nucleic acid can be DNA and the non-target extracellularnucleic acid can be RNA or vice versa. Target specific nucleic acidisolation methods which specifically aim at isolating DNA or RNA arealso well known in the prior art and thus, do not need any detaileddescription herein. According to one embodiment, the non-target nucleicacid is destroyed by adding an appropriate enzyme which specificallydestroys the non-target nucleic acid, e.g. a RNase if the target nucleicacid is DNA or a DNase if the target nucleic acid is RNA. Said enzymecan be added to the lysis or binding mixture or can be added afterextracellular nucleic acids were bound to a solid phase. Suitableembodiments for performing a respective non-target nucleic aciddigestion step are known in the prior art and thus, do not need anyfurther description herein. According to one embodiment which isfeasible if DNA and RNA are bound to a solid support, elution conditionsselective for the target nucleic acid can be applied to predominantlyand thus selectively recover the target nucleic acid from the solidsupport. According to one embodiment, an isolation method is used,wherein the target nucleic acid, e.g. DNA, is selectively bound to asolid phase under conditions wherein non-target nucleic acids, e.g. RNAdo not bind. Suitable binding conditions are well-known in the prior artand are e.g. described in WO 95/21849. According to one embodiment, thenon-target nucleic acid is removed by binding at least a portion of thenon-target nucleic acid under appropriate conditions to a solid phaseand then separating the non-target nucleic acid bound to the solid phasefrom the remaining sample comprising the target extracellular nucleicacid. This can be achieved e.g. by the addition of a suitable solidphase under conditions wherein mainly the non-target nucleic acids e. g.DNA are bound to the solid phase while the non-target nucleic acid, e.g.RNA, remains in the sample and is recovered therefrom in a separatestep. Suitable methods for selectively removing a non-target nucleicacid from a target nucleic acid are for example described in EP 0 880537 and WO 95/21849, herein incorporated by reference. If desired, saidnon-target nucleic acid may also be further used, e.g. further processedsuch as e.g. eluted from the solid phase. However, it may also bediscarded. It is also within the scope of the present invention to e.g.digest the non-target nucleic acid or remainders thereof using nucleasesafter isolation of the target nucleic acid.

The term target nucleic acid may also refer to a specific kind ofnucleic acid, e.g. a specific extracellular nucleic acid that is knownto be a certain disease marker. As discussed above, the isolation ofextracellular nucleic acids may also comprise the specific isolation ofa respective target nucleic acid e.g. by using appropriate captureprobes which support the selective isolation of the target nucleic acid.

The term target nucleic acid may also refer to nucleic acids having acertain length, e.g. a nucleic acid having a length of 5000 nt or less,2000 nt or less, 1000 nt or less, 900 nt or less, 800 nt or less, 700 ntor less, 600 nt or less, 500 nt or less, 400 nt or less or 350 nt orless. Isolating target nucleic acids of a certain maximum size can beadvantageous in the context of the present invention. It is known thatextracellular nucleic acids usually have a size of less than 2000 nt,less than 1000 nt and often even less than 500 nt. The sizes,respectively size ranges indicated herein refer to the chain length.I.e. in case of double-stranded nucleic acids such as double-strandedDNA it refers to bp. Selectively isolating smaller nucleic acids in stepb) can increase the portion of extracellular nucleic acids obtained inthe isolated nucleic acids. The stabilization methods according to thepresent invention allow, in particular due to the inhibition of therelease of genomic DNA and/or the inhibition of the fragmentation ofreleased genomic DNA, for a more efficient separation of such highmolecular weight genomic DNA from the smaller extracellular nucleic acidpopulation. As the substantial size difference between genomic DNA andextracellular nucleic acids is essentially preserved using thestabilization technology according to the present invention, genomic DNAcan be removed more efficiently e.g. using a size selective nucleic acidisolation protocol. As the size difference between genomic DNA (usuallylarger than >10,000 bp) and extracellular nucleic acids (usually <1000nt/bp) in a sample stabilized as described herein is usually relativelylarge due to the efficient stabilization, known methods for selectivelyisolating nucleic acids of a certain target length can be used. Thus,according to one embodiment, step b) comprises selectively isolatingtarget nucleic acids having a length of 5000 nt or less, 2000 nt orless, 1500 nt or less, 1000 nt or less, 900 nt or less, 800 nt or less,700 nt or less, 600 nt or less or 500 nt or less. Suitable methods toachieve a respective size selective isolation of nucleic acids e.g. bydepleting high molecular weight genomic DNA, are known in the prior artand thus, need no detailed description herein. A classic method forisolating DNA of a target size involves the separation of the DNA in agel, cutting out the desired gel band(s) and then isolating the DNA ofthe target size from the gel fragment(s). Another widely used technologyis the size selective precipitation with polyethylene glycol basedbuffers (Lis and Schleif Nucleic Acids Res. 1975 March; 2(3):383-9) orthe binding/precipitation on carboxyl-functionalized beads (DeAngelis etal, Nuc. Acid. Res. 1995, Vol 23(22), 4742-3; U.S. Pat. Nos. 5,898,071and 5,705,628, commercialized by Beckman-Coulter (AmPure XP; SPRIselect)and U.S. Pat. No. 6,534,262). Furthermore, size selective isolationmethods that are based on the use of solid supports comprising anionexchange groups and varying pH values are known. A size selectiveisolation provides further opportunities in order to reduce the amountof intracellular nucleic acids in the isolated extracellular nucleicacids. For example, when the target extracellular nucleic acid ofinterest is DNA, the removal of genomic DNA during nucleic acidisolation step b) could also supplement or even replace a separate highg-force centrifugation of a plasma sample before starting the nucleicacid extraction in order to remove residual cells. Genomic DNA that isreleased from said residual cells is prevented from becoming massivelydegraded due to the stabilization according to the present invention, inparticular if a caspase inhibitor is used in addition to the at leastone primary and/or secondary carboxylic acid amide, and accordingly,said unfragmented or less fragmented genomic DNA can be depleted byusing a size-selective nucleic acid isolation protocol in step b). Thisoption is of particular advantage, as many clinical laboratories do nothave a centrifuge capable of performing such a high g-forcecentrifugation or other means for removing in particular trace amountsof residual cells.

Furthermore, intracellular nucleic acids can be isolated from containedcells, e.g. after the cells were separated from the remaining sample.E.g. RNA can be isolated and used for gene expression analysis.

The isolated nucleic acids can then be analyzed and/or further processedin a step c) using suitable assay and/or analytical methods. E.g. theycan be identified, modified, contacted with at least one enzyme,amplified, reverse transcribed, cloned, sequenced, contacted with aprobe, be detected (their presence or absence) and/or be quantified.Respective methods are well-known in the prior art and are commonlyapplied in the medical, diagnostic and/or prognostic field in order toanalyze extracellular nucleic acids (see also the detailed descriptionin the background of the present invention). Thus, after extracellularnucleic acids were isolated, optionally as part of total nucleic acid,total RNA and/or total DNA (see above), they can be analyzed to identifythe presence, absence or severity of a disease state including but notbeing limited to a multitude of neoplastic diseases, in particularpremalignancies and malignancies such as different forms of cancers.E.g. the isolated extracellular nucleic acids can be analyzed in orderto detect diagnostic and/or prognostic markers (e.g., fetal- ortumor-derived extracellular nucleic acids) in many fields ofapplication, including but not limited to non-invasive prenatal genetictesting respectively screening, disease screening, pathogen screening,oncology, cancer screening, early stage cancer screening, cancer therapymonitoring, genetic testing (genotyping), infectious disease testing,injury diagnostics, trauma diagnostics, transplantation medicine or manyother diseases and, hence, are of diagnostic and/or prognosticrelevance. According to one embodiment, the isolated extracellularnucleic acids are analyzed to identify and/or characterize a disease ora fetal characteristic. Thus, as discussed above, the isolation methoddescribed herein may further comprise a step c) of nucleic acid analysisand/or processing. Therefore, according to one embodiment, the isolatedextracellular nucleic acids are analyzed in step c) to identify, detect,screen for, monitor or exclude a disease and/or at least one fetalcharacteristic.

The analysis/further processing of the nucleic acids can be performedusing any nucleic acid analysis/processing method including, but notlimited to amplification technologies, polymerase chain reaction (PCR),isothermal amplification, reverse transcription polymerase chainreaction (RT-PCR), quantitative real time polymerase chain reaction(Q-PCR), digital PCR, gel electrophoresis, capillary electrophoresis,mass spectrometry, fluorescence detection, ultraviolet spectrometry,hybridization assays, DNA or RNA sequencing, restriction analysis,reverse transcription, NASBA, allele specific polymerase chain reaction,polymerase cycling assembly (PCA), asymmetric polymerase chain reaction,linear after the exponential polymerase chain reaction (LATE-PCR),helicase-dependent amplification (HDA), hot-start polymerase chainreaction, intersequence-specific polymerase chain reaction (ISSR),inverse polymerase chain reaction, ligation mediated polymerase chainreaction, methylation specific polymerase chain reaction (MSP),multiplex polymerase chain reaction, nested polymerase chain reaction,solid phase polymerase chain reaction, or any combination thereof.Respective technologies are well-known to the skilled person and thus,do not need further description here.

According to one embodiment, either or both of the isolating oranalyzing steps b) and c) occurs at least one day up to 7 days after thesample has been collected, respectively stabilized according to theteachings of the present invention. Suitable time periods for which thesample, in particular a blood sample, respectively the extracellularnucleic acid population contained therein can be stabilized using themethod according to the present invention are also described above andalso apply here. According to one embodiment, the isolation step isperformed at least one day, at least 2 days, at least 3 days, at least 4days, at least 5 days or at least 6 days after the sample was collectedand stabilized according to the method according to the presentinvention. According to one embodiment, either or both of the isolatingor analyzing steps occur without freezing the sample and/or without theuse of formaldehyde or a formaldehyde releaser for preserving thecell-containing biological sample. The biological sample is stabilizedafter the contact with the at least one primary or secondary carboxylicacid amide which preferably is a compound according to formula 1 asdefined above, preferably in combination with a further additive such asan anticoagulant like EDTA. An anticoagulant is preferably used whenstabilizing blood or a sample derived from blood. The respectivelystabilized samples can be handled, e.g. stored and/or shipped at roomtemperature. As described above, according to one embodiment, anapoptosis inhibitor, preferably a caspase inhibitor is additionally usedfor stabilization.

Composition

Furthermore, according to a third aspect of the present invention acomposition suitable for stabilizing a biological sample is provided,comprising:

-   -   a) at least one carboxylic acid amide, preferably in a        concentration of at least 1%, wherein the carboxylic acid amide        is selected from primary carboxylic acid amides and secondary        carboxylic acid amides; and    -   b) at least one anticoagulant.

As discussed above, a respective stabilizing composition is particularlyeffective in stabilizing a cell-containing biological sample, inparticular whole blood, plasma and/or serum by stabilizing the comprisedcells, transcript levels and the comprised extracellular nucleic acidsthereby substantially preserving, respectively stabilizing theextracellular nucleic acid population. A respective stabilizingcomposition allows the storage and/or handling, e.g. shipping, of thesample, which preferably is whole blood, at room temperature for atleast two, preferably at least three days without substantiallycompromising the quality of the sample, respectively the extracellularnucleic acid population contained therein. Furthermore, the geneexpression profile on thus the transcriptome of contained cells ispreserved. Of course, it is not mandatory to make use of the fullpossible stabilization period; the samples may also be processed earlierif desired. Contacting the biological sample with the stabilizingcomposition allows the sample to be stored, and or handled, e.g.shipped, even at room temperature prior to isolating and optionallyanalyzing and/or processing the contained nucleic acids. Thus, the timebetween the collection or stabilization of the sample and the nucleicacid extraction can vary without substantially affecting the population,respectively the composition of the extracellular nucleic acidpopulation contained therein. In particular, dilutions, respectivelycontaminations with intracellular nucleic acids, in particularfragmented genomic DNA, are reduced. Furthermore, as the genetranscription profile of contained cells is stabilized, intracellularRNA can be isolated and e.g. used in methods that analyze geneexpression and can be used for gene expression profiling. Preferably,the stabilization composition is contacted with the sample immediatelyafter or during collection of the sample. The stabilization compositionmay also comprise further stabilizing agents as described herein, e.g.an apoptosis inhibitor, which preferably is a caspase inhibitor.

Suitable and preferred embodiments of primary and secondary carboxylicacid amides and the apoptosis inhibitor as well as suitable andpreferred concentrations of the respective compounds when mixed with thecell-containing sample are described in detail above in conjunction withthe stabilization method. It is referred to the above disclosure whichalso applies with respect to the stabilization composition. Saidcompound can also be used in combination with an apoptosis inhibitor,preferably a caspase inhibitor (preferred embodiments are describedabove, it is referred to the above disclosure). Furthermore, a tertiaryamide as described can be used in combination. Preferred and suitableembodiments as well as suitable concentrations were described above andit is referred to the above disclosure which also applies here.According to one embodiment, the stabilizing agent is a primarycarboxylic acid amide selected from butanamide and formamide. Asbutanamide is non-toxic, it is particularly preferred. As describedherein, butanamide is particularly effective for stabilizing theextracellular nucleic acid population. According to one embodiment,formamide is used as stabilizing agent. As is shown by the examples,formamide is highly effective in stabilizing the extracellular nucleicacid population as well as the transcriptome of contained cells. Thus,advantageously, formamide can be used for both stabilization purposes.According to one embodiment, the primary carboxylic acid amide is notpropanamide.

According to one embodiment, the composition additionally comprises atleast one poly(oxyethylene) polymer, preferably a polyethylene glycol.The molecular weight may lie in a range of e.g. 200 to 20000 Da.Including a polyethylene glycol in the stabilization composition isadvantageous, because it supports and thus assists the stabilization ofthe cells contained in the sample to be stabilized.

Furthermore, it is preferred that the stabilization compositioncomprises further additives, e.g. an anticoagulant such as a chelatingagent in particular if the composition is used for stabilizing wholeblood, plasma or serum.

The stabilizing composition provided by the present invention stabilizesthe cell-containing biological sample and thus, does not induce thelysis and/or disruption of nucleated cells and preferably also anucleated cells, contained in the sample. Therefore, the stabilizationcomposition does not comprise additives in a concentration wherein saidadditives would induce or promote cell lysis of respective cells andpreferably cells in general. The stabilizing composition may reduce thedamage of cells comprised in the sample as can be e.g. determined by theassay methods described in the example section. In particular, thestabilization composition described herein is according to oneembodiment capable of reducing the release of genomic DNA from cellscontained in the cell-containing biological sample into the cell-freeportion of the sample. Furthermore, in particular when comprising acaspase inhibitor, the stabilization composition may be capable ofreducing the degradation of nucleic acids, in particular genomic DNA,present in the stabilized sample. As described, the stabilizationcomposition is capable of reducing or preventing the contamination ofthe extracellular DNA population comprised in the biological sample withgenomic DNA originating from cells contained in the stabilized sample.Preferably, it is capable of reducing or preventing the contamination ofthe extracellular nucleic acid population comprised in the biologicalsample with intracellular nucleic acids, in particular DNA and RNA,originating from cells contained in the stabilized sample. Preferably,the stabilization composition does not comprise a cross-linking agentthat induces protein-DNA and/or protein-protein crosslinks. Inparticular, the stabilization composition does not compriseformaldehyde, formaline, paraformaldehyde or a formaldehyde releaser orsimilar crosslinking agents. Furthermore, as described herein and shownby the examples, according to one embodiment the stabilizationcomposition results in a stabilization of the transcriptome.

According to one embodiment, the stabilizing composition consistsessentially of the mentioned stabilizers and optional additives andoptionally, buffering agents. The stabilizing composition stabilizes thesample and thus, does not promote the lysis and/or disruption of thecells contained in the sample. The stabilizing composition may reducethe damage of the cells comprised in the sample as can be e.g.determined by the assay methods described in the example section.

The composition may be provided in a solid form. This is e.g. a suitableoption if the biological sample to be stabilized contains liquid todissolve the solid (such as for example cell-containing body fluids,cells in medium, urine) or if liquid, e.g. water is added thereto todissolve the solid. The advantage of using a solid stabilizingcomposition is that solids are usually chemically more stable. However,also a liquid composition may be used. Liquid compositions often havethe advantage that the mixture with the sample to be stabilised can bequickly achieved, thereby basically providing an immediate stabilisingeffect as soon as the sample comes into contact with the liquidstabilizing composition. Preferably, stabilising agent(s) present in theliquid stabilizing composition remain stable in solution and require nopre-treatment-such as for example the dissolving of precipitates oflimited solubility-by the user because pre-treatments of this kind posea risk of variations in the stabilising efficiency.

Also provided is a mixture comprising the stabilizing compositionaccording to the present invention mixed with a biological sample.Suitable and preferred examples of biological samples as well assuitable concentrations of the stabilizing agent(s) when mixed with thebiological sample are described above in conjunction with thestabilizing method. It is referred to the above disclosure which alsoapplies here. Preferably, the stabilizing composition is pre-filled in asample collection device so that the sample is immediately stabilizedduring collection. According to one embodiment, the stabilizingcomposition is contacted with the biological sample, preferably a bloodsample, in a volumetric ratio selected from 10:1 to 1:20, 5:1 to 1:15,1:1 to 1:10 and 1:2 to 1:5. It is a particular advantage of thestabilizing composition of the present invention that stabilization of alarge sample volume can be achieved with a small volume of thestabilizing composition. Therefore, preferably, the ratio of stabilizingcomposition to sample lies in a range from 1:2 to 1:7, more preferred1:3 to 1:5.

Uses

The stabilizing composition according to the third aspect of the presentinvention can be used to stabilize the extracellular nucleic acidpopulation comprised in a cell-containing sample. Furthermore, thestabilizing composition according to the third aspect of the presentinvention may also be used for stabilizing cells contained in a sample.As described above, the stabilizing composition inter alia reduces therelease of genomic DNA from cells that results from decaying cells.Thus, a respective use is also an advantageous and provided by theteachings according to the present invention. Furthermore, thestabilizing composition according to the third aspect of the presentinvention may also be used for stabilizing transcript levels incontained cells.

Manufacturing Method

Also provided is a method of manufacturing a composition according tothe third aspect of the present invention is provided, wherein thecomponents of the composition are mixed, preferably in an aqueoussolution.

The composition of the present invention may also be incorporated into asample collection device, in particular blood collection assembly,thereby providing for a new and useful version of such a device. Suchdevices typically include a container having an open and a closed end.The container is preferably a blood collection tube. The container typealso depends on the sample to be collected, other suitable formats aredescribed below.

Container

Furthermore, the present invention provides a container for collecting acell-containing biological sample, preferably a blood sample, whichcomprises

a) at least one carboxylic acid amide, preferably in a concentration ofat least 1%, wherein the carboxylic acid amide is selected from primarycarboxylic acid amides and secondary carboxylic acid amides; and

b) at least one anticoagulant.

The container for collecting a cell-containing biological sample,preferably a blood sample, may comprise a stabilizing compositionaccording to the present invention. Providing a respective container,e.g. a sample collection tube, which comprises the mentioned componentsor the stabilizing composition according to the present invention, hasthe advantage that the sample is quickly stabilized when the sample iscollected in the respective container. Details with respect to the useof the agents used for stabilizing and the stabilizing composition weredescribed above, it is referred to the above disclosure which alsoapplies here.

According to one embodiment, a collection container for receiving andcollecting a biological sample is provided wherein the containercomprises:

-   -   a) at least one carboxylic acid amide, preferably in a        concentration of at least 1%, wherein the carboxylic acid amide        is selected from primary carboxylic acid amides and secondary        carboxylic acid amides; and    -   b) at least one anticoagulant.

Suitable embodiments and concentrations are also described above inconjunction with the method and it is referred to the above disclosure.According to one embodiment, the primary carboxylic acid amide isselected from butanamide and formamide. According to one embodiment, thecontainer additionally comprises at least one apoptosis inhibitor suchthat when the sample is collected, the concentration of the apoptosisinhibitor or combination of two or more apoptosis inhibitors in theresulting mixture is selected from at least 0.01 μM, at least 0.05 μM,at least 0.1 μM, at least 0.5 μM, at least 1 μM, at least 2.5 μM or atleast 3.5 μM and preferably is present in a concentration range selectedfrom 0.01 μM to 100 μM, 0.05 μM to 100 μM, 0.1 μM to 50 μM, 1 μM to 40μM, 1.0 μM to 30 μM or 2.5 μM to 25 μM. According to one embodiment, thecontainer additionally comprises at least one poly(oxyethylene) polymer,preferably at least one polyethylene glycol. Details were describedabove and it is referred to the above disclosure.

The pre-filled components can be provided in a liquid or in a dry form.According to one embodiment, the stabilizing components are provided asa stabilizing composition. A dry form is e.g. a suitable option if thebiological sample to be stabilized contains liquid to dissolve the solid(such as for example cell-containing body fluids, cells in medium,urine) or if liquid, e.g. water is added thereto to dissolve the solid.The advantage of using a solid stabilizing composition is that solidsare usually chemically more stable than liquids. According to oneembodiment, the inner wall of the container is treated/covered with astabilizing composition according to the present invention. Saidcomposition can be applied to the inner walls using e.g. aspray-dry-method. Liquid removal techniques can be performed on thestabilising composition in order to obtain a substantially solid stateprotective composition. Liquid removal conditions may be such that theyresult in removal of at least about 50% by weight, at least about 75% byweight, or at least about 85% by weight of the original amount of thedispensed liquid stabilising composition. Liquid removal conditions maybe such that they result in removal of sufficient liquid so that theresulting composition is in the form of a film, gel or othersubstantially solid or highly viscous layer. For example it may resultin a substantially immobile coating (preferably a coating that can bere-dissolved or otherwise dispersed upon contact with thecell-containing sample which preferably is a blood product sample). Itis possible that lyophilization or other techniques may be employed forrealizing a substantially solid form of the protective agent (e.g., inthe form of one or more pellet). Thus, liquid removal conditions may besuch that they result in a material that upon contact with the sampleunder consideration (e.g., a whole blood sample) the protective agentwill disperse in the sample, and substantially preserve components(e.g., extracellular nucleic acids) in the sample. Liquid removalconditions may be such that they result in a remaining composition thatis substantially free of crystallinity, has a viscosity that issufficiently high that the remaining composition is substantiallyimmobile at ambient temperature; or both.

According to one embodiment, a liquid composition is used. Liquidcompositions often have the advantage that the mixture with the sampleto be stabilised can be quickly achieved, thereby basically providing animmediate stabilising effect as soon as the sample comes into contactwith the liquid stabilizing composition. Preferably, the stabilisingagent(s) present in the liquid stabilizing composition remain stable insolution and require no pre-treatment-such as for example the dissolvingof precipitates of limited solubility-by the user because pre-treatmentsof this kind pose a risk of variations in the stabilising efficiency.

The stabilizing composition is comprised in the container in an amounteffective to provide the stabilisation of the amount of sample to becollected in said container. According to one embodiment, the liquidstabilizing composition is contacted with the biological sample in avolumetric ratio selected from 10:1 to 1:20, 5:1 to 1:15, 1:1 to 1:10and 1:2 to 1:5. It is a particular advantage of the stabilizingcomposition of the present invention that stabilization of a largesample volume can be achieved with a small volume of the stabilizingcomposition. Therefore, preferably, the ratio of stabilizing compositionto sample lies in a range from 1:2 to 1:7, more preferred 1:3 to 1:5.

According to one embodiment, the container is evacuated. The evacuationis preferably effective for drawing a specific volume of a fluid sampleinto the interior. Thereby, it is ensured that the correct amount ofsample is contacted with the pre-filled amount of the stabilizingcomposition comprised in the container, and accordingly, that thestabilization is efficient. According to one embodiment, the containercomprises a tube having an open end sealed by a septum. E.g. thecontainer is pre-filled with a defined amount of the stabilizingcomposition either in solid or liquid form and is provided with adefined vacuum and sealed with a septum. The septum is constructed suchthat it is compatible with the standard sampling accessories (e.g.cannula, etc.). When contacted with e.g. the canula, a sample amountthat is predetermined by the vacuum is collected in the container. Arespective embodiment is in particular advantageous for collectingblood. A suitable container is e.g. disclosed in U.S. Pat. No.6,776,959.

The container according to the present invention can be made of glass,plastic or other suitable materials. Plastic materials can be oxygenimpermeable materials or may contain an oxygen impermeable layer.Alternatively, the container can be made of water- and air-permeableplastic material. The container according to the present inventionpreferably is made of a transparent material. Examples of suitabletransparent thermoplastic materials include polycarbonates,polyethylene, polypropylene and polyethyleneterephthalate. The containermay have a suitable dimension selected according to the required volumeof the biological sample being collected. As described above,preferably, the container is evacuated to an internal pressure belowatmospheric pressure. Such an embodiment is particularly suitable forcollecting body fluids such as whole blood. The pressure is preferablyselected to draw a predetermined volume of a biological sample into thecontainer. In addition to such vacuum tubes also non-vacuum tubes,mechanical separator tubes or gel-barrier tubes can be used as samplecontainers, in particular for the collection of blood samples. Examplesof suitable containers and capping devices are disclosed in U.S. Pat.No. 5,860,397 and US 2004/0043505. As container for collecting thecell-containing sample also further collection devices, for example asyringe, a urine collection device or other collection devices can beused. The type of the container may also depend on the sample type to becollected and suitable containers are also available to the skilledperson.

Beneficial results are obtained when the container respectively thedevice is filled or is pre-filled with at least one compound accordingto formula 1 as defined above as stabilizing agent. Preferably, ananticoagulant is encompassed in addition to the primary or secondarycarboxylic acid amide described above which preferably is selected fromformamide and butanamide. The anticoagulant is preferably a chelatingagent such as EDTA. Furthermore, the stabilizing composition comprisedin the container may also comprise an apoptosis inhibitor, preferably acaspase inhibitor and optionally further additives. According to oneembodiment, the stabilizing composition comprised in the containercomprises a caspase inhibitor and an anticoagulant. According to oneembodiment, the stabilizing composition comprises a tertiary amide asdescribed above.

According to one embodiment, the container has an open top, a bottom,and a sidewall extending therebetween defining a chamber, wherein thestabilizing agents and/or the stabilization composition according to thepresent invention is comprised in the chamber. It may be comprisedtherein in liquid or solid form. According to one embodiment thecontainer is a tube, the bottom is a closed bottom, the containerfurther comprises a closure in the open top, and the chamber is at areduced pressure. The advantages of a reduced pressure in the chamberwere described above. Preferably, the closure is capable of beingpierced with a needle or cannula, and the reduced pressure is selectedto draw a specified volume of a liquid sample into the chamber.According to one embodiment, the chamber is at a reduced pressureselected to draw a specified volume of a liquid sample into the chamber,and the stabilizing composition is a liquid and is disposed in thechamber such that the volumetric ratio of the stabilising composition tothe specified volume of the cell-containing sample is selected from 10:1to 1:20, 5:1 to 1:15, 1:1 to 1:10 and 1:2 to 1:5. The associatedadvantages were described above.

Preferably, the container is for drawing blood from a patient.

Collection Method

According to a fifth aspect, a method is provided comprising the step ofcollecting a sample from a patient directly into a chamber of acontainer according to the fourth aspect of the present invention.Details with respect to the container and the sample were describedabove. It is referred to the respective disclosure. According to oneembodiment, a blood sample is collected, preferably it is withdrawn fromthe patient.

The methods and compositions disclosed herein allow for the efficientpreservation and isolation of extracellular nucleic acids while reducingpossible mixing with nucleic acids, in particular fragmented genomicDNA, which originates from cells comprised in the biological sample andwhich may enter a biological sample due to cell damage, respectivelycell lysis. The methods according to the present invention, as well asthe compositions and the disclosed devices (e.g. the collectioncontainers) reduce the degradation of extracellular nucleic acids andalso reduce cell lysis and/or release of genomic nucleic acids, inparticular fragmented genomic DNA, so that the extracellular nucleicacids contained in the sample do not become contaminated withintracellular nucleic acids, respectively a respective contamination isreduced by the teachings according to the present invention. Asdiscussed above, an intermixing of extracellular nucleic acids andintracellular nucleic acids, in particular fragmented genomic DNA, mayreduce the accuracy of any measurement of the amount of extracellularnucleic acids in a biological sample. As discussed above, an importantadvantage of the present invention is the possibility for essentiallysimultaneous stabilizing of both the cells contained in the sample (inparticular white blood cells or types of white blood cells in case ofwhole blood, plasma or serum) and the extracellular nucleic acids. Thishelps to prevent cellular nucleic acids such as genomic DNA from beingreleased into the cell-free portion of the sample, and further dilutingthe comprised extracellular nucleic acids (and associated biomarkers) ofinterest, while also maintaining the structural integrity of theextracellular nucleic acids. As discussed herein, contacting thecell-containing biological sample such as whole blood or plasma with thestabilising agent(s) allows the sample to be stored for a period of timeprior to isolating the extracellular nucleic acids. More preferably, thecell-containing biological sample, e.g. blood or plasma, may be drawn atone location (e.g., a health care facility), contacted with thestabilising agent(s), and later transported to a different remotelocation (e.g., a laboratory) for the nucleic acid isolation and testingprocess. Furthermore, the stabilization technologies described hereinallow to stabilize intracellular nucleic acids and in particulartranscript levels as was described in detail above. The stabilization ofthe transcriptome that can be achieved with the methods and compositiondescribed herein is a further important advantage. According to oneembodiment, formamide is used for stabilizing the transcriptome. Asdescribed above and shown in the examples, formamide is highly effectivein stabilizing the transcriptome as well as the extracellular nucleicacid population. Furthermore, cells can be isolated from the samplethereby allowing the analysis of specific cell populations such as e.g.tumor cells, e.g. circulating tumor cells in blood samples. Theadvantages and technical effects were described in detail above and itis referred to the above disclosure.

Furthermore, the stabilization reagents and methods, as disclosed inherein, provide an advantage over known state-of-the-art stabilizationreagents and methods which involve the use of cross-linking reagents,such as formaldehyde, formaldehyde releasers and the like, as thestabilization of samples according to the present invention does notinvolve the use to such crosslinking reagents. Crosslinking reagentscause inter- or intra-molecular covalent bonds between nucleic acidmolecules or between nucleic acids and proteins. This effect can lead toa reduced recovery of such stabilized and partially crosslinked nucleicacids after a purification or extraction from a complex biologicalsample. As, for example, the concentration of circulating nucleic acidsin a whole blood samples is already relatively low, any measure whichfurther reduces the yield of such nucleic acids should be avoided. Thismay be of particular importance when detecting and analyzing very rarenucleic acid molecules derived from malignant tumors or from adeveloping fetus in the first trimester of pregnancy. Therefore, noformaldehyde releaser is comprised in the stabilizing composition,respectively is not additionally used for stabilization. Thus, accordingto one embodiment, no cross-linking agents such as formaldehyde orformaldehyde releasers are comprised in the stabilizing composition,respectively are not additionally used for stabilization. Thus, here thestabilization composition does not comprise a cross-linking agent thatinduces nucleic acid-nucleic acid, nucleic-acid-protein, in particularprotein DNA and/or protein-protein crosslinks. In particular, thestabilization composition does not comprise formaldehyde, formaline,paraformaldehyde or a formaldehyde releaser. Furthermore, as described,the stabilizing composition does preferably not comprise any additivesthat would induce the lysis of cells, such as e.g. chaotropic salts.Furthermore, according to one embodiment, the stabilization methodaccording to the invention does not involve the use of additives thatclassify as toxic agents.

Particularly preferred aspects and embodiments are described again inthe following.

In a first aspect, the present invention is in particular directed to amethod for stabilizing a cell-containing biological sample by contactingthe sample with at least one carboxylic acid amide, wherein thecarboxylic acid amide is selected from primary carboxylic acid amidesand secondary carboxylic acid amides. Preferably, the resultingcomposition comprising the cell-containing biological sample and the atleast one carboxylic acid amide comprises the carboxylic acid amide in aconcentration of at least 0.25%. According to one embodiment, thestabilization results in a stabilization of intracellular RNA and/orwherein the extracellular nucleic acid population comprised in thecell-containing sample is stabilized. As described herein, the method isnot based on cell lysis and wherein the stabilization does not involvethe use of a cross-linking agent that induces protein-nucleic acidand/or protein-protein crosslinks and does not involve the use of aformaldehyde releaser.

According to one embodiment, the carboxylic acid amide which is selectedfrom primary carboxylic acid amides and secondary carboxylic acid amideshas the formula 1

wherein R1 is a hydrogen residue or an alkyl residue, wherein R2 isselected from a hydrogen residue and a hydrocarbon residue with a lengthof the carbon chain of 1-20 atoms arranged in a linear or branchedmanner, wherein R3 is a hydrogen residue, and wherein R4 is oxygen.

According to one embodiment, the cell-containing sample is contactedwith at least one primary carboxylic acid amide which is selected fromthe group consisting of formamide, acetamide, propanamide andbutanamide, preferably butanamide. According to another embodiment, thecell-containing biological sample is contacted with at least onesecondary carboxylic acid amide which is selected from the groupconsisting of N-alkylformamide, N-alkylacetamide and N-alkylpropanamide,and preferably is selected from N-methylformamide, N-methylacetamide andN-methylpropanamide.

According to one embodiment, the method for stabilizing acell-containing biological sample comprises contacting the sample withat least one carboxylic acid amide, wherein the carboxylic acid amide isformamide and wherein the resulting composition comprising thecell-containing biological sample and formamide comprises formamide in aconcentration of at least 0.25% and wherein the stabilization results ina stabilization of intracellular RNA and/or wherein the extracellularnucleic acid population comprised in the cell-containing sample isstabilized and wherein said method is not based on cell lysis andwherein the stabilization does not involve the use of a cross-linkingagent that induces protein-nucleic acid and/or protein-proteincrosslinks and wherein said method does not involve the use of aformaldehyde releaser.

According to one embodiment, the mixture that is obtained whencontacting the cell-containing biological sample with the at least onecarboxylic acid amide which is selected from primary carboxylic acidamides and secondary carboxylic acid amides comprises said carboxylicacid amide in a concentration of at least 0.1%, at least 0.25%, at least0.5%, at least 0.75%, at least 1%, at least 1.25%, at least 1.5% or atleast 2%. Suitable concentration ranges were also described above.According to one embodiment, the carboxylic acid amide is formamide.

According to one embodiment, the cell-containing sample is a bloodsample and is additionally contacted with an anticoagulant.

According to one embodiment, the degradation of nucleic acids present inthe cell-containing sample is reduced due to the stabilization. Inparticular, intracellular RNA is stabilized. Preferably, thetranscriptome and/or transcript levels in cells contained in the sampleis stabilized. According to one embodiment, the transcript level of oneor more marker genes selected from c-fos, IL-1beta, IL-8 and p53 isstabilized for at least 24 h, preferably at least 48 h uponstabilization. According to one embodiment, the method is suitable forstabilizing an extracellular nucleic acid population comprised in thecell-containing sample. In particular, the release of genomic DNA fromcells contained in the sample into the cell-free portion of the sampleis reduced.

According to one embodiment, said method one or more of the followingcharacteristics:

-   -   a) the stabilization allows the isolation of cells from the        stabilized sample;    -   b) the cell-containing sample is a blood sample and wherein        white blood cells are stabilized;    -   c) the morphology of cells is preserved;    -   d) the morphology of nucleated cells is preserved;    -   e) the sample is a blood sample and contained lymphocytes and/or        monocytes are stabilized;    -   f) cell surface epitopes are preserved; and/or    -   g) cell surface proteins are preserved.

According to one embodiment, the cell-containing sample is additionallycontacted with an apoptosis inhibitor for stabilization. Preferably, theapoptosis inhibitor is a caspase inhibitor, more preferably a pancaspaseinhibitor. Suitable caspase inhibitors were described above and it isreferred to the above disclosure.

According to one embodiment, the cell-containing sample is additionallycontacted with at least one poly(oxyethylene) polymer for stabilization.Preferably, the poly(oxyethylene) polymer is a polyethylene glycol.Details were described above and it is referred to the above disclosure.

According to one embodiment, the method has one or more of the followingcharacteristics:

-   -   a) the at least one carboxylic acid amide which is a primary or        secondary carboxylic acid amide and optionally further additives        are comprised in a stabilising composition and wherein the        volumetric ratio of the stabilising composition to the specified        volume of the cell-containing sample is selected from 10:1 to        1:20, 5:1 to 1:15, 1:1 to 1:10 and 1:2 to 1:5;    -   b) the stabilized cell-containing sample is subjected to a        nucleic acid analysis and/or detection method;    -   c) intra- and/or extracellular nucleic acids are isolated from        the stabilized sample and the isolated nucleic acids are        analyzed and/or detected;    -   d) cells comprised in the stabilized sample are removed; and/or    -   e) (i) the stabilized cell-containing biological sample, (ii)        the stabilized sample from which cells have been removed        and/or (iii) cells removed from the sample are stored.

According to one embodiment, nucleic acids are isolated from thestabilized sample. E.g. RNA can be isolated from cells contained in thestabilized sample. According to one embodiment, cells are removed fromthe stabilized sample and wherein preferably, removed cells are analyzedand/or wherein biomolecules such as nucleic acids or proteins areisolated from removed cells.

According to one embodiment, the cell-containing sample is additionallycontacted with at least one tertiary amide which is a compound accordingto formula 1

wherein R1 is a hydrogen residue or an alkyl residue, wherein R2 and R3are identical or different hydrocarbon residues with a length of thecarbon chain of 1-20 atoms arranged in a linear or branched manner, andwherein R4 is an oxygen, sulphur or selenium residue, preferably R4 isoxygen. The tertiary amide according to formula 1 may be a carboxylicacid amide. It may be a N,N-dialkylpropanamide, preferablyN,N-dimethylpropanamide. According to one embodiment, the tertiary amideaccording to formula 1 is selected from the group consisting ofN,N-dimethylformamide, N,N-dimethylacetamide, N,N-dimethylpropanamide,N,N-dimethylbutanamide. According to one embodiment, after thecell-containing biological sample has been contacted with at least oneprimary or secondary carboxylic acid amide, preferably butanamide, and atertiary amide according to formula 1 and optionally further additivesused for stabilization, the resulting mixture comprises the tertiaryamide according to formula 1

-   -   i) in a concentration of at least 0.1%, at least 0.25%, at least        0.5%, at least 0.75%, at least 1%, at least 1.25% or at least        1.5%; and/or    -   ii) in a concentration that lies in the range of 0.1% to 30%,        0.25% to 20%, 0.5% to 15%, 0.7% to 10%, 0.8% to 7.5%, 0.9% to 6%        or 1% to 5%.

In a second aspect, the present disclosure pertains to a method forisolating nucleic acids from a biological sample comprising the stepsof:

-   -   a) stabilizing a cell-containing sample according to the method        according to the first aspect;    -   b) isolating nucleic acids from the stabilized sample.

According to one embodiment, step b) comprises isolating intracellularnucleic acids, preferably intracellular RNA. In particular, step b) maycomprise removing cells from the stabilized sample and isolating nucleicacids from the removed cells.

According to one embodiment, step b) comprises isolating extracellularnucleic acids. In particular, cells may be separated from the remainingsample and wherein in step b) extracellular nucleic acids are isolatedfrom the remaining sample and/or intracellular nucleic acids areisolated from the removed cells. Thus, as described above, the methodallows to isolate extra- and intracellular nucleic acids in parallel ifdesired. Preferably, the sample is blood.

According to one embodiment, the isolated nucleic acids are in a furtherstep c) processed and/or analyzed and preferably are:

-   -   i) modified;    -   ii) contacted with at least one enzyme;    -   iii) amplified;    -   iv) reverse transcribed;    -   v) cloned;    -   vi) sequenced;    -   vii) contacted with a probe;    -   viii) detected;    -   ix) quantified;    -   ix) identified; and/or    -   x) analysed for gene expression profiling.

According to a third aspect, a composition suitable for stabilizing acell-containing biological sample is provided, comprising

-   -   a) at least one carboxylic acid amide preferably in a        concentration of at least 1%, wherein the carboxylic acid amide        is selected from primary carboxylic acid amides and secondary        carboxylic acid amides; and    -   b) at least one anticoagulant.

Suitable and preferred embodiments for the at least one carboxylic acidamide were described above. According to one embodiment, the compositioncomprises at least one primary carboxylic acid amide which is selectedfrom the group consisting of formamide, acetamide, propanamide andbutanamide. Preferably, the primary carboxylic acid amide is selectedfrom formamide and butanamide. According to another embodiment, thecomposition comprises at least one secondary carboxylic acid amide whichis selected from the group consisting of N-alkylformamide,N-alkylacetamide and N-alkylpropanamide, and preferably is selected fromN-methylformamide, N-methylacetamide and N-methylpropanamide. Accordingto one embodiment, the anticoagulant is a chelating agent, preferablyEDTA.

According to one embodiment, the composition comprises at least onepoly(oxyethylene) polymer for stabilization. Preferably, thepoly(oxyethylene) polymer is a polyethylene glycol. Details weredescribed above and it is referred to the above disclosure.

According to one embodiment, the composition is for stabilizing a bloodsample as cell-containing sample.

According to one embodiment, the composition comprises at least onetertiary amide according to formula 1 as described above in conjunctionwith the first aspect. Such tertiary amide can be e.g. used incombination with butanamide.

According to one embodiment, the composition comprises at least oneapoptosis inhibitor, preferably a caspase inhibitor, more preferred apancaspase inhibitor, wherein preferably, the pancaspase inhibitor isselected from the group consisting of Q-VD-OPh andZ-Val-Ala-Asp(OMe)-FMK, and the caspase inhibitor preferably isQ-VD-OPh.

According to one embodiment, the composition additionally comprises atleast one poly(oxyethylene) polymer, preferably polyethylene glycol andan apoptosis inhibitor, preferably a caspase inhibitor.

According to one embodiment, the composition is capable of stabilizingthe gene transcription profile of contained cells and/or is capable ofstabilizing an extracellular nucleic acid population comprised in acell-containing sample. According to one embodiment, the composition hasone or more of the following characteristics:

-   -   a) it is capable of stabilizing cells and reducing the release        of genomic DNA from cells contained in the cell-containing        biological sample into the cell-free portion of the sample;    -   b) it is capable of reducing the dilution of the extracellular        DNA population comprised in the biological sample with genomic        DNA originating from cells contained in the stabilized sample;    -   c) it is capable of reducing the dilution of the extracellular        nucleic acid population comprised in the biological sample with        intracellular nucleic acids originating from cells contained in        the stabilized sample;    -   d) the stabilization composition does not comprise additives in        a concentration wherein said additives would induce or promote        cell lysis;    -   e) the stabilization composition does not comprise a        cross-linking agent that induces protein-DNA and/or        protein-protein crosslinks;    -   f) the stabilization composition does not comprise formaldehyde,        formaline, paraformaldehyde or a formaldehyde releaser;    -   g) the stabilization composition does not comprise a toxic agent        and/or    -   h) the stabilization composition is capable of stabilizing        extracellular nucleic acid population comprised in the        cell-containing biological sample without refrigeration,        preferably at room temperature, for a time period selected from        at least two days, at least three days, at least two days to        three days, at least two days to six days and/or at least two        days to seven days.

According to one embodiment, upon contact of the stabilizing compositionwith a blood sample the transcript level of one or more marker genesselected from c-fos, IL-1beta, IL-8 and p53 is stabilized for at least48 h upon stabilization, and wherein, preferably, the volumetric ratioof the stabilizing composition to the cell-containing sample is selectedfrom 10:1 to 1:20, 5:1 to 1:15, 1:1 to 1:10 and 1:2 to 1:5. According toone embodiment, the sample is a blood sample and wherein the morphologyof and/or cell surface epitopes on white blood cells, preferablylymphocytes, is preserved.

According to one embodiment, the stabilizing composition is provided asmixture with a biological sample. According to one embodiment, thestabilizing composition is provided as mixture with a biological sampleand wherein said sample has one or more of the followingcharacteristics:

-   -   a) it comprises extracellular nucleic acids;    -   b) it is whole blood.

The present invention also pertains to the use of a compositionaccording to the third aspect in a stabilization method according to thefirst aspect.

According to a fourth aspect, a container for collecting acell-containing biological sample, preferably a blood sample, isprovided which comprises

a) at least one carboxylic acid amide in a concentration of at least 1%,wherein the carboxylic acid amide is selected from primary carboxylicacid amides and secondary carboxylic acid amides; and

b) at least one anticoagulant.

According to one embodiment, the container comprises at least oneprimary carboxylic acid amide which is selected from the groupconsisting of formamide, acetamide, propanamide and butanamide.Preferably, the primary carboxylic acid amide is selected from formamideand butanamide. According to another embodiment, the container comprisesat least one secondary carboxylic acid amide which is selected from thegroup consisting of N-alkylformamide, N-alkylacetamide andN-alkylpropanamide, and preferably is selected from N-methylformamide,N-methylacetamide and N-methylpropanamide. According to one embodiment,the anticoagulant is a chelating agent, preferably EDTA.

According to one embodiment, the container additionally comprises atleast one poly(oxyethylene) polymer for stabilization. Preferably, thepoly(oxyethylene) polymer is a polyethylene glycol. Details weredescribed above and it is referred to the above disclosure.

As described, the container may comprise a composition according to thethird aspect of the present invention. Therefore, according to oneembodiment, the aforementioned compounds may be comprised in acomposition.

According to a fifth aspect, a method is provided comprising the step ofcollecting, preferably withdrawing, a biological sample, preferablyblood, from a patient directly into a chamber of a container accordingto the fourth aspect of the present invention.

According to a sixth aspect, a method of producing a compositionaccording to the third aspect of the present invention is provided,wherein the components of the composition are mixed, preferably aremixed in a solution.

This invention is not limited by the exemplary methods and materialsdisclosed herein, and any methods and materials similar or equivalent tothose described herein can be used in the practice or testing ofembodiments of this invention. Numeric ranges are inclusive of thenumbers defining the range. The headings provided herein are notlimitations of the various aspects or embodiments of this inventionwhich can be read by reference to the specification as a whole.

The term “solution” as used herein in particular refers to a liquidcomposition, preferably an aqueous composition. It may be a homogenousmixture of only one phase but it is also within the scope of the presentinvention that a solution comprises solid additives such as e.g.precipitates, in particular of contained chemicals such as stabilizingagents.

The sizes, respectively size ranges indicated herein with reference tonucleotides (nt), refer to the chain length and thus are used in orderto describe the length of single-stranded as well as double-strandedmolecules. In double-stranded molecules said nucleotides are paired.

According to one embodiment, subject matter described herein ascomprising certain steps in the case of methods or as comprising certainingredients in the case of compositions, solutions and/or buffers refersto subject matter consisting of the respective steps or ingredients. Itis preferred to select and combine preferred embodiments describedherein and the specific subject-matter arising from a respectivecombination of preferred embodiments also belongs to the presentdisclosure.

Table 1: Overview of apoptosis inhibitors

TABLE 1 Overview of apoptosis inhibitors Apoptosis inhibitorDescription 1. Metabolic inhibitors AICA-Riboside, Acadesine, Offersprotection against cell death induced by glucose deprivation AICAr,5-Aminoimidazole-4- carboxamide-1-β-riboside, Z- Riboside ApoptosisInhibitor II, diarylurea prevents the active ~700-kDa apoptosome complexformation compound Bax Channel Blocker, (±)-1- A cell-permeabledibromocarbazolo-piperazinyl derivative that(3,6-Dibromocarbazol-9-yl)-3- displays anti-apoptotic properties.Effectively blocks Bid-induced piperazin-1-yl-propan-2-ol, biscyctochrome c release from HeLa cell mitochondria (~80% TFA, iMAC1inhibition at 5 μM) by inhibiting Bax channel-forming activity (IC50 =520 nM in a liposome channel assay). Bax-Inhibiting Peptide, V5 Acell-permeable pentapeptide based on the Ku70-Bax inhibiting Peptidesequence: domain that offers cytoprotection. Functions as effectively asthe H-Val-Pro-Met-Leu-Lys-OH Caspase Inhibitor VI (Z-VAD-FMK; Cat. No.219007) for Bax- (SEQ ID NO: 1) mediated apoptosis (~50-200 μM). Alsoeffectively blocks caspase- independent necrotic cell death. Shown to beKu70 competitive, interact with Bax, prevent its conformational changeand mitochondrial translocation. Displays extended stability in culturemedium (~3 days). Bcl-xL BH44-23, Human, Cell- A cell-permeable peptidethat prevents apoptotic cell death by Permeable directly binding to thevoltage-dependent anion channel (VDAC) and blocking its activity. Leadsto the inhibition of cytochrome c release and loss of mitochondrialmembrane potential (Δψm). Contains the conserved N-terminal homologydomain (BH4) of Bcl- xL (amino acids 4-23) that has been shown to beessential for inhibiting VDAC activity in liposomes and in isolatedmitochondria. The BH4 domain is linked to a carrier peptide, a 10-aminoacid HIV-TAT48-57 sequence with a β-alanine residue as a spacer formaximum flexibility. Following its uptake, it is mainly localized to themitochondria Bongkrekic Acid, Triammonium Acts as a ligand of theadenine nucleotide translocator. A potent Salt inhibitor ofmitochondrial megachannel (permeability transition pore). Significantlyreduces signs of apoptosis induced by nitric oxide. Prevents theapoptotic breakdown of the inner mitochondrial transmembrane potential(Δψm), as well as a number of other phenomena linked to apoptosisDaunorubicin, Hydrochloride Potent cell-permeable anticancer agent whosepotential target site may be mitochondrial cytochrome c oxidase. Hasbeen shown to inhibit RNA and DNA synthesis. Inhibits eukaryotictopoisomerases I and II. Induces DNA single-strand breaks. Also inducesapoptosis in HeLa S3 tumor cells. According to one embodiment, saidcompound is not used as stabilizer according to the present invention.Humanin, Human, Synthetic A 24-residue anti-apoptotic peptide that, whenexpressed intracellularly, offers protection against neuronal apoptosisinduced by presenilin and APP (amyloid precursor protein) mutantsassociated with familial Alzheimer's disease (AD). Shown to reducecytochrome c release in vitro by directly binding to Bax(Bcl-2-associated X protein; Kd ~2 nM) and preventing its associationwith isolated mitochondria Phorbol-12-myristate-13-acetate Mostcommonly-used phorbol ester. Activates protein kinase C in vivo and invitro, even at nM concentrations. Activates Ca2+- ATPase and potentiatesforskolin-induced cAMP formation. Inhibits apoptosis induced by the Fasantigen, but induces apoptosis in HL-60 promyelocytic leukemia cells.Pifithrin-α A cell-permeable chemical inhibitor of p53. Reversiblyinhibits p53- dependent transactivation of p53-responsive genes andreversibly blocks p53-mediated apoptosis. Inhibits p53-dependent growtharrest of human diploid fibroblasts in response to DNA damage but has noeffect on p53-deficient fibroblasts. Protects normal tissues from thedeleterious side effects of chemotherapy. Has been reported to protectneurons against β-amyloid peptide and glutamate-induced apoptosisPifithrin-μ A cell-permeable sulfonamide that blocks p53 interactionwith Bcl- xL and Bcl-2 proteins and selectively inhibits p53translocation to mitochondria without affecting the transactivationfunction of p53. Effectively protects against γ radiation-induced celldeath in vitro and animal lethality in vivo. Because Pifithrin-μ targetsonly the mitochondrial branch of the p53 pathway without affecting theimportant transcriptional functions of p53, it is superior toPifithrin-α in in vivo studies. Shown to selectively interact withinducible HSP70 and disrupt its functions Pifithrin-α, Cyclic- Acell-permeable and very stable analog of Pifithrin-α, with similarbiological function, but with reduced cytotoxicity. A chemical inhibitorof p53. Reversibly inhibits p53-dependent transactivation ofp53-responsive genes; also reversibly blocks p53-mediated apoptosis.Acts as a P-gp modulator by changing relative substrate specificity ofthe transporter. This compound has been reported to be a potent STAT6transcriptional inhibitor Pifithrin-α, p-Nitro A cell-permeable p53inhibitor that serves as the prodrug form of Pifithrin-α, p-Nitro,Cyclic. Although its in vitro efficacy (ED50 = 0.3 μM in protectingetoposide-induced cortical neuron death) is similar to that ofPifithrin-α, it is 100-fold more potent than Pifithrin-α whenadminstered in rats in vivo due to its long-lasting, steady conversionto the corresponding cyclic form of active compound in biologicalsystems (t½ = 8 h in neuron culture medium at 37° C.). Pifithrin-α,p-Nitro, Cyclic A cell-permeable p53 inhibitor that exhibits 10-foldhigher potency (ED50 = 30 nM in protecting etoposide-induced corticalneuron death) and 50% longer half-life (t½ = 6 h in neuron culturemedium at 37° C.) than Pifithrin-α. It shows in vitro efficacy. STAT3Inhibitor Peptide A Stat3-SH2 domain binding phosphopeptide that acts asa Peptide sequence: selective inhibitor of Stat3 (signal transducers andactivators of Ac-Pro-Tyr(PO3H2)-Leu-Lys- transcription 3) signaling witha DB50 of 235 μM (concentration of Thr-Lys-OH (SEQ ID NO: 2) peptide atwhich DNA-binding activity is inhibited by 50%). Significantly lowersthe DNA-binding activity of Stat3 by forming an inactive Stat3:peptidecomplex and reduces the levels of active Stat3:Stat3 dimers that canbind DNA. Displays greater affinity for Stat3, and to a lesser extentStat1, over Stat5. Supplied as a trifluoroacetate salt. STAT3 InhibitorPeptide, Cell- A cell-permeable analog of the Stat3-SH2 domain-bindingPermeable phosphopeptide that contains a C-terminal mts (membranePeptide sequence: translocating sequence) and acts as a highlyselective, potent Ac-Pro-Tyr(PO3H2)-Leu-Lys- blocker of Stat3activation. Also suppresses constitutive Stat-3 Thr-Lys-OH (SEQ ID NO:2) dependent Src transformation with no effect on Stat-3 independent Rastransformation. The unphosphorylated inactive control peptide is alsoavailable. Supplied as a trifluoroacetate salt. CAY10500,6,7-dimethyl-3- Tumor necrosis factor α (TNFα) inhibitor that preventsbinding to {[methyl-[1-(3-trifluoromethyl- the TNF Receptor 1 (TNFR1). 6Binds to the biologically active phenyl)-1H-indol-3-ylmethyl]- TNFαtrimer and promotes accelerated displacement of a singleamino}-ethyl)-amino]-methyl}- subunit to rapidly inactivate thecytokine. In a cell based assay, chromen-4-one compound inhibitedTNFα-mediated stimulation of IKB degradation. Gambogic amide A selectiveagonist for TrkA which mimics the actions of NGF. This compoundpossesses robust neurotrophic actvity, while it prevents neuronal celldeath 1. Maslinic Acid A pentacyclic triterpene with antioxidant andanti-inflammatory properties. Shown to block the generation of nitricoxide, and inhibits the secretion of IL-6 and TNF-α induced bylipopolysaccharides Naringin hydrate A citrus bioflavonoid found toinhibit cytochrome P450 monooxygenase activity in mouse liver. Itprevents toxin-induced cytoskeletal disruption and apoptotic liver celldeath. Necrostatin-1 An inhibitor of necroptosis, a non-apoptotic celldeath pathway. Does not affect Fas/TNFR-triggered apoptosis. Accordingto one embodiment, said compound is not used as stabilizer according tothe present invention. NSC348884 hydrate, N1,N2- This product is anucleolar phosphoprotein that displays severalbis((3-imino-6-methyl-3H-indol- biological activities in ribosomebiogenesis, cell proliferation, 2-yl)methyl)-N1,N2-bis((6-cytoplasmic/nuclear shuttle transportation, nucleic acid binding,methyl-1H-benzo[d]imidazol-2- ribonucleic cleavage, centrosomeduplication and molecular yl)methyl)ethane-1,2-diamine chaperoning, andis found in higher levels in tumor cells. hydrate Overexpression hasbeen shown to lead to inhibition of apoptosis. NSC34884 upregulates p53.Orsellinic acid Benzoic acid. Blocks PAF-mediated neuronal apoptosis.Shows free radical scavenging activity. tetramethyl A syntheticderivative of NDGA and a non-selective lipoxygenase NordihydroguaiareticAcid inhibitor. It inhibits Sp1 transcription factor binding at the HIVlong terminal repeat promoter and at the α-ICP4 promoter (a geneessential for HSV replication). GW 4869, 3,3′-(1,4- A cell-permeable,symmetrical dihydroimidazolo-amide compound phenylene)bis[N-[4-(4,5-that acts as a potent, specific, non-competitive inhibitor of N-dihydro-1H-imidazol-2- SMase (neutral sphingomyelinase) [IC50 = ~1 μM,rat brain; Km yl)phenyl]-hydrochloride-2- for sphingomyelin ~13 μM].Does not inhibit human A-SMase (acid propenamide sphingomyelinase) evenat 150 μM. Weakly inhibits the activities of bovine protein phosphatase2A and mammalian lyso-PAF PLC, while no inhibition is observed forbacterial phosphatidylcholine- specific PLC. Reported to offer completeprotection against TNF-α or diamine-induced cell death in MCF7 breastcancer cells at 20 μM. Does not modify the intracellular glutathionelevels or interfere with TNF-α or diamine-mediated signaling effects. SP600125, 1,9- SP600125 is a JNK inhibitor (IC50 = 40 nM for JNK-1 andJNK-2 Pyrazoloanthrone, and 90 nM for JNK-3). This agent exhibitsgreater than 300-fold Anthrapyrazolone selectivity for JNK againstrelated MAP kinases ERK1 and p38-2, and the serine threonine kinase PKA.SP600125 is a reversible ATP-competitive inhibitor. Mdivi-1,3-(2,4-Dichloro-5- Mdivi-1 is a selective inhibitor of mitochondrialdivision in yeast and methoxyphenyl)-2,3-dihydro-2- mammalian cellswhich acts via inhibiting the mitochondrial divisionthioxo-4(1H)-quinazolinone, 3- dynamin. In cells, Mdivi-1 inhibitsapoptosis by inhibiting (2,4-Dichloro-5-methoxyphenyl)- mitochondrialouter membrane permeabilization. 2-sulfanyl-4(3H)-quinazolinoneMinocycline•hydrochloride Tetracycline derivative with antimicrobialactivity. Inhibitor of angiogenesis, apoptosis and poly(ADP-ribose)polymerase-1 (PARP-1). Anti-inflammatory and neuroprotective Ro 08-2750(C13H10N4O3) Inhibitor of NGF-induced apoptosis. RKTS-33 (C7H8O4)selective inhibition of Fas ligand-dependent pathway alone 2. Nucleicacids 3,4-Dichloroisocoumarin Inhibitor of serine proteases −> granzymeB and blocks apoptotic internucleosomal DNA cleavage in thymocyteswithout the involvement of endonucleases. Does not affect thiolproteases and metalloproteases Actinomycin D, Streptomyces Also acts asa competitive inhibitor of serine proteases; Classical sp.anti-neoplastic drug. Cytotoxic inducer of apoptosis against tumorcells. A DNA dependent inhibitor of RNA synthesis, actinomycin promotesinduction of apoptosis by some specific stimuli, for example, TRAIL andFas (CD95). Actinomycin D can also alleviate or block the apoptoticprocess and decrease the cytotoxicity induced by several stimuli such asthe dihydrofolate reductase inhibitor aminopterin and the prostaglandinderivative 15-deoxy-D12,14-prostaglandin J2, thus it can have both proand anti-apoptotic activities in some systems. According to oneembodiment, said compound is not used as stabilizer according to thepresent invention. Aurintricarboxylic Acid Inhibitor of DNAtopoisomerase II Baicalein A cell-permeable flavone that inhibits theactivity of 12- lipoxygenase (IC50 = 120 nM) and reverse transcriptase.Protects cortical neurons from β-amyloid induced toxicity. Reducesleukotriene biosynthesis and inhibits the release of lysosomal enzymes.Also inhibits cellular Ca2+ uptake and mobilization, andadjuvant-induced arthritis. Reported to inhibit microsomal lipidperoxidation by forming an iron-baicalein complex. Inhibitstopoisomerase II and induces cell death in hepatocellular carcinoma celllines. Potentiates contractile responses to nerve stimulation. Inhibitsprotein tyrosine kinase and PMA-stimulated protein kinase CCamptothecin, A cell-permeable DNA topoisomerase I inhibitor. Exhibitsanti- Camptotheca acuminata leukemic and antitumor properties. Inducesapoptosis in HL-60 cells and mouse thymocytes. Arrests cells at the G2/Mphase. According to one embodiment, said compound is not used.Diisopropylfluorophosphate serine protease inhibitorPhenylmethylsulfonyl Fluoride Irreversible inhibitor of serineproteases. Its mechanism of action is (PMSF) analogous to that ofdiisopropylfluorophosphate. PMSF causes sulfonylation of the active-siteserine residues. Also reported to inhibit internucleosomal DNAfragmentation in immature thymocytes. For a related, more stableinhibitor, see AEBSF (−)-Huperzine A An inhibitor of AChE. Antagonist ofNMDA receptors. Protects against glutamate-mediated excitotoxicity.Razoxane Inhibits topoisomerase II without inducing DNA strand breaks(topo II catalytic inhibitor). Suptopin-2 Suppressor of topoisomerase IIinhibition. Reverses cell cycle arrest; bypass of checkpoint function.Has inherent fluorescence and a distinct advantage in identification ofmolecule targets; effective concentraion in the μM range. 3. Enzymes3.1. Caspases Apoptosis Inhibitor; 2-(p- Effects attributable to theinhibition of caspase-3 activation Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate cIAP-1, Human, Recombinant, Recombinant, humancIAP-1 (amino acids 1-618) fused to the E. coli peptide sequenceMATVIDH10SSNG at the N-terminus and expressed in E. coli. cIAP is amember of the inhibitor of apoptosis family of proteins that inhibitsproteolytic activity of mature caspases by interaction of the BIR domainwith the active caspase CrmA, Recombinant CrmA (cowpox viral serpincytokine response modifier A) is purified from E. coli transformed witha construct containing the full-length coding region of the CrmA geneand 7 additional amino acids that do not affect the activity. CrmA is anatural inhibitor of human caspase-1 and granzyme B, enzymes that areinvolved in apoptosis Group III Caspase Inhibitor I A potent,cell-permeable, and irreversible inhibitor of Group III Peptidesequence: caspases (caspase-6, -8, -9, and -10), although more effectiveAc-Ile-Glu-Pro-Asp-CHO (SEQ towards caspases-6 and -8. Also inhibitscaspase-1 and caspase- ID NO: 3), Ac-IEPD-CHO (SEQ 3. When using withpurified native or recombinant enzyme, ID NO: 3), Caspase-8 inhibitorpretreatment with an esterase is required. III Kaempferol Acell-permeable phytoestrogen that inhibits topoisomerase I- catalyzedDNA religation in HL-60 cells. Offers protection against Aβ25-35-inducedcell death in neonatal cortical neurons. Its protective effects arecomparable to that of estradiol. Blocks the Aβ-induced activation ofcaspase-2, -3, -8, and -9, and reduces NMDA-induced neuronal apoptosis.Reported to be a potent inhibitor of monoamine oxidases. Acts as aninhibitor of COX-1 activity (IC50 = 180 μM), and of transcriptionalactivation of COX-2 (IC50 < 15 μM Q-VD-OPH General, PancaspaseBoc-D(OMe)-FMK General, Pancaspase Z-D(OMe)E(OMe)VD(OMe)- Caspase 3, 7FMK (SEQ ID NO: 4) Z-LE(OMe)TD(OMe)-FMK (SEQ Caspase 8 ID NO: 5)Z-YVAD(OMe)-FMK (SEQ ID Caspase 1, 4 NO: 6) Z-FA-FMK Inhibits CathepsinB Z-FF-FMK Cathepsin B, L Mu-PheHphe-FMK Cathepsin B, LZ-AE(OMe)VD(OMe)-FMK Caspase 10 (SEQ ID NO: 7) Z-ATAD(OMe)-FMK (SEQ IDCaspase 12 NO: 8) Z-VK(Biotin)-D(OMe)-FMK General CaspaseZ-LE(OMe)VD(OMe)-FMK Caspase 4 (SEQ ID NO: 9) Z-VAM-FMK Antiviralpeptide inhibitor, Inhibits HRV2 and HRV14 4′-Azidocytidine HCVInhibitor Caspase-13 Inhibitor I A potent, reversible inhibitor ofcaspase-13 (ERICE). Peptide sequence: Ac-Leu-Glu-Glu-Asp-CHO (SEQ ID NO:10) Caspase-13 Inhibitor II A cell-permeable, irreversible inhibitor ofcaspase-13. When using Peptide sequence: with purified native orrecombinant enzyme, pretreatment with an Z-Leu-Glu(OMe)-Glu(OMe)-esterase is required. Asp(OMe)-FMK (SEQ ID NO: 11) Caspase-1 Inhibitor IA potent, specific, and reversible inhibitor of caspase-1 (Ki = 200Peptide sequence: pM for human recombinant caspase-1), caspase-4, andcaspase- Ac-Tyr-Val-Ala-Asp-CHO (SEQ 5. Strongly inhibits anti-APO-1induced apoptosis in L929-APO-1 ID NO: 12) cells. Caspase-1 Inhibitor I,Cell- A cell-permeable inhibitor of caspase-1 (ICE; Interleukin-1βPermeable Converting Enzyme), caspase-4, and caspase-5. The C-terminalPeptide sequence: YVAD-CHO (SEQ ID NO: 72) sequence of this peptide is ahighly Ac-Ala-Ala-Val-Ala-Leu-Leu- specific, potent, and reversibleinhibitor of caspase-1 (Ki = 1 nM). Pro-Ala-Val-Leu-Leu-Ala-Leu- TheN-terminal sequence (amino acid residues 1-16) correspondsLeu-Ala-Pro-Tyr-Val-Ala-Asp- to the hydrophobic region (h-region) of thesignal peptide of the CHO (SEQ ID NO: 13) Kaposi fibroblast growthfactor (K-FGF) and confers cell- permeability to the peptide Caspase-1Inhibitor II A cell-permeable and irreversible inhibitor of caspase-1(Ki = 760 Peptide sequence: pM), caspase-4, and caspase-5. InhibitsFas-mediated apoptosis Ac-Tyr-Val-Ala-Asp-CMK (SEQ and acidicsphingomyelinase activation ID NO: 14) Caspase-1 Inhibitor IV A highlyselective, competitive, cell-permeable, and irreversible Peptidesequence: inhibitor of caspase-1 , caspase-4, and caspase-5. Inactivatesthe Ac-Tyr-Val-Ala-Asp-AOM (SEQ enzyme with a rate limited by diffusionand is relatively inert toward ID NO: 15) (AOM = 2,6- otherbionucleophiles such as glutathione, making it an excellentdimethylbenzoyloxymethyl candidate for in vivo studies of enzymeinhibition ketone) Caspase-1 Inhibitor V A potent inhibitor ofcaspase-1-like proteases. Blocks apoptotic cell Peptide sequence: deathin human myeloid leukemia U937 cells and blocks Z-Asp-CH2-DCBetoposide-induced DNA fragmentation Caspase-1 Inhibitor VI A potent,cell-permeable, and irreversible inhibitor of caspase-1 Peptidesequence: (ICE), caspase-4, and caspase-5 Z-Tyr-Val-Ala-Asp(OMe)—CH2F*(SEQ ID NO: 16) Caspase-2 Inhibitor I A cell-permeable and irreversibleinhibitor of caspase-2 (ICH-1 Peptide sequence: Z-Val-Asp(OMe)-Val-Ala-Asp(OMe)—CH2F* (SEQ ID NO: 17) Caspase-2 Inhibitor II A reversibleinhibitor of caspase-2 and caspase-3 Peptide sequence:Ac-Leu-Asp-Glu-Ser-Asp-CHO (SEQ ID NO: 18) Caspase-3/7 Inhibitor I Apotent, cell-permeable, and specific, reversible inhibitor of Peptidesequence: caspase-3 (Ki = 60 nM) and caspase-7 (Ki = 170 nM).5-[(S)-(+)-2- (Methoxymethyl)pyrrolidino]sul- fonylisatin Caspase-3Inhibitor I A very potent, specific, and reversible inhibitor ofcaspase-3 (IC50 = Peptide sequence: 200 pM), caspase-6, caspase-7,caspase-8, and caspase-10. Ac-Asp-Glu-Val-Asp-CHO (SEQ ID NO: 19)Caspase-3 Inhibitor I, Cell- A cell-permeable inhibitor of caspase-3, aswell as caspase-6, Permeable caspase-7, caspase-8, and caspase-10. TheC-terminal DEVD- Peptide sequence: CHO (SEQ ID NO: 73) sequence of thispeptide is a highly Ac-Ala-Ala-Val-Ala-Leu-Leu- specific, potent, andreversible inhibitor of caspase-3 (Ki < 1 nM)Pro-Ala-Val-Leu-Leu-Ala-Leu- that has also been shown to stronglyinhibit PARP cleavage in Leu-Ala-Pro-Asp-Glu-Val-Asp- cultured humanosteosarcoma cell extracts (IC50 = 200 pM). The CHO (SEQ ID NO: 20)N-terminal sequence (amino acid residues 1-16) corresponds to thehydrophobic region (h-region) of the signal peptide of Kaposi fibroblastgrowth factor (K-FGF) and confers cell-permeability to the peptide. A 5mM (1 mg/100 μl) solution of Caspase-3 Inhibitor I, Cell-permeable (Cat.No. 235427) in DMSO is also available. Caspase-3 Inhibitor II A potent,cell-permeable, and irreversible inhibitor of caspase-3 as Peptidesequence: well as caspase-6, caspase-7, caspase-8, and caspase-10. WhenZ-Asp(OCH3)-Glu(OCH3)-Val- using with purified native or recombinantenzyme, pretreatment Asp(OCH3)-FMK (SEQ ID NO: with an esterase isrequired. A 5 mM (250 μg/75 μl) solution of Z- 21) DEVD-FMK (SEQ ID NO:74)(Cat. No. 264156) in DMSO is also available Caspase-3 Inhibitor III Apotent, cell-permeable, and irreversible inhibitor of caspase-3 asPeptide sequence: well as caspase-6, caspase-7, caspase-8, andcaspase-10 Ac-Asp-Glu-Val-Asp-CMK (SEQ ID NO: 22) Caspase-3 Inhibitor IVA specific inhibitor of caspase-3. This tetrapeptide inhibitor hasPeptide sequence. been used with the caspase-6 inhibitor Ac-VEID-CHO(SEQ ID Ac-Asp-Met-Gln-Asp-CHO NO: 75) to dissect the pathway of caspaseactivation in Fas- (SEQ ID NO: 23) stimulated Jurkat cells Caspase-3Inhibitor V A potent, cell-permeable, and irreversible inhibitor ofcaspase-3, Peptide sequence: also recognizes caspase-1. When using withpurified native or Z-Asp(OMe)-Gln-Met- recombinant enzyme, pre-treatmentwith an esterase is required Asp(OMe)—CH2F* (SEQ ID NO: 24) Caspase-3Inhibitor VII A cell-permeable, non-peptidyl pyrroloquinoline compoundthat Peptide sequence: acts as a potent, reversible, and non-competitiveinhibitor of 2-(4-Methyl-8-(morpholin-4- caspase-3 (IC50 = 23 nM) with10-100-fold greater selectivity. ylsulfonyl)-1,3-dioxo-1,3- Shown todisplay higher anti-apoptotic activity than Z-VAD-FMKdihydro-2H-pyrrolo[3,4- (Cat. No. 627610) in a model of Staurosporine-(Cat. No. 569397) c]quinolin-2-yl)ethyl acetate induced apoptosis inhuman Jurkat T cells. Caspase-4 Inhibitor I A reversible caspase-4inhibitor Peptide sequence: Ac-Leu-Glu-Val-Asp-CHO (SEQ ID NO: 25)Caspase-4 Inhibitor I, Cell- A potent, cell-permeable, and reversibleinhibitor of caspase-4. Permeable The N-terminal sequence (amino acidresidues 1-16) corresponds Peptide sequence: to the hydrophobic regionof the signal peptide of Kaposi fibroblast Ac-Ala-Ala-Val-Ala-Leu-Leu-growth factor and confers cell permeability to the peptide.Pro-Ala-Val-Leu-Leu-Ala-Leu- Leu-Ala-Pro-Leu-Glu-Val-Asp- CHO (SEQ IDNO: 26) Caspase-5 Inhibitor I A potent, cell-permeable, and irreversibleinhibitor of caspase-5. Peptide sequence: Strongly inhibits caspase-1.Also inhibits caspase-4 and caspase-8 Z-Trp-Glu(OMe)-His- Asp(OMe)—CH2F*(SEQ ID NO: 27) Caspase-6 Inhibitor I A cell-permeable, irreversibleinhibitor of caspase-6. When using Peptide sequence: with purifiednative or recombinant enzyme, pretreatment with an Z-Val-Glu(OMe)-Ile-esterase is required Asp(OMe)—CH2F* (SEQ ID NO: 28) Caspase-6 InhibitorII, Cell- A potent, cell-permeable, and reversible inhibitor ofcaspase-6. The Permeable N-terminal sequence (amino acids 1-16)corresponds to the Peptide sequence: hydrophobic region of the signalpeptide of Kaposi fibroblast Ac-Ala-Ala-Val-Ala-Leu-Leu- growth factorand confers cell permeability to the peptidePro-Ala-Val-Leu-Leu-Ala-Leu- Leu-Ala-Pro-Val-Glu-Ile-Asp- CHO (SEQ IDNO: 29) Caspase-8 Inhibitor I, Cell- A potent, cell-permeable, andreversible inhibitor of caspase-8 and Permeable Granzyme B. TheN-terminal sequence (amino acids 1-16) Peptide sequence: corresponds tothe hydrophobic region of the signal peptide ofAc-Ala-Ala-Val-Ala-Leu-Leu- Kaposi fibroblast growth factor and conferscell permeability to the Pro-Ala-Val-Leu-Leu-Ala-Leu- peptideLeu-Ala-Pro-Ile-Glu-Thr-Asp- CHO (SEQ ID NO: 30) Caspase-8 Inhibitor IIA potent, cell-permeable, and irreversible inhibitor of caspase-8Peptide sequence: and granzyme B. Effectively inhibits influenzavirus-induced Z-Ile-Glu(OMe)-Thr- apoptosis in HeLa cells. Also inhibitsgranzyme B. When using with Asp(OMe)—CH2F* (SEQ ID NO: 31) purifiednative or recombinant enzyme, pretreatment with an esterase is required.A 5 mM (250 μg/76 μl) solution of Z-IETD- FMK (SEQ ID NO: 76) (Cat. No.218840) in DMSO is also available. Caspase-9 Inhibitor I A potent,cell-permeable, and irreversible inhibitor of caspase-9. Peptidesequence: May also inhibit caspase-4 and caspase-5. When using withZ-Leu-Glu(OMe)-His- purified native or recombinant enzyme, pretreatmentwith an Asp(OMe)—CH2F* (SEQ ID NO: 32) esterase is required. A 5 mM (250μg/72 μl) solution of Z-LEHD- FMK (SEQ ID NO: 77) (Cat. No. 218841) inDMSO is also available Caspase-9 Inhibitor II, Cell- A potent,cell-permeable, and reversible inhibitor of caspase-9. Permeable Mayalso inhibit caspase-4 and caspase-5. The N-terminal Peptide sequence:sequence (amino acids 1-16) corresponds to the hydrophobicAc-Ala-Ala-Val-Ala-Leu-Leu- region of the signal peptide of Kaposifibroblast growth factor and Pro-Ala-Val-Leu-Leu-Ala-Leu- confers cellpermeability to the peptide Leu-Ala-Pro-Leu-Glu-His-Asp- CHO (SEQ ID NO:33) Caspase-9 Inhibitor III A potent, irreversible inhibitor ofcaspase-9. Reported to reduce Peptide sequence: myocardial infarct sizeduring reperfusion (~70 nM). Ac-Leu-Glu-His-Asp-CMK (SEQ ID NO: 34)Caspase Inhibitor I A cell-permeable, irreversible, pan-caspaseinhibitor. Inhibits Fas- Peptide sequence: mediated apoptosis in Jurkatcells and staurosporine-induced cell Z-Val-Ala-Asp(OMe)—CH2F* death incorneal epithelial cells. When using with purified native or recombinantenzyme, pre-treatment with an esterase is required. Caspase Inhibitor IIA potent and reversible pan-caspase inhibitor. Peptide sequence:Ac-Val-Ala-Asp-CHO Caspase Inhibitor II, Cell- A cell-permeable,reversible pan-caspase inhibitor produced by Permeable attaching theN-terminal sequence (amino acids 1-16) of the Peptide sequence: Kaposifibroblast growth factor signaling peptide, which impartsAc-Ala-Ala-Val-Ala-Leu-Leu- cell-permeability to VAD peptide.Pro-Ala-Val-Leu-Leu-Ala-Leu- Leu-Ala-Pro-Val-Ala-Asp-CHO (SEQ ID NO: 35)Caspase Inhibitor III A cell-permeable, irreversible, broad-spectrumcaspase inhibitor. Peptide sequence: Boc-Asp(OMe)—CH2F* CaspaseInhibitor IV A general, irreversible caspase inhibitor. Peptidesequence: Boc-Asp(OBzl)-CMK Caspase Inhibitor VI An irreversible generalcaspase inhibitor. Useful for studies Peptide sequence: involvingrecombinant, isolated, and purified caspase enzymes. Z-Val-Ala-Asp-CH2F*Unlike Caspase Inhibitor I (Cat. No. 627610), this inhibitor does notrequire pretreatment with esterase for in vitro studies. A 10 mM (1mg/221 μl) solution of Caspase Inhibitor VI (Cat. No. 219011) in DMSO isalso available Caspase Inhibitor VIII A potent, reversible inhibitor ofcaspase-2 (Ki = 3.5 nM), caspase-3 Peptide sequence: (Ki = 1 nM) andcaspase-7 (Ki = 7.5 nM). Also serves as an Ac-Val-Asp-Val-Ala-Asp-CHOinhibitor of DRONC (Drosophila caspase), a glutamate/aspartate (SEQ IDNO: 36) protease. Caspase Inhibitor X A benzodioxane containing2,4-disubstituted thiazolo compound Peptide sequence: that acts as aselective, reversible and competitive inhibitor of BI-9B12 caspases (Ki= 4.3 μM, 6.2 μM and 2.7 μM for caspase-3, -7 and -8, respectively). Thebenzodioxane moiety is shown to fit in the ‘aspartate hole’ of thecaspases and possibly disrupt caspase-8 assisted cleavage of BID, aproapoptotic protein. Weakly affects the activity of anthrax lethalfactor, a metalloprotease, at ~20 μM Caspase-1 Inhibitors Including, butnot limited to Ac—N—Me-Tyr-Val-Ala-Asp-aldehyde (pseudo acid) (SEQ IDNO: 37) Ac-Trp-Glu-His-Asp-aldehyde (pseudo acid) (SEQ ID NO: 38)Ac-Tyr-Val-Ala-Asp-aldehyde (pseudo acid) (SEQ ID NO: 39)Ac-Tyr-Val-Ala-Asp-chloromethylketone (SEQ ID NO: 40)Ac-Tyr-Val-Ala-Asp-2,6-dimethylbenzoyloxymethylketone (SEQ ID NO: 41)Ac-Tyr-Val-Ala-Asp(OtBu)-aldehyde-dimethyl acetal (SEQ ID NO: 41)Ac-Tyr-Val-Lys-Asp-aldehyde (pseudo acid) (SEQ ID NO: 42)Ac-Tyr-Val-Lys(biotinyl)-Asp-2,6-dimethylbenzoyloxymethylketoneBiotinyl-Tyr-Val-Ala-Asp-chloromethylketone (SEQ ID NO: 43)Biotinyl-Val-Ala-DL-Asp-fluoromethylketoneFluorescein-6-carbonyl-Tyr-Val-Ala-DL-Asp(OMe)- fluoromethylketone (SEQID NO: 78) Fluorescein-6-carbonyl-Val-Ala-DL-Asp(OMe)-fluoromethylketoneZ-Asp-2,6-dichlorobenzoyloxymethylketoneZ-Tyr-Val-Ala-Asp-chloromethylketone (SEQ ID NO: 79)Z-Val-Ala-DL-Asp-fluoromethylketoneZ-Val-Ala-DL-Asp(OMe)-fluoromethylketone Caspase-2 Inhibitors Including,but not limited to Ac-Val-Asp-Val-Ala-Asp-aldehyde (pseudo acid) (SEQ IDNO: 44) Fluorescein-6-carbonyl-Val-Asp(OMe)-Val-Ala-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 45)Z-Val-Asp(OMe)-Val-Ala-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 45)Caspase-3 Precursor Protease Including, but not limited to InhibitorsAc-Glu-Ser-Met-Asp-aldehyde (pseudo acid) (SEQ ID NO: 46)Ac-Ile-Glu-Thr-Asp-aldehyde (pseudo acid) (SEQ ID NO: 47) Caspase-3Inhibitors Including, but not limited to Ac-Asp-Glu-Val-Asp-aldehyde(pseudo acid) (SEQ ID NO: 48) Ac-Asp-Met-Gln-Asp-aldehyde (pseudo acid)(SEQ ID NO: 49) Biotinyl-Asp-Glu-Val-Asp-aldehyde (pseudo acid) (SEQ IDNO: 80) Caspase-3/7 Inhibitor IIFluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 81)Z-Asp(OMe)-Gln-Met-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 50)Z-Asp-Glu-Val-Asp-chloromethylketone (SEQ ID NO: 51)Z-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 52)Caspase-4 Inhibitors Including, but not limited toAc-Leu-Glu-Val-Asp-aldehyde (pseudo acid) (SEQ ID NO: 53)Z-Tyr-Val-Ala-DL-Asp-fluoromethylketone (SEQ ID NO: 54) Caspase-6Inhibitors Including, but not limited to Ac-Val-Glu-Ile-Asp-aldehyde(pseudo acid) (SEQ ID NO: 55)Fluorescein-6-carbonyl-Val-Glu(OMe)-Ile-DL-Asp(OMe)- fluoromethylketone(SEQ ID NO: 56) Z-Val-Glu(OMe)-Ile-DL-Asp(OMe)-fluoromethylketone (SEQID NO: 56) Caspase-8 Inhibitors Including, but not limited toAc-Ile-Glu-Pro-Asp-aldehyde (pseudo acid) (SEQ ID NO: 57)Boc-Ala-Glu-Val-Asp-aldehyde (pseudo acid) (SEQ ID NO: 58)Fluorescein-6-carbonyl-Ile-Glu(OMe)-Thr-DL-Asp(OMe)- fluoromethylketone(SEQ ID NO: 59) Fluorescein-6-carbonyl-Leu-Glu(OMe)-Thr-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 60)Z-Ile-Glu(OMe)-Thr-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 59)Z-Leu-Glu(OMe)-Thr-DL-Asp(OMe)-fluoromethylketone (SEQ ID NO: 60)Z-LE(OMe)TD(OMe)-FMK (SEQ ID NO: 60) Caspase-9 Inhibitors Including, butnot limited to Ac-Leu-Glu-His-Asp-aldehyde (pseudo acid) (SEQ ID NO: 61)Ac-Leu-Glu-His-Asp-chloromethylketone (SEQ ID NO: 62)Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)- fluoromethylketone(SEQ ID NO: 82) Caspase-10 Inhibitors Including, but not limited toFluorescein-6-carbonyl-Ala-Glu(OMe)-Val-DL-Asp(OMe)- fluoromethylketone(SEQ ID NO: 83) Z-Ala-Glu-Val-DL-Asp-fluoromethylketone (SEQ ID NO: 63)3.2. Calpain Calpain Inhibitor III A potent, cell-permeable inhibitor ofcalpain I and II (Ki = 8 nM). Peptide sequence: Reducescapsaicin-mediated cell death in cultured dorsal root Z-Val-Phe-CHOganglion. Reported to block A23187-induced suppression of neuriteoutgrowth in isolated hippocampal pyramidal neurons. Exhibitsneuroprotective effect in glutamate-induced toxicity. Calpain InhibitorIV A potent, cell-permeable, and irreversible inhibitor of calpain II(k2 = Peptide sequence: 28,900 M−1s−1). Also acts as an inhibitor ofcathepsin L (k2 = Z-Leu-Leu-Tyr-CH2F 680,000 M−1s−1). Calpain InhibitorV A potent, cell-permeable, and irreversible inhibitor of calpainPeptide sequence: Mu-Val-HPh—CH2F (Mu = morpholinoureidyl; HPh =homophenylalanyl) Ac-Leu-Leu-Nle-al Cell-permeable, peptide aldehydeinhibitor of calpain I (Ki = 190 nM), calpain II (Ki = 150 nM),cathepsin L (Ki = 0.5 nM) and other neutral cysteine proteases. Inhibitscell cycle progression at G1/S and metaphase/anaphase in CHO cells byinhibiting cyclin B degradation. Also stimulates HMG-CoA synthasetranscription by inhibiting degradation of active SREBP-1 (sterolregulatory element-binding protein 1). Protects against neuronal damagecaused by hypoxia and ischemia. Inhibits apoptosis in thymocytes andmetamyelocytes. Also prevents nitric oxide production by activatedmacrophages by interfering with the transcription of inducible nitricoxide synthase (iNOS; NOS II). Inhibits proteolytic degradation ofIkBalpha and IkBβ in RAW macrophages induced with LPS. It also prolongassociation of MHC class I molecules with the transporters associatedwith antigen processing Z-LLY-FMK Calpain N-Acetyl-Leu-Leu-Met Calpain IN-Acetyl-Leu-Leu-Nle-CHO Calpain I 3.3. others BAPTA/AMMembrane-permeable form of BAPTA. Can be loaded into a wide variety ofcells, where it is hydrolyzed by cytosolic esterases and is trappedintracellularly as the active chelator BAPTA. Prevents cocaine-inducedventricular fibrillations. Abolishes vitamin D3- induced increase inintracellular Ca2+. Induces inactivation of protein kinase C. Alsoinhibits thapsigargin-induced apoptosis in rat thymocytes. Granzyme BInhibitor I A weak inhibitor of the human and murine granzyme B. AlsoPeptide sequence: inhibits the apoptosis-related DNA fragmentation inlymphocytes Z-Ala-Ala-Asp-CH2Cl by fragmentin 2, a rat lymphocytegranule protease homologous to granzyme B (ID50 = 300 nM). Granzyme BInhibitor II A potent, reversible inhibitor of granzyme B and caspase-8(Ki = 1 Peptide sequence: nM). Also inhibits caspase-1 (<6 nM),caspase-6 (5.6 nM), and Ac-Ile-Glu-Thr-Asp-CHO (SEQ caspase-10 (27 nM).ID NO: 64) Granzyme B Inhibitor IV A reversible inhibitor of granzyme Band caspase-8 Peptide sequence: Ac-Ile-Glu-Pro-Asp-CHO (SEQ ID NO: 65)Leupeptin, Hemisulfate, A reversible inhibitor of trypsin-like proteasesand cysteine Microbial proteases. Also known to inhibitactivation-induced programmed cell death and to restore defective immuneresponses of HIV+ donors N-Ethylmaleimide Sulfhydryl alkylating reagentthat inhibits H+-ATPase and suppresses the short circuit current (IC50 =22 μM) in pancreatic duct cells. Inactivates NADP-dependent isocitratedehydrogenase. Also a potent inhibitor of both Mg2+ andCa2+/Mg2+-stimulated DNA fragmentation in rat liver nuclei. Stimulatesarachidonic acid release through activation of PLA2 in endothelial cellsNα-Tosyl-Lys Chloromethyl Inhibits trypsin-like serine proteinases.Irreversibly inactivates Ketone, Hydrochloride (TLCK) trypsin withoutaffecting chymotrypsin. Prevents nitric oxide production by activatedmacrophages by interfering with transcription of the iNOS gene. Blockscell-cell adhesion and binding of HIV-1 virus to the target cells. Inmacrophages, blocks nitric oxide synthase induced by interferon-γ andlipopolysaccharides (EC50 = 80 μM). Prevents endonucleolysisaccompanying apoptotic death of HL-60 leukemia cells and normalthymocytes Omi/HtrA2 Protease Inhibitor, A cell-permeablefurfurylidine-thiobarbituric acid compound that Ucf-101 acts as apotent, specific, competitive, and reversible inhibitor of thepro-apoptotic, heat-inducible, mitochondrial serine protease Omi/HtrA2(IC50 = 9.5 μM for His-Omi134-458). Shows very little activity againstvarious other serine proteases tested (IC50 ≥ 200 μM). Reported to blockOmi/HtrA2 induced cell death in caspase-9 (−/−) null fibroblasts.Phenylarsine Oxide A membrane-permeable protein tyrosine phosphataseinhibitor (IC50 = 18 μM). Stimulates 2-deoxyglucose transport ininsulin- resistant human skeletal muscle and activates p56lck proteintyrosine kinase. Blocks TNF-α-dependent activation of NF-κB in humanmyeloid ML-1a cells. PAO inhibits the protease activities of recombinanthuman caspases as well as endogenous caspases that are active inextracts of pre-apoptotic chicken DU249 cells (S/M extracts).Phorbol-12,13-dibutyrate Activates protein kinase C. Stimulates thephosphorylation of Na+,K+-ATPase, thereby inhibiting its activity.Promotes the expression of inducible NOS in cultured hepatocytes.Hypericin Inhibits PKC, CKII, MAP Kinase, Insulin R, EGFR, PI-3 Kinaseand also noted to possess antiviral activity. Butyrolactone I Acell-permeable and highly selective inhibitor of cyclin-dependentprotein kinases (Cdks) that inhibits cell cycle progression at the G1/Sand G2/M transitions. Inhibits p34cdk1/cyclinB (Cdk1; IC50 = 680 nM).Also selectively inhibits Cdk2 and Cdk5 kinases. Has little effect oncasein kinase I, casein kinase II, EGF receptor kinase, MAP kinase, PKA,and PKC. Shown to prevent the phosphorylation of retinoblastoma proteinand H1 histone. Also blocks Fas-induced apoptosis in HL-60 cells andshows antitumor effects on human lung cancer cell lines NilotinibSpecific BCR-ABL-Tyrosinkinase-Inhibitor Quercetin(Sophoretin) Quercetinis a PI3K and PKC inhibitor with IC50 of 3.8 μM and 15 μg/ml. Itstrongly abrogated PI3K and Src kinases, mildly inhibited Akt1/2, andslightly affected PKC, p38 and ERK1/2. [1][2] Quercetin is anaturally-occurring polar auxin transport inhibitor with IC50 of 0.8,16.7, 6.1, 11.36 μM for the inhibition of LDH % release, the inhibitionof TNF-induced PMN-EC adhesion, TNF- induced inhibition of DNA synthesisand proliferation

EXAMPLES

In the following examples, materials and methods of the presentinvention are provided. It should be understood that these examples arefor illustrative purpose only and are not to be construed as limitingthis invention in any manner.

I. Cell and Transcript Level Stabilising Properties of Different Primaryand Secondary Carboxylic Acid Amides

1. Materials and Methods

A test system and study setup was established that allows theidentification of reagent compositions that have gene transcriptstabilisation capabilities, as indicated by constant levels oftranscripts from selected genes (c-fos, IL-1beta, IL-8, p53). Thesetranscripts were identified in prior studies as very unstabletranscripts during storage, which are induced or down regulated (gainsand losses of transcripts) within minutes after blood collection andwere therefore chosen as “worst case” markers for screening purposes.

Moreover to exclude any possible influence of the RNA preparationprotocol on the analysis of transcript levels, the same RNA preparationtechnology used for the [+] control of sample stabilisation was alsoused for [−] control of samples stabilisation and for test samples.

Blood was collected from multiple donors into replicate EDTA blood tubes(BD, [−] control of sample stabilisation) and PAXgene Blood RNA Tubes(PreAnalytiX) serving as [+] control of sample stabilisation. PAXgeneBlood RNA tubes contain a composition (see also background of theinvention) that lysis cells and thereby “freeze” the gene transcriptionprofile. PAXgene Blood RNA tubes are for stabilizing blood for geneexpression analysis. One aim was to find stabilization method that notbased on cell lysis but achieves the same or similar performance as thePAXgene Blood RNA tubes in transcript level stabilization. Therefore,samples collected in PAXgene Blood and thus treated with thestabilization composition contained therein were used as positivecontrol in the experimental set up. Immediately after blood collectionhalf of the EDTA blood samples were treated with RNA stabilisation testsolution, resulting in blood test samples. 1 ml stabilisation additivewas added to 9 ml EDTA blood. The blood and stabiliser solution wasmixed by tube inversion for 8-10 times. All blood tubes were incubatedat RT for 0, 24 and 72 hours. PAXgene Blood RNA Tubes defined as withoutincubation (test timepoint 0 h) were incubated for 2 h as this is theminimal cell lysis and RNA precipitation time required to isolate RNAfrom PAXgene Blood RNA Tubes. After incubation, PAXgene Blood RNA Tubesamples were frozen at −20° C., while aliquots of 2.5 ml per EDTA bloodand samples of EDTA blood mixed with stabiliser were transferred at testtimepoint 0 h or after the stabilization period to PAXgene Blood RNATubes, mixed by tube inversion as described and incubated for 6 h inPAXgene Blood RNA Tubes for lysis followed by storage at −20° C.

RNA preparation was performed from all blood samples that were finallyin PAXgene Blood RNA Tubes with the PAXgene 96 Blood RNA Kit (QIAGEN)according to the protocol described in the handbook after thawing andequilibration of tubes to room temperature

Quantity (RNA yield) and quality (RNA purity, RNA integrity) of RNA wasmeasured by UV spectroscopy and miniaturised capillary gelelectrophoresis with RIN calculation (Nanochips on Agilent Bioanalyzer).

Transcript levels of all RNA samples were analysed by real time RT-PCRusing monoplex assays of FOS, IL1B, IL8 and TP53, normalized to theamount of template input into the reaction. Resulting CT valuesreflecting the amount of transcripts were directly compared. Relativetranscripts levels unaffected from blood sample incubation at RT wereindicated by constant CT values, while gains of transcripts (e.g., bygene induction) were indicated by lower CT and loss of transcripts(e.g., by gene repression) by higher CT values.

Where indicated, cell morphology was investigated by microscopicevaluation of blood smears and cell integrity by flow cytometry (FC).

2. Tested Carboxylic Acid Amides

Example 1: Stabilization Using Formamide

Blood was collected from multiple donors into replicate EDTA blood tubes(BD, [−] control of sample stabilisation) and PAXgene Blood RNA Tubes(PreAnalytiX) serving as [+] control of sample stabilisation.Immediately after blood collection half of the EDTA blood samples weretreated with RNA stabilisation test solution, resulting in blood testsamples. In detail, 1 ml stabilisation additive (50% v/v formamide,5×MOPS buffer, pH5.5) was added to 9 ml EDTA blood. Blood mixing,incubation, transfer of blood sample aliquots to PAXgene Blood RNATubes, freezing, storage and RNA preparation was done as describedabove. RNA was subjected to transcript level analysis as described abovein Material and methods. Quantity (RNA yield) and quality (RNA purity,RNA integrity) of RNA was measured by UV spectroscopy and miniaturisedcapillary gel electrophoresis with RIN calculation (Nanochips on AgilentBioanalyzer). Transcript levels of all RNA samples were analysed by realtime RT-PCR using monoplex assays of FOS, IL1B, IL8 and TP53, normalizedto the amount of template input into the reaction. Resulting CT valuesreflecting the amount of transcripts were directly compared. Relativetranscripts levels unaffected from blood sample incubation at RT wereindicated by constant CT values, while gains of transcripts (e.g., bygene induction) were indicated by lower CT and loss of transcripts(e.g., by gene repression) by higher CT values. Cell morphology wasinvestigated by microscopic evaluation of blood smears and cellintegrity by flow cytometry (FC).

RNA could be isolated from all samples with high yield. Thus, it wasconfirmed that the stabilization did not impair the subsequent RNAisolation. Purity of RNA prepared from all samples was in the range ofhighly pure RNA (A260/A280 in the range of 2.0 to 2.2). Furthermore, RNAintegrity of the isolated RNA was high (RIN>8).

As expected, the relative levels of transcripts from four selectedmarker genes stayed stable in the PAXgene Blood RNA Tubes and werealtered in the EDTA tubes that did not receive the stabiliser (ex vivogene induction/gain of transcripts of FOS, IL8 and gene repression/lossof transcripts of IL1B, TP53). EDTA blood samples mixed with thestabiliser formamide showed stabilised expression levels indicated byunchanged or by only minor minimal changes of CT values over time ofblood sample storage. Thus, formamide is highly effective in stabilizingtranscript levels and thus the gene transcription profile of cellscontained in the blood sample. The results are shown in FIGS. 1 to 4.

Intact white blood cells were detected in untreated EDTA blood and EDTAblood mixed with the stabilisation additive (test solution) that wasincubated at RT for up to three days (see FIG. 5). This demonstratedthat the stabilisation additive did not act lytic on WBC. Blood wasdirectly drawn into BD EDTA tubes and replicate samples were keptuntreated ([+] control [EDTA]) or were treated with test solution (finalconcentration of 5% v/v formamide and 0.5×MOPS buffer [pH5.5]) asdescribed above. Immediately after collection and treatment of samples,blood aliquots were analysed without incubation (0 h samples), whileremaining samples were incubated at RT for one and three days (24 h and72 h samples) prior to microscopic cell integrity analysis. Blood smearswere 40× magnified and microscopic images were taken to evaluate cellintegrity. Image sections containing single WBC were digitally enlargedto document the presence of intact cells. Untreated EDTA blood samples([+] control [EDTA]) served as positive control of blood samplescontaining intact cells. Indicated by white arrow heads within eachpicture are WBC (nucleus containing cells) surrounded by erythrocytes(nucleus-free cells).

The results obtained by microscopic analysis were verified by theanalysis of cell integrity with flow cytometry. FC showed the presenceof intact WBC in untreated EDTA blood and EDTA blood mixed with thestabilisation additive (test solution) that was incubated at RT for upto three days (see FIG. 6). Lymphocytes and monocytes were not affectedby lysis as the result of blood incubation in untreated and treatedsamples. Some lysis appeared to have occurred with neutrophilicgranuloctes at longer storage. However, as the release of genomic DNA isstill efficiently prevented (see examples in section II below), it maywell be that the seen differences in the FC profiles have other reasons.However, not all white blood cells may be equally well stabilized duringlonger stabilization periods. However, intact cells were detected andthe detected cell populations are important for certail diagnosticapplications which aim e.g. at the analysis of lymphocytes.

The experiments performed in example 1 show that formamide is effectivein stabilizing transcript levels and thus the transcriptome in bloodsamples. RNA could be isolated with good yield and purity suitable forRT-PCR analysis. Furthermore, cells could be isolated from thestabilized samples.

Example 2: Stabilization Using Acetamide

EDTA blood samples were kept untreated or mixed with 8% w/v acetamideimmediately after blood collection. Blood samples collected in PAXgeneRNA blood tubes served again as control. Sample handling and RNAisolation was performed from blood samples without and from replicatetubes after incubation for one day at RT as described in material andmethods. Transcript levels of all RNA samples were analysed as describedin material and methods by real time RT-PCR using monoplex assays ofFOS, IL1B, IL8 and TP53, normalized to the amount of template input intothe reaction. The results are shown in FIGS. 7 to 10. Resulting CTvalues reflecting the amount of transcripts were directly compared.Relative transcripts levels unaffected from blood sample incubation atRT were indicated by constant CT values, while gains of transcripts(e.g., by gene induction) were indicated by lower CT and losses oftranscripts (e.g., by gene repression) by higher CT values. As can beseen, also the primary carboxylic acid amide acetamide was highlyeffective in stabilizing transcript levels.

Example 3: Stabilization Using N-Methylacetamide

Samples were prepared and processed as described in example 2, howeverusing 2% (w/v) N-methylacetamide as stabilizer in the compositioncomprising the blood sample and the stabilising agent. The results areshown in FIGS. 11 to 14. As can be seen, the secondary carboxylic acidamide N-methylacetamide was effective in stabilizing transcript levelsfor up to three days.

Examples 1 to 3 show that different primary and secondary carboxylicacid amides are highly effective in stabilizing the gene transcriptionprofile of cells in blood samples.

II. Stabilization of the Extracellular Nucleic Acid Population in BloodSamples Using Different Primary and Secondary Carboxylic Acid Amides

Materials and Methods

Different primary and secondary carboxylic acid amides were tested fortheir ability to stabilize a cell-containing biological sample, here awhole blood sample, either alone or in combination with a caspaseinhibitor. As can be seen from the below examples, primary and secondarycarboxylic acid amides were found to efficiently stabilize blood samplesand in particular, were found to inhibit the release of genomic DNA fromcells comprised in the stabilized blood sample. Thus, they were capableof stabilizing the extracellular nucleic acid population. Furthermore,it was found that using primary and secondary carboxylic acid amides incombination with a caspase inhibitor advantageously improved theachieved stabilization effect. A respective combination resulted in aprolonged stabilization effect and furthermore, showed less variation inthe stabilization effect achieved with blood samples obtained fromdifferent donors. This is an important advantage, as it provides auniform, reliable stabilization method for blood samples which preservesthe extracellular nucleic acid population.

Blood Collection and Stabilization

Blood obtained from donors was collected into 10 ml K2 EDTA tubes (BD).4.5 ml of the respectively collected blood was mixed with 0.9 ml ofdifferent stabilization solutions (see below examples on the details ofthe tested stabilization solutions).

All stabilized blood samples were set up in triplicates per conditionand test time point. At time point 0 (reference), immediately aftermixing the stabilization solution and blood, plasma was generated andthe circulating extracellular DNA was extracted. The residual stabilizedblood sample was stored for three days and six days at room temperature.

As a reference control, the EDTA stabilized blood sample (collected inK2 EDTA tubes without further additives) was also stored for 3 and 6days. Furthermore, where indicated in the examples, a stabilizationsolution comprising a caspase inhibitor and N,N-dimethylacetamide (DMAA)was included in the comparison (final concentration in the mixture thatis obtained when adding said stabilization solution to the blood sample:7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2-OPH (caspase inhibitor)and 5% DMAA) (see unpublished PCT/EP2012/070211 and PCT/EP2012/068850).DMAA stabilized samples as tested herein always included additionally acaspase inhibitor. No DMAA containing stabilizing solutions withoutcaspase inhibitor were tested in the subsequent examples.

Extracellular Nucleic Acid Isolation and Analysis

Plasma was generated from the stabilized and unstabilized (EDTA) bloodsamples by inverting the blood containing tubes for four times. Then,the tubes were centrifuged for 10 minutes at 1900×g at 4° C. 2.5 ml ofthe plasma fraction was transferred into a fresh 15 ml falcon tube andcentrifuged for 10 minutes at 16.000×g at 4° C. 2 ml of the respectivelycleared plasma was used for extracellular nucleic acid isolation usingthe QIAamp circulating nucleic acid kit (QIAGEN) according to themanufacturer's instructions.

The isolated extracellular DNA was analyzed using two different qPCRassays, targeting different fragment lengths of the 18S ribosomal DNA:

18S ribosomal DNA: 66 bp amplicon

18S ribosomal DNA: 500 bp amplicon

TABLE 2 summarizes the information of the used DNA targetsequences detected by qPCR Target description position positionSequence 5′-3′ dye h 18S rDNA p12-region of ForwardGCCGCTAGAGGTGAAATTCTTG 5′ Cy5- 66 bp  chromosome 13, (SEQ ID NO: 66)BHQ 3′ amplicon 14, 15, 21, 22 reverse CATTCTTGGCAAATGCTTTCG(SEQ ID NO: 67) probe ACCGGCGCAAGACGGACCAGA (SEQ ID NO: 68) h18S rDNAp12-region of forward GTCGCTCGCTCCTCTCCTACTT 5′ FAM- 500 bpchromosome 13, (SEQ ID NO: 69) BHQ 3′ amplicon 14, 15, 21, 22 reverseGGCTGCTGGCACCAGACTT (SEQ ID NO: 70) probe CTAATACATGCCGACGGGCGCTGAC (SEQ ID NO: 71)

Cycle threshholds of the individual samples were translated into amountof gDNA in the eluate, according to a gDNA standard curve. The gDNAamount of the storage time points was compared to the time zero gDNAlevel from the same donor and is shown as fold increase in the figures.Especially the increase of the 500 bp fragment in the plasma fraction ofthe blood sample after storage is an indication for a lysis/destructionof white blood cells. Thus, the lower the amount of released 500 bp DNA,the better the performance of the stabilization method.

Results

The figures corresponding to the subsequently described examples showthe increase of DNA relative to time point 0 with the differentstabilization solutions (fold change) using different amplicon lengthsof 18S rRNA gene. Bars indicate the mean of the triplicate samples percondition and test time point.

Example 4: Stabilization Using Formamide without and with CaspaseInhibitor

In example 4, different concentrations of formamide were used eitheralone or in combination with a caspase inhibitor for stabilizing bloodsamples. The focus of the analysis was the stabilization of theextracellular nucleic acid population as determined by analyzing theincrease of 18S rDNA. Stabilization and processing of the samples wereperformed as described in materials and methods under II.

Stabilization Solutions without Caspase Inhibitor

The stabilization solutions without the caspase inhibitor comprisedformamide in different concentrations and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture: 7.2 mg/ml K2 EDTA and different concentrations of formamide(see figures for details)

Stabilization Solutions with Caspase Inhibitor

These stabilization solutions comprised formamide in differentconcentrations, a caspase inhibitor and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2—OPH (caspase inhibitor)and different concentrations of formamide (see figures for details).

FIGS. 15 to 18 show the stabilization results obtained for blood fromdifferent donors. FIGS. 15 to 18 compare the results that were achievedeither with formamide alone or formamide in combination with the caspaseinhibitor. As can be seen, formamide alone was in differentconcentrations effective to stabilize the extracellular nucleic acidpopulation as can be seen from the significantly reduced increase in 18SrDNA in formamide stabilized samples. However, variations in thestabilization effectivity were seen between different donors. Suchvariations did not occur when using a caspase inhibitor in addition toformamide. Therefore, it is preferred to use formamide in combinationwith a caspase inhibitor.

FIGS. 19 to 21 show the stabilization results obtained for blood fromdifferent donors wherein the blood samples were stabilized withformamide in different concentrations (see figures for details) incombination with a caspase inhibitor. Therefore, the stabilizationsolutions used comprised formamide and the caspase inhibitor. As can beseen, uniform stabilization results were obtained with variousconcentrations of formamide.

Example 5: Stabilization Using Acetamide with Caspase Inhibitor

In example 5, different concentrations of acetamide were used incombination with a caspase inhibitor for stabilizing blood samples. Thefocus of the analysis was the stabilization of the extracellular nucleicacid population as determined by analyzing the increase of 18S rDNA.Stabilization and processing of the samples were performed as describedin materials and methods under II.

The stabilization solutions comprised acetamide in differentconcentrations, a caspase inhibitor and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2-OPH (caspase inhibitor)and different concentrations of acetamide (see figures for details).

FIGS. 22 and 23 show the stabilization results obtained for blood fromdifferent donors wherein the blood samples were stabilized withacetamide in different concentrations (see figures for details) and acaspase inhibitor. As can be seen, the tested stabilization compositionscomprising acetamide in different concentrations were effective tostabilize the extracellular nucleic acid population as can be seen fromthe significantly reduced increase in 18S rDNA in the acetamnidestabilized samples.

Example 6: Stabilization Using Propanamide with Caspase Inhibitor

In example 6, different concentrations of propanamide were used incombination with a caspase inhibitor for stabilizing blood samples. Thefocus of the analysis was the stabilization of the extracellular nucleicacid population as determined by analyzing the increase of 18S rDNA.Stabilization and processing of the samples were performed as describedin materials and methods under II.

The stabilization solutions comprised propanamide in differentconcentrations, a caspase inhibitor and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2—OPH (caspase inhibitor)and different concentrations of propanamide (see figures for details).

FIG. 24 shows the stabilization results obtained when blood wasstabilized with propanamide in different concentrations (see figure fordetails) and a caspase inhibitor. As can be seen, the testedstabilization compositions comprising propanamide were in differentconcentrations effective to stabilize the extracellular nucleic acidpopulation as can be seen from the significantly reduced increase in 18SrDNA in the propanamide stabilized samples.

Example 7: Stabilization Using Butanamide without and with CaspaseInhibitor

In example 7, different concentrations of butanamide were used eitheralone or in combination with a caspase inhibitor for stabilizing bloodsamples. The focus of the analysis was the stabilization of theextracellular nucleic acid population as determined by analyzing theincrease of 18S rDNA. Stabilization and processing of the samples wereperformed as described in materials and methods under II.

Stabilization Solutions without Caspase Inhibitor

The stabilization solutions without the caspase inhibitor comprisedbutanamide in different concentrations and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA and different concentrations of butanamide (seefigures for details)

Stabilization Solutions with Caspase Inhibitor

These stabilization solutions comprised butanamide in differentconcentrations, a caspase inhibitor and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2—OPH (caspase inhibitor)and different concentrations of butanamide (see figures for details).

FIGS. 25 to 29 show the stabilization results obtained for blood fromdifferent donors using stabilization solutions comprising butanamide.FIGS. 25 and 26 compare the results that were achieved either withbutanamide alone or butanamide in combination with the caspaseinhibitor. As can be seen, butanamide alone was in differentconcentrations effective to stabilize the extracellular nucleic acidpopulation as can be seen from the significantly reduced increase in 18SrDNA in butanamide stabilized samples. However, variations in thestabilization effectivity were seen between different donors. Suchvariations did not occur when using a caspase inhibitor in addition tobutanamide. Therefore, it is preferred to use butanamide in combinationwith a caspase inhibitor. FIGS. 27 to 29 show the stabilization resultsobtained for blood from different donors wherein the blood samples werestabilized with butanamide in different concentrations (see figures fordetails) in combination with a caspase inhibitor. Therefore, thestabilization solutions used comprised formamide and the caspaseinhibitor. As can be seen, uniform stabilization results were obtainedwith various concentrations of butanamide.

Example 8: Stabilization Using N-Methylformamide with Caspase Inhibitor

In example 8, different concentrations of N-methylformamide were used incombination with a caspase inhibitor for stabilizing blood samples. Thefocus of the analysis was the stabilization of the extracellular nucleicacid population as determined by analyzing the increase of 18S rDNA.Stabilization and processing of the samples were performed as describedin materials and methods under II.

The stabilization solutions comprised N-methylformamide in differentconcentrations, a caspase inhibitor and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2—OPH (caspase inhibitor)and different concentrations of N-methylformamide (see figures fordetails).

FIG. 30 shows the stabilization results obtained when blood wasstabilized with N-methylformamide in different concentrations (seefigure for details) and a caspase inhibitor. As can be seen, the testedstabilization compositions comprising N-methylformamide were indifferent concentrations effective to stabilize the extracellularnucleic acid population as can be seen from the significantly reducedincrease in 18S rDNA in the N-methylformamide stabilized samples.

Example 9: Stabilization Using N-Methylacetamide with Caspase Inhibitor

In example 9, different concentrations of N-methylacetamide were used incombination with a caspase inhibitor for stabilizing blood samples. Thefocus of the analysis was the stabilization of the extracellular nucleicacid population as determined by analyzing the increase of 18S rDNA.Stabilization and processing of the samples were performed as describedin materials and methods under II.

The stabilization solutions comprised N-methylacetamide in differentconcentrations, a caspase inhibitor and EDTA. When adding thesestabilization solutions to the blood sample, the following finalconcentrations were obtained in the blood/stabilization solutionmixture:

7.2 mg/ml K2 EDTA, 1 μM Quinoline-Val-Asp-CH2—OPH (caspase inhibitor)and different concentrations of N-methylacetamide (see figures fordetails).

FIG. 31 shows the stabilization results obtained when blood wasstabilized with N-methylacetamide in different concentrations (seefigure for details) and a caspase inhibitor. As can be seen, the testedstabilization compositions comprising N-methylacetamide were indifferent concentrations effective to stabilize the extracellularnucleic acid population as can be seen from the significantly reducedincrease in 18S rDNA in the N-methylacetamide stabilized samples.

Examples 4 to 9 demonstrate that stabilizing solutions according to thepresent invention which accordingly comprise primary or secondarycarboxylic acid amides show significantly lower amounts of released DNAafter storage for 3 days at room temperature compared to unstabilizedEDTA blood. As can be seen, all tested stabilizing agents achieved astabilizing effect on the extracellular nucleic acid population for atleast three days. Furthermore, for many stabilization solutions astabilization effect of up to 6 days and longer was observed.Furthermore, the examples show that the stabilizing effect could beimproved with all tested carboxylic acid amides when they were used incombination with a caspase inhibitor. Stabilization solutions whichadditionally comprised a caspase inhibitor achieved a prolongedstabilization effect for at least 6 days. Furthermore, when testing thestabilization solutions of the inventions on blood samples obtained froma plurality of different donors, it was found that the stabilizationeffect that is achieved with the combination of a primary or secondarycarboxylic acid amide and a caspase inhibitor showed less variations inthe achieved stabilization effect. Therefore, the stabilization wassignificantly improved when using these carboxylic acid amides incombination with a caspase inhibitor.

1. A container for collecting a cell-containing biological sample,comprising c) at least one carboxylic acid amide, wherein the carboxylicacid amide is selected from primary carboxylic acid amides and secondarycarboxylic acid amides; and d) at least one anticoagulant.
 2. Thecontainer according to claim 1, wherein the container additionallycomprises (i) at least one apoptosis inhibitor; and/or (ii) at least onepoly(oxyethylene) polymer, preferably at least one polyethylene glycol.3. The container according to claim 2, wherein the container comprises apolyethylene glycol as poly(oxyethylene) polymer.
 4. The containeraccording to claim 1, having one or more of the following features: (i)the container is evacuated; (ii) the container is a tube, the bottom isa closed bottom, the container further comprises a closure in the opentop, and the chamber is at a reduced pressure; and/or (iii) thecontainer is for drawing blood from a patient.
 5. The containeraccording to claim 1, wherein the at least one carboxylic acid amide andthe at least one anticoagulant are provided as a stabilizingcomposition.
 6. The container according to claim 5, wherein the at leastone carboxylic acid amide is in a concentration of at least 1% in thestabilizing composition.
 7. The container according to claim 1, whereinthe at least one carboxylic acid amide has formula 1

wherein R1 is a hydrogen residue or an alkyl residue, wherein R2 isselected from a hydrogen residue and a hydrocarbon residue with a lengthof the carbon chain of 1-20 atoms arranged in a linear or branchedmanner, wherein R3 is a hydrogen residue, and wherein R4 is oxygen. 8.The container according to claim 1, wherein the at least one carboxylicacid amide has one or more of the following characteristics: a) it isselected from the group consisting of formamide, acetamide, propanamideand butanamide, b) it is selected from butanamide and formamide, and/orc) it is butanamide.
 9. The container according to claim 1, wherein theat least one carboxylic acid amide is selected from the group consistingof N-alkylformamide, N-alkylacetamide and N-alkylpropanamide or isselected from N-methylformamide, N-methylacetamide andN-methylpropanamide.
 10. The container according to claim 1, wherein theanticoagulant is a chelating agent, preferably EDTA.
 11. The containeraccording to claim 1, further comprising at least one tertiary amide.12. The container according to claim 11, wherein the tertiary amide is acompound according to formula 1

wherein R1 is a hydrogen residue or an alkyl residue, wherein R2 and R3are identical or different hydrocarbon residues with a length of thecarbon chain of 1-20 atoms arranged in a linear or branched manner, andwherein R4 is an oxygen, sulphur or selenium residue.
 13. The containeraccording to claim 12, having one or more of the following features: a)the tertiary amide according to formula 1 is a carboxylic acid amide; b)the tertiary amide according to formula 1 is a N,N-dialkylpropanamide;and/or c) the tertiary amide according to formula 1 is selected from thegroup consisting of N, N-dimethylformamide, N, N-dimethylacetamide, N,N-dimethylpropanamide, N, N-dimethylbutanamide.
 14. The containeraccording to claim 6, wherein the composition further comprises at leastone apoptosis inhibitor, preferably a caspase inhibitor.
 15. Thecontainer according to claim 14, wherein the apoptosis inhibitor is acaspase inhibitor which has one or more of the followingcharacteristics: a) the caspase inhibitor is a pancaspase inhibitor, b)the caspase inhibitor is a caspase specific peptide modified by analdehyde, nitrile or ketone compound, c) the caspase inhibitor isselected from the group consisting of Q-VD-OPh andZ-Val-Ala-Asp(OMe)-FMK, and/or d) the caspase inhibitor is Q-VD-OPh. 16.The container according to claim 6, wherein the composition is capableof stabilizing the gene transcription profile of contained cells and/oris capable of stabilizing an extracellular nucleic acid populationcomprised in a cell-containing sample.
 17. The container according toclaim 6, wherein the stabilization composition does not compriseadditives in a concentration that induce or promote cell lysis, andwherein the stabilization composition does not comprise a cross-linkingagent that induces protein-DNA and/or protein-protein crosslinks orinvolve the use of a formaldehyde releaser.
 18. The container accordingto claim 6, wherein the stabilization composition has one or more of thefollowing characteristics: a) it is capable of stabilizing cells andreducing the release of genomic DNA from cells contained in thecell-containing biological sample into the cell-free portion of thesample; b) it is capable of reducing the dilution of the extracellularDNA population comprised in the biological sample with genomic DNAoriginating from cells contained in the stabilized sample; c) it iscapable of reducing the dilution of the extracellular nucleic acidpopulation comprised in the biological sample with intracellular nucleicacids originating from cells contained in the stabilized sample; d) thestabilization composition does not comprise additives in a concentrationwherein said additives would induce or promote cell lysis; e) thestabilization composition does not comprise a cross-linking agent thatinduces protein-DNA and/or protein-protein crosslinks; f) thestabilization composition does not comprise formaldehyde, formaline,paraformaldehyde or a formaldehyde releaser; g) the stabilizationcomposition does not comprise a toxic agent; h) the stabilizationcomposition is capable of stabilizing extracellular nucleic acidpopulation comprised in the cell-containing biological sample withoutrefrigeration, preferably at room temperature, for a time periodselected from at least two days, at least three days, at least two daysto three days, at least two days to six days and/or at least two days toseven days; and/or i) the stabilization composition comprises at leastone poly(oxyethylene) polymer, preferably a polyethylene glycol.
 19. Thecontainer according to claim 1, wherein the cell-containing sample is ablood sample.
 20. The container according to claim 19, wherein uponcontact of the stabilizing composition with a blood sample, thetranscript level of one or more marker genes selected from c-fos,IL-1beta, IL-8 and p53 is stabilized for at least 48 h uponstabilization.
 21. The container according to claim 5, wherein thecontainer is pre-filled with a defined amount of the stabilizingcomposition either in solid or liquid form and is provided with adefined vacuum and sealed with a septum.
 22. The container according toclaim 5, comprising the stabilizing composition mixed with acell-containing sample, wherein preferably, the volumetric ratio of thestabilizing composition to the cell-containing sample is selected from10:1 to 1:20, 5:1 to 1:15, 1:1 to 1:10 and 1:2 to 1:5.
 23. The containeraccording to claim 6, wherein the sample is a blood sample, and whereinthe morphology of and/or cell surface epitopes on white blood cells,preferably lymphocytes, is preserved.
 24. The container according toclaim 6, wherein the stabilizing composition is provided as a mixturewith a biological sample, and wherein said sample has one or both of thefollowing characteristics: a) it comprises extracellular nucleic acids;b) it is whole blood; c) it is a body fluid; and/or d) it is urine. 25.A method comprising the step of collecting a sample from a patient intoa chamber of a container according to claim
 1. 26. A system comprising acontainer according to claim 1 configured to collecting a sample from apatient into a chamber of the container.